BioMedLib Search Engine
[ goto HOMEPAGE ]
Save time; Find better answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
benign female breast tumor 2005:2010[pubdate] *count=100
1099 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
benign female breast tumor
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 1099
1.
Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M, Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, Dunn SP, Krueger LJ:
Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR.
Breast Cancer Res
; 2006;8(6):R70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analysis of Epstein-Barr virus reservoirs in paired blood and
breast
cancer primary biopsy specimens by real time PCR.
This infection is considered
benign
, even though in limited cases EBV is associated with infectious and neoplastic conditions.
Over the past decade, the EBV association with
breast
cancer has been constantly debated.
Adding to this clinical and biological uncertainty, different techniques gave contradictory results for the presence of EBV in
breast
carcinoma specimens.
In this study, minor groove binding (MGB)-TaqMan real time PCR was used to detect the presence of EBV DNA in both peripheral blood and
tumor
samples of selected patients.
METHODS: Peripheral blood and
breast
carcinoma specimens from 24 patients were collected.
RESULTS: Of 24
breast tumor
specimens, 11 (46%) were positive for EBV DNA.
Of these 11
breast tumor
specimens, 7 (64%) were also positive for EBV DNA in the peripheral blood, while 4 (36%) were positive for EBV DNA in the
tumor
, but negative in the blood.
Furthermore, our finding of the presence of EBV in the
tumor
specimens coupled to the absence of detection of EBV genomic DNA in the peripheral blood is consistent with the epithelial nature of the virus.
Because of the low levels of viral DNA in
tumor
tissue, further studies are needed to assess the biological input of EBV in
breast
cancer.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Pathol. 2000 Jan;156(1):1-3
[
10623645.001
]
[Cites]
J Virol. 1999 Oct;73(10):8857-66
[
10482644.001
]
[Cites]
J Natl Cancer Inst. 2000 Nov 15;92(22):1849-51
[
11078764.001
]
[Cites]
J Natl Cancer Inst. 2001 Jan 17;93(2):148-50
[
11208885.001
]
[Cites]
Br J Cancer. 2001 Mar 23;84(6):783-90
[
11259092.001
]
[Cites]
Am J Pathol. 2001 Aug;159(2):571-8
[
11485915.001
]
[Cites]
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
[
11602373.001
]
[Cites]
Virology. 2001 Sep 30;288(2):223-35
[
11601894.001
]
[Cites]
Nat Med. 2002 Jun;8(6):594-9
[
12042810.001
]
[Cites]
Mod Pathol. 2002 Jul;15(7):759-64
[
12118114.001
]
[Cites]
Lab Invest. 2002 Sep;82(9):1193-9
[
12218080.001
]
[Cites]
Breast Cancer Res. 2003;5(1):R13-7
[
12559053.001
]
[Cites]
Nat Med. 2003 Mar;9(3):307-14
[
12592401.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2338-43
[
12727860.001
]
[Cites]
Br J Cancer. 2003 Jul 7;89(1):113-9
[
12838311.001
]
[Cites]
J Natl Cancer Inst. 2003 Aug 20;95(16):1253-4; author reply 1254-5
[
12928356.001
]
[Cites]
J Virol. 2003 Dec;77(24):13267-74
[
14645583.001
]
[Cites]
Nat Rev Cancer. 2003 Nov;3(11):832-44
[
14668814.001
]
[Cites]
Mod Pathol. 2003 Dec;16(12):1242-7
[
14681325.001
]
[Cites]
Eur J Haematol. 2004 Mar;72(3):203-12
[
14962239.001
]
[Cites]
Med Hypotheses. 2004;62(3):387-91
[
14975509.001
]
[Cites]
J Virol. 2004 May;78(10):5007-14
[
15113881.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):688-97
[
15159298.001
]
[Cites]
J Gen Virol. 2004 Oct;85(Pt 10):2767-78
[
15448337.001
]
[Cites]
J Mol Diagn. 2004 Nov;6(4):378-85
[
15507678.001
]
[Cites]
Cell. 1988 Jan 15;52(1):51-61
[
2830981.001
]
[Cites]
J Clin Pathol. 1994 Jun;47(6):538-40
[
8063937.001
]
[Cites]
Cancer Res. 1995 Jan 1;55(1):39-45
[
7805038.001
]
[Cites]
Am J Clin Pathol. 1995 Mar;103(3):308-15
[
7872253.001
]
[Cites]
IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424
[
9190379.001
]
[Cites]
Int J Cancer. 1998 Feb 9;75(4):555-8
[
9466655.001
]
[Cites]
Cancer Lett. 1998 Feb 13;124(1):53-7
[
9500191.001
]
[Cites]
Diagn Mol Pathol. 2005 Mar;14(1):29-33
[
15714061.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):809-14
[
15824148.001
]
[Cites]
Breast Cancer Res. 2005;7(3):86-95
[
15987436.001
]
[Cites]
J Virol. 2006 Jan;80(2):845-53
[
16378986.001
]
[Cites]
J Virol. 1998 May;72(5):4371-8
[
9557727.001
]
[Cites]
Cancer Res. 1998 Jul 1;58(13):2825-31
[
9661897.001
]
[Cites]
Ann Med. 1998 Jun;30(3):249-59
[
9677010.001
]
[Cites]
J Virol. 1999 Feb;73(2):1286-92
[
9882333.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50
[
10451431.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 18;91(16):1376-81
[
10451442.001
]
[Cites]
J Natl Cancer Inst. 2000 Apr 19;92(8):655-6; author reply 656
[
10772685.001
]
(PMID = 17163997.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / P20 RR016472; United States / NCRR NIH HHS / RR / 2 P20 RR016472-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Viral
[Other-IDs]
NLM/ PMC1797024
2.
Enfield LC, Gibson AP, Hebden JC, Douek M:
Optical tomography of breast cancer-monitoring response to primary medical therapy.
Target Oncol
; 2009 Sep;4(3):219-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Optical tomography of
breast
cancer-monitoring response to primary medical therapy.
Studies have demonstrated that diffuse optical imaging and spectroscopy are able to distinguish malignant lesions from
benign
tissues.
Breast
cancer is characterized by an increase in total hemoglobin and a decrease in tissue oxygen saturation.
Benign
lesions such as cysts and fibroadenomas have also been studied, with less conclusive results.
This provides a unique functional and dynamic imaging method that reflects changes in
tumor
angiogenesis and hypoxia.
When
breast
cancers are treated with primary medical therapy, this can result in a selective antiangiogenic effect that could help predict response to treatment earlier than by assessment of
tumor
size.
Diffuse optical imaging and spectroscopy have been used to scan women at several points prior to and during their neoadjuvant chemotherapy treatment, with images and data showing physiological changes in the
tumor
in response to treatment.
In the women who respond to therapy, the total hemoglobin concentration decreases and the level of oxygenation increases in the
tumor
over the course of the treatment.
[MeSH-major]
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / therapy. Tomography, Optical / methods
[MeSH-minor]
Animals.
Female
. Humans. Prognosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biomed Opt. 2005 Sep-Oct;10(5):051504
[
16292948.001
]
[Cites]
J Biomed Opt. 2005 Sep-Oct;10(5):051503
[
16292947.001
]
[Cites]
Appl Opt. 2007 Jun 10;46(17 ):3628-38
[
17514325.001
]
[Cites]
Appl Opt. 2003 Nov 1;42(31):6412-21
[
14649285.001
]
[Cites]
J Biomed Opt. 2003 Apr;8(2):308-15
[
12683859.001
]
[Cites]
J Biomed Opt. 1999 Oct;4(4):397-402
[
23014611.001
]
[Cites]
Cancer. 1999 May 1;85(9):1996-2000
[
10223241.001
]
[Cites]
Phys Med Biol. 2005 Jun 7;50(11):2489-502
[
15901950.001
]
[Cites]
Adv Exp Med Biol. 1997;411:227-32
[
9269431.001
]
[Cites]
Antioxid Redox Signal. 2007 Aug;9(8):1143-56
[
17627478.001
]
[Cites]
Appl Opt. 2005 Apr 10;44(11):2140-53
[
15835360.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4420-5
[
11287650.001
]
[Cites]
Photochem Photobiol. 2000 Sep;72(3):383-91
[
10989610.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12 ):6468-73
[
9177241.001
]
[Cites]
Med Phys. 2006 Mar;33(3):627-36
[
16878566.001
]
[Cites]
Opt Lett. 2005 Nov 1;30(21):2915-7
[
16279468.001
]
[Cites]
J Biomed Opt. 2006 Jul-Aug;11(4):044005
[
16965162.001
]
[Cites]
Cancer Res. 1989 Dec 1;49(23):6449-65
[
2684393.001
]
[Cites]
Med Phys. 2008 Jun;35(6):2493-501
[
18649482.001
]
[Cites]
Acad Radiol. 2005 Aug;12(8):925-33
[
16023383.001
]
[Cites]
Phys Med Biol. 2007 Jun 21;52(12):3619-41
[
17664563.001
]
[Cites]
Phys Med Biol. 2005 Jun 7;50(11):2429-49
[
15901947.001
]
[Cites]
Cancer Res. 2002 Sep 15;62(18):5381-5
[
12235011.001
]
[Cites]
Neoplasia. 2002 Jul-Aug;4(4):347-54
[
12082551.001
]
[Cites]
Neoplasia. 2003 Sep-Oct;5(5):379-88
[
14670175.001
]
[Cites]
Ann N Y Acad Sci. 1998 Feb 9;838:171-93
[
9511805.001
]
[Cites]
J Clin Oncol. 1998 Aug;16(8):2672-85
[
9704717.001
]
[Cites]
Phys Med Biol. 1990 Sep;35(9):1317-34
[
2236211.001
]
[Cites]
J Biomed Opt. 2006 Nov-Dec;11(6):064016
[
17212539.001
]
[Cites]
J Biomed Opt. 2004 May-Jun;9(3):504-10
[
15189088.001
]
[Cites]
Acad Radiol. 2004 Jan;11(1):53-60
[
14746402.001
]
[Cites]
Med Phys. 2008 Feb;35(2):446-55
[
18383664.001
]
[Cites]
Eur Radiol. 2000;10(1):46-58
[
10663717.001
]
[Cites]
Nat Clin Pract Oncol. 2005 Mar;2(3):128-9
[
16264902.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12349-54
[
14514888.001
]
[Cites]
Opt Lett. 2003 Jul 15;28(14):1212-4
[
12885024.001
]
[Cites]
Endocr Relat Cancer. 2002 Sep;9(3):183-95
[
12237246.001
]
[Cites]
Br J Cancer. 2006 Feb 13;94(3):427-35
[
16465174.001
]
[Cites]
Am J Prev Med. 1996 Sep-Oct;12(5):340-1
[
8909643.001
]
[Cites]
J Biomed Opt. 2004 Jan-Feb;9(1):230-8
[
14715078.001
]
[Cites]
Mol Imaging Biol. 2009 Mar-Apr;11(2):64-70
[
19030937.001
]
[Cites]
Radiology. 2007 May;243(2):350-9
[
17400760.001
]
[Cites]
Appl Opt. 2003 Sep 1;42(25):5181-90
[
12962399.001
]
[Cites]
IEEE Trans Med Imaging. 2009 Jan;28(1):30-42
[
19116186.001
]
[Cites]
Appl Opt. 2008 Jun 1;47(16):3053-63
[
18516127.001
]
[Cites]
AJR Am J Roentgenol. 2005 Mar;184(3):868-77
[
15728611.001
]
[Cites]
Phys Med Biol. 2005 Jun 7;50(11):2451-68
[
15901948.001
]
[Cites]
Phys Med Biol. 2005 Jun 7;50(11):2469-88
[
15901949.001
]
[Cites]
J Clin Oncol. 2001 Sep 15;19(18):3817-27
[
11559719.001
]
[Cites]
Opt Express. 1997 Dec 22;1(13):391-403
[
19377563.001
]
[Cites]
Top Magn Reson Imaging. 2008 Jun;19(3):143-50
[
18941394.001
]
[Cites]
Phys Med Biol. 2005 Jun 7;50(11):2503-17
[
15901951.001
]
[Cites]
J Biomed Opt. 2006 Jul-Aug;11(4):041102
[
16965130.001
]
[Cites]
Cancer Res. 1991 Jun 15;51(12):3316-22
[
2040005.001
]
[Cites]
Opt Lett. 1998 Jun 1;23(11):882-4
[
18087373.001
]
[Cites]
J Biomed Opt. 2004 May-Jun;9(3):541-52
[
15189092.001
]
[Cites]
Appl Opt. 2005 Apr 1;44(10 ):1898-904
[
15813526.001
]
[Cites]
J Biomed Opt. 2008 Jul-Aug;13(4):044001
[
19021329.001
]
[Cites]
Med Phys. 2003 Feb;30(2):235-47
[
12607841.001
]
[Cites]
Acad Radiol. 2001 Mar;8(3):211-8
[
11249084.001
]
[Cites]
Cancer Res. 1996 Sep 15;56(18):4264-6
[
8797602.001
]
[Cites]
Appl Opt. 2003 Jan 1;42(1):135-45
[
12518832.001
]
[Cites]
Breast Cancer Res. 2005;7(6):279-85
[
16457705.001
]
[Cites]
Neoplasia. 2005 Mar;7(3):263-70
[
15799826.001
]
[Cites]
J Biomed Opt. 2009 Mar-Apr;14(2):024020
[
19405750.001
]
[Cites]
Wien Med Wochenschr. 2002;152(13-14):334-42
[
12168517.001
]
[Cites]
Clin Cancer Res. 2008 Oct 15;14(20):6580-9
[
18927299.001
]
[Cites]
J Biomed Opt. 2007 Sep-Oct;12(5):051903
[
17994886.001
]
[Cites]
Annu Rev Med. 2006;57:1-18
[
16409133.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):401-10
[
12778130.001
]
[Cites]
J Biomed Opt. 2006 May-Jun;11(3):33001
[
16822050.001
]
[Cites]
J Biomed Opt. 2005 Sep-Oct;10(5):054011
[
16292971.001
]
[Cites]
Eur J Radiol. 2009 Jan;69(1):43-9
[
18829193.001
]
[Cites]
Radiology. 2001 Jan;218(1):261-6
[
11152812.001
]
[Cites]
Breast Cancer Res Treat. 2008 Mar;108(1):9-22
[
17468951.001
]
[Cites]
Med Phys. 2005 Apr;32(4):1128-39
[
15895597.001
]
[Cites]
Med Phys. 2008 Jun;35(6):2443-51
[
18649477.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9
[
17360469.001
]
[Cites]
J Biomed Opt. 2005 Mar-Apr;10(2):024033
[
15910106.001
]
[Cites]
Phys Med Biol. 2004 Apr 7;49(7):1165-81
[
15128196.001
]
[Cites]
Sociol Health Illn. 2010 Jan;32(1):74-88
[
19619154.001
]
[Cites]
Opt Lett. 2007 Apr 15;32(8):933-5
[
17375158.001
]
[Cites]
Neoplasia. 2008 Oct;10 (10 ):1028-40
[
18813360.001
]
[Cites]
Opt Express. 2008 Oct 27;16(22):17903-14
[
18958072.001
]
[Cites]
Radiology. 2009 Aug;252(2):551-60
[
19508985.001
]
[Cites]
Breast Cancer Res Treat. 2003;79 Suppl 1:S19-24
[
12868802.001
]
(PMID = 19777322.001).
[ISSN]
1776-260X
[Journal-full-title]
Targeted oncology
[ISO-abbreviation]
Target Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
France
[Number-of-references]
99
3.
Dordević M, Jovanović B, Mitrović S, Dordević G:
Ectopic mammary tissue in vulva.
Vojnosanit Pregl
; 2008 May;65(5):407-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CASE REPORT: A woman, 27-year old, admitted to Obstetrics and Gynecology Clinic Kragujevac for surgery, of goose-egg size, vulva
tumor
, of elastic consistency.
Excision of the
tumor
was completely done in the total endotracheal anesthesia.
CONCLUSION: Ectopic mammary tissue in vulva in adult period is very rarely seen, and can be changed pathologically as well as normally positioned
breast
tissue into
benign
cystic changes,
benign
tumors, adenomas and fibroadenomas and tumors.
[MeSH-minor]
Adult.
Female
. Humans
MedlinePlus Health Information.
consumer health - Vulvar Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18630137.001).
[ISSN]
0042-8450
[Journal-full-title]
Vojnosanitetski pregled
[ISO-abbreviation]
Vojnosanit Pregl
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Serbia
Advertisement
4.
Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ:
Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Am J Surg Pathol
; 2009 Jan;33(1):111-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Germline mutations in the hereditary
breast
/ovary carcinoma genes BRCA1 or BRCA2 confer increased lifetime risk for ovarian, fallopian tube, and primary peritoneal carcinoma.
Transitional cell metaplasia is a
benign
epithelial alteration that is a common finding in the serosa of the tube but is underrecognized in the tubal fimbriae, where it may mimic tubal intraepithelial carcinoma.
Median
tumor
size was 2.7 mm (range: 1 to 11 mm).
No particular clinical variables (BRCA 1 vs. BRCA 2 mutation, parity, personal history of
breast
cancer, prior abdomino-pelvic surgery, or intraoperative findings) or
benign
pathologic alterations in the RRSO specimens were associated with the presence of transitional cell metaplasia of the fimbriae.
This study demonstrates that transitional cell metaplasia of the fimbriae is a common
benign
finding in RRSO specimens that should not be confused with the much less common finding of tubal intraepithelial carcinoma.
[MeSH-minor]
Adult. Aged.
Diagnosis
, Differential.
Female
. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Ovariectomy. Risk Factors.
Tumor
Suppressor Protein p53 / metabolism
Genetic Alliance.
consumer health - Transitional cell carcinoma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18830124.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Protein p53
5.
Hisaoka M, Takamatsu Y, Hirano Y, Maeda H, Hamada T:
Sebaceous carcinoma of the breast: case report and review of the literature.
Virchows Arch
; 2006 Oct;449(4):484-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sebaceous carcinoma of the
breast
: case report and review of the literature.
Sebaceous differentiation has been described in only limited examples of
benign
and malignant epithelial lesions of the
breast
.
Microscopically, the
tumor
, arising in the right mammary gland of a 63-year-old woman, was composed of well-defined solid sheets or lobules of atypical epithelial cells including many large pale or clear cells with often scalloped nuclei and coarsely vacuolated cytoplasm, in which abundant lipid droplets were identified with oil-red-O staining.
Besides, a subset of the
tumor
cells co-expressed synaptophysin, neurofilament, and PGP9.5, suggesting neuroendocrine differentiation that is a hitherto undescribed phenomenon in the mammary tumors with sebaceous features.
This case would expand the morphologic diversity of carcinoma of the
breast
.
[MeSH-major]
Adenocarcinoma, Sebaceous / pathology.
Breast
Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
[MeSH-minor]
Azo Compounds. Biomarkers,
Tumor
/ analysis. Coloring Agents.
Female
. Fluorescent Antibody Technique, Indirect. Humans. Keratins / analysis. Mammography. Mastectomy, Modified Radical. Middle Aged. Mucin-1 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Dermatopathol. 1999 Oct;21(5):426-31
[
10535570.001
]
[Cites]
Pathology. 1995 Jul;27(3):280-3
[
8532397.001
]
[Cites]
Am J Dermatopathol. 2005 Jun;27(3):195-203
[
15900121.001
]
[Cites]
Arch Ophthalmol. 1999 Jun;117(6):776-83
[
10369589.001
]
[Cites]
AJR Am J Roentgenol. 2000 Feb;174(2):541-2
[
10658739.001
]
[Cites]
Pathol Int. 2000 Jan;50(1):63-6
[
10692180.001
]
[Cites]
Semin Diagn Pathol. 2000 May;17(2):127-37
[
10839613.001
]
[Cites]
Histopathology. 1992 Aug;21(2):181-4
[
1324221.001
]
[Cites]
Hum Pathol. 1982 Feb;13(2):113-22
[
7076199.001
]
[Cites]
Histopathology. 1993 Feb;22(2):127-33
[
7681028.001
]
[Cites]
Virchows Arch A Pathol Anat Histol. 1977 Oct 7;375(4):345-53
[
199989.001
]
[Cites]
Arch Pathol Lab Med. 1986 Nov;110(11):1045-53
[
3022669.001
]
[Cites]
Virchows Arch. 2001 May;438(5):505-8
[
11407480.001
]
[Cites]
Endocr J. 2005 Jun;52(3):317-25
[
16006726.001
]
(PMID = 16944238.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Azo Compounds; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 68238-35-7 / Keratins; G7S71FND9B / oil red O
6.
Calaf GM:
Susceptibility of human breast epithelial cells in vitro to hormones and drugs.
Int J Oncol
; 2006 Feb;28(2):285-95
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Susceptibility of human
breast
epithelial cells in vitro to hormones and drugs.
Breast
cancer is often hormone responsive with growth or regression of tumors modulated by endocrine manipulations.
Knowledge of
tumor
response to hormones will greatly improve the ability to plan therapy for
breast
cancer patients.
Chemoprevention of
breast
cancer has been mostly aimed at reducing the rate of cell division through administration of anti-hormones.
Normal,
benign
lesions, and duct carcinomas of human
breast
tissues were processed for organ culture.
In the case of the normal
breast
tissue it was enzymatically digested and culture as organoid culture as well.
Several immortalized normal and malignant human
breast
cell lines were also used in these studies to analyze the effect of 17beta estradiol, progesterone, tamoxifen and anti-progestin RU486.
[MeSH-major]
Antineoplastic Agents, Hormonal / pharmacology. Cell Line,
Tumor
/ drug effects. Epithelial Cells / drug effects. Estradiol / pharmacology. Estrogen Antagonists / pharmacology. Tamoxifen / pharmacology
[MeSH-minor]
Breast
.
Breast
Neoplasms. Carcinoma, Ductal,
Breast
. Cell Proliferation / drug effects.
Female
. Humans. Mifepristone / pharmacology. Organ Culture Techniques. Progesterone / pharmacology. Progestins / pharmacology
Hazardous Substances Data Bank.
TAMOXIFEN
.
Hazardous Substances Data Bank.
ESTRADIOL
.
Hazardous Substances Data Bank.
PROGESTERONE
.
Hazardous Substances Data Bank.
MIFEPRISTONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16391781.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Progestins; 094ZI81Y45 / Tamoxifen; 320T6RNW1F / Mifepristone; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol
7.
Kuroda H, Saito K, Kuroda M, Suzuki Y:
Differential expression of glu-tubulin in relation to mammary gland disease.
Virchows Arch
; 2010 Oct;457(4):477-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Of the 78 malignant
tumor
cases, staining for glu-tubulin was observed in 56 (71.8%), and only 22 cases showed no significant staining.
However, in
benign
disease, glu-tubulin staining was detected in the cytoplasm of fibroblasts and endothelial cells, but was completely absent from epithelial cells in 64 of 69 cases.
When the expression of glu-tubulin was compared between malignant
tumor
,
benign tumor
, and other
benign
disease, a significant differentiation was found among expressions of this protein.
These results indicate that glu-tubulin represents a strong selective expression for cancer cells and may be useful to identify and quantify human
breast
cancer.
[MeSH-major]
Breast
Diseases / metabolism.
Breast
Neoplasms / chemistry. Glutamic Acid / analysis. Tubulin / analysis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Female
. Humans. Middle Aged. Tyrosine / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
Hazardous Substances Data Bank.
GLUTAMIC ACID HYDROCHLORIDE
.
Hazardous Substances Data Bank.
L-TYROSINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 1999 Jun;80(8):1162-8
[
10376967.001
]
[Cites]
J Clin Invest. 1997 Sep 1;100(5):1282-93
[
9276747.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5024-7
[
11431336.001
]
[Cites]
EMBO J. 1987 Sep;6(9):2597-606
[
3315650.001
]
[Cites]
J Cell Biol. 1987 Nov;105(5):2167-77
[
3316248.001
]
[Cites]
J Cell Sci. 2001 Nov;114(Pt 21):3795-803
[
11719546.001
]
[Cites]
J Clin Oncol. 2007 Jan 1;25(1):118-45
[
17159189.001
]
[Cites]
J Cell Sci. 1989 Oct;94 ( Pt 2):227-36
[
2621221.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Aug;85(16):5946-50
[
3413068.001
]
[Cites]
Nat Cell Biol. 2003 Jul;5(7):599-609
[
12833063.001
]
[Cites]
Nat Rev Cancer. 2004 Apr;4(4):253-65
[
15057285.001
]
[Cites]
Eur J Cell Biol. 1986 Dec;42(2):288-94
[
3545837.001
]
[Cites]
Br J Cancer. 2009 Sep 15;101(6):951-6
[
19690549.001
]
[Cites]
Histopathology. 1991 Nov;19(5):403-10
[
1757079.001
]
[Cites]
J Cell Sci. 1999 Jun;112 ( Pt 12):1803-11
[
10341200.001
]
[Cites]
Clin Cancer Res. 2005 Aug 1;11(15):5481-6
[
16061864.001
]
[Cites]
Nat Cell Biol. 2004 Sep;6(9):820-30
[
15311282.001
]
[Cites]
Clin Breast Cancer. 2002 Dec;3(5):341-5
[
12533264.001
]
[Cites]
Annu Rev Cell Dev Biol. 2004;20:867-94
[
15473863.001
]
(PMID = 20697907.001).
[ISSN]
1432-2307
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Tubulin; 3KX376GY7L / Glutamic Acid; 42HK56048U / Tyrosine
8.
Onuma K, Dabbs DJ, Bhargava R:
Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
Int J Gynecol Pathol
; 2008 Jul;27(3):418-25
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mammaglobin expression in the
female
genital tract: immunohistochemical analysis in
benign
and neoplastic endocervix and endometrium.
Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for
breast
carcinoma, but is also reported to be expressed in the
female
genital tract and its neoplasms.
Details of MGB expression pattern and its pathologic significance in the
female
genital tract have not been systematically studied.
Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in
benign
endocervical glandular epithelium.
Reduction of MGB staining was seen in transition from
benign
epithelium to AIS.
These results confirm that MGB is not specific for
breast
carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2
tumor
types.
[MeSH-major]
Adenocarcinoma / metabolism. Biomarkers,
Tumor
/ biosynthesis. Carcinoma in Situ / metabolism.
Neoplasm
Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
[MeSH-minor]
Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism.
Female
. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Uterine Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18580321.001).
[ISSN]
1538-7151
[Journal-full-title]
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
[ISO-abbreviation]
Int. J. Gynecol. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
9.
Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI:
Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
Cancer Lett
; 2006 Feb 20;233(1):98-107
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with
breast
disease,
breast
cancer and at risk of developing
breast
cancer.
Specifically, MMP2 and MMP9 are implicated in both early and late processes of
tumor
development.
However, there is limited knowledge on the role of each form in disease and/or the significance of changes in the plasma concentration and/or activity in
breast
cancer patients.
The aim of this study was to determine if patients with
breast
cancer,
benign
disease and at risk for developing
breast
cancer display characteristic levels of active and/or total MMP2 and MMP9 in plasma.
Concentration and activity of MMP2 and MMP9 were determined quantitatively in the plasma of 124
female
volunteers diagnosed with
breast
cancer (n=31),
benign
disease (n=38), or determined by the Gail Model to be at high risk (n=31) or low risk (controls, n=24) of developing
breast
cancer.
Concentration of total MMP2 was significantly lower in control individuals than
benign
, high risk (P<0.001 respectively) and
breast
cancer patients (P=0.002).
Activity of total MMP2 was significantly lower in controls compared to cancer,
benign
and high risk patients (P<0.001 respectively).
Attempts to build a predictive/descriptive model using canonical discriminant analysis (utilizing all eight features; concentrations and activity levels of active/total MMP2 and MMP9) enabled the distinction of the controls from the high risk,
benign
and cancer groups.
Our results suggest that preoperative plasma concentration and activity of MMP2 and MMP9 may permit sub-classification of
female
patients with
breast
disorders.
[MeSH-major]
Breast
Diseases / enzymology.
Breast
Neoplasms / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood
[MeSH-minor]
Adult. Aged. Biomarkers,
Tumor
/ blood.
Female
. Humans. Middle Aged
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16473671.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
10.
Chung EM, Cube R, Hall GJ, González C, Stocker JT, Glassman LM:
From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.
Radiographics
; 2009 May-Jun;29(3):907-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
From the archives of the AFIP:
breast
masses in children and adolescents: radiologic-pathologic correlation.
The spectrum of
breast
lesions in children and adolescents varies markedly from that for adults, with the former lesions being overwhelmingly
benign
.
A
breast
mass in a young boy or girl may arise from normal and abnormal
breast
development.
After onset of puberty, most cases of
breast
enlargement arise from
benign
fibroadenoma in girls and gynecomastia in boys.
These conditions have specific imaging appearances, although juvenile (often giant) fibroadenoma cannot be distinguished from phyllodes
tumor
, which can be
benign
or malignant.
A
diagnosis of
juvenile papillomatosis (a
benign
lesion) portends later development of
breast
cancer, and patients with this condition should be closely monitored.
Malignant lesions of the
breast
in children are rare.
The most common primary
breast
malignancy is malignant phyllodes
tumor
.
Primary
breast
carcinoma is exceedingly rare in the pediatric age group, but its imaging appearance in children is the same as seen in adults and is different from that of almost all
benign
lesions.
In girls, diagnostic interventions may injure the developing
breast
and cause subsequent disfigurement.
Given this risk and the low prevalence of malignant disease in this population, a prudent course should be followed in
the diagnosis
of
breast
lesions.
[MeSH-major]
Breast
Diseases / radiography
[MeSH-minor]
Adolescent.
Breast
/ abnormalities.
Breast
/ anatomy & histology.
Breast
/ growth & development.
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / pathology.
Breast
Neoplasms / radiography.
Breast
Neoplasms, Male /
diagnosis
.
Breast
Neoplasms, Male / pathology.
Breast
Neoplasms, Male / radiography.
Breast
Neoplasms, Male / secondary. Carcinoma, Ductal,
Breast
/
diagnosis
. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Ductal,
Breast
/ radiography. Carcinoma, Ductal,
Breast
/ ultrasonography. Child. Child, Preschool.
Female
. Fibroadenoma /
diagnosis
. Fibroadenoma / pathology. Fibroadenoma / radiography. Granular Cell
Tumor
/
diagnosis
. Granular Cell
Tumor
/ pathology. Granular Cell
Tumor
/ radiography. Gynecomastia / pathology. Gynecomastia / radiography. Humans. Infant. Infant, Newborn. Male. Nipples / abnormalities. Papilloma /
diagnosis
. Papilloma / pathology. Papilloma / radiography. Phyllodes
Tumor
/
diagnosis
. Phyllodes
Tumor
/ pathology. Phyllodes
Tumor
/ radiography. Puberty. Puberty, Precocious /
diagnosis
. Young Adult
MedlinePlus Health Information.
consumer health - Breast Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19448124.001).
[ISSN]
1527-1323
[Journal-full-title]
Radiographics : a review publication of the Radiological Society of North America, Inc
[ISO-abbreviation]
Radiographics
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
90
11.
Tremblay G, Deschênes J, Alpert L, Quenneville LA:
Overexpression of estrogen receptors in columnar cell change and in unfolding breast lobules.
Breast J
; 2005 Sep-Oct;11(5):326-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Overexpression of estrogen receptors in columnar cell change and in unfolding
breast
lobules.
However, some investigators have suggested that it may be a marker for increased risk of
breast
cancer.
To see whether CCC is subject to hormonal influences, the distribution of estrogen receptors (ER) was determined in a series of
breast
specimens showing this change.
The cases came from 51 women age 35-80 years (mean 52 years) with the following associated findings: 27 carcinomas and 24
benign
lesions.
It is now recognized that columnar cell lesions include a wide spectrum of changes reaching a point at the upper end where the differential
diagnosis
is ductal carcinoma in situ.
[MeSH-major]
Breast
Neoplasms / pathology. Carcinoma, Ductal,
Breast
/ pathology. Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology. Receptors, Estrogen / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ analysis. Biopsy, Needle. Disease Progression.
Female
. Humans. Immunohistochemistry. Middle Aged. Prognosis. Risk Factors. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16174153.001).
[ISSN]
1075-122X
[Journal-full-title]
The breast journal
[ISO-abbreviation]
Breast J
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Receptors, Estrogen
12.
Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G:
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.
Clin Exp Metastasis
; 2006;23(2):117-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Activin A circulating levels in patients with bone metastasis from
breast
or prostate cancer.
Activin A serum concentrations were determined, by a commercially available enzyme-linked immunosorbent assay kit, in 72 patients with
breast
cancer (BC) or prostatic cancer (PC) with (BM+) or without (BM-) bone metastases, in 15
female
patients with age-related osteoporosis (OP), in 20 patients with
benign
prostatic hypertrophy (BPH) and in 48 registered healthy blood donors (HS) of both sex (25
female
and 23 male).
[MeSH-major]
Activins / blood. Bone Neoplasms / secondary.
Breast
Neoplasms / pathology. Prostatic Neoplasms / pathology
[MeSH-minor]
Aged. Aged, 80 and over. Biomarkers,
Tumor
/ blood.
Female
. Humans. Male. Middle Aged. Osteoporosis / blood. Prostatic Hyperplasia / blood. Sensitivity and Specificity
Genetic Alliance.
consumer health - Bone Cancer
.
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Thyroid. 2001 Jan;11(1):3-14
[
11272093.001
]
[Cites]
Int J Cancer. 1998 Sep 11;77(6):860-8
[
9714055.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E927-31
[
14761877.001
]
[Cites]
Mol Cell Endocrinol. 2001 Jun 30;180(1-2):183-8
[
11451590.001
]
[Cites]
JAMA. 1997 Mar 19;277(11):925-6
[
9062334.001
]
[Cites]
J Cell Biochem. 2003 Sep 1;90(1):59-67
[
12938156.001
]
[Cites]
Gynecol Oncol. 1999 Jul;74(1):93-7
[
10385557.001
]
[Cites]
Curr Drug Targets Immune Endocr Metabol Disord. 2004 Jun;4(2):157-66
[
15180456.001
]
[Cites]
Trends Endocrinol Metab. 2005 Mar;16(2):73-8
[
15734148.001
]
[Cites]
Endocr Relat Cancer. 2000 Dec;7(4):243-56
[
11174846.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1655-64
[
15084698.001
]
[Cites]
Exp Biol Med (Maywood). 2002 Feb;227(2):75-87
[
11815670.001
]
[Cites]
Endocr Rev. 2001 Dec;22(6):836-58
[
11739336.001
]
[Cites]
Eur J Endocrinol. 2001 Sep;145(3):225-36
[
11517001.001
]
[Cites]
Int J Oncol. 2003 Jan;22(1):75-80
[
12469187.001
]
[Cites]
Oncogene. 2005 Jan 20;24(4):680-7
[
15580313.001
]
[Cites]
Breast Cancer Res Treat. 2002 Jun;74(3):255-69
[
12206515.001
]
[Cites]
Cancer Res. 2003 Nov 15;63(22):7791-8
[
14633705.001
]
[Cites]
Mol Endocrinol. 2004 Mar;18(3):696-707
[
14684851.001
]
[Cites]
Cancer Detect Prev. 2000;24(2):150-5
[
10917135.001
]
[Cites]
Cancer Lett. 2000 May 29;153(1-2):137-43
[
10779642.001
]
[Cites]
Cytokine Growth Factor Rev. 2006 Jun;17(3):157-71
[
16481210.001
]
[Cites]
J Clin Endocrinol Metab. 2002 May;87(5):2277-82
[
11994376.001
]
[Cites]
Gut. 2001 Sep;49(3):409-17
[
11511564.001
]
[Cites]
Scand J Gastroenterol. 2002 Feb;37(2):233-8
[
11843063.001
]
[Cites]
J Cell Biochem. 2004 Mar 1;91(4):718-29
[
14991763.001
]
[Cites]
Anal Quant Cytol Histol. 2000 Feb;22(1):1-10
[
10696454.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Feb 5;268(1):2-7
[
10652202.001
]
[Cites]
Endocr Rev. 2002 Dec;23(6):787-823
[
12466190.001
]
[Cites]
Bone. 2000 Mar;26(3):235-40
[
10709995.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3783-90
[
12839974.001
]
[Cites]
Prostate. 1999 Jun 1;39(4):246-61
[
10344214.001
]
[Cites]
Endocr Relat Cancer. 2004 Mar;11(1):35-49
[
15027884.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Dec;163(2):123-9
[
16337854.001
]
(PMID = 16841234.001).
[ISSN]
0262-0898
[Journal-full-title]
Clinical & experimental metastasis
[ISO-abbreviation]
Clin. Exp. Metastasis
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / activin A; 104625-48-1 / Activins
13.
McNeill RE, Miller N, Kerin MJ:
Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer.
BMC Mol Biol
; 2007;8:107
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of
breast
cancer.
BACKGROUND: Real-time quantitative PCR (RQ-PCR) forms the basis of many
breast
cancer biomarker studies and novel prognostic assays, paving the way towards personalised cancer treatments.
Despite widespread recognition that the accuracy of the normalised data is largely dependent on the reliability of the EC, there are no reports of the systematic validation of genes commonly used for this purpose in the analysis of gene expression by RQ-PCR in primary
breast
cancer tissues.
The aim of this study was to identify the most suitable endogenous control genes for RQ-PCR analysis of primary
breast
tissue from a panel of eleven candidates in current use.
RESULTS: The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6
benign
and 21 malignant primary
breast
cancer tissues.
ESR1 expression was appreciably higher in malignant compared to
benign
tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
CONCLUSION: We have validated two endogenous control genes, MRPL19 and PPIA, for RQ-PCR analysis of gene expression in primary
breast
tissue.
The combination identified here is a good candidate for use as a two-gene endogenous control in a broad spectrum of future research and diagnostic applications in
breast
cancer.
[MeSH-major]
Breast
Neoplasms / genetics. Gene Expression Profiling. Reverse Transcriptase Polymerase Chain Reaction / methods
[MeSH-minor]
Biomarkers,
Tumor
/ genetics. Estrogen Receptor alpha / genetics.
Female
. Gene Expression Regulation, Neoplastic. Humans. Reproducibility of Results
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2000 May 5;275(18):13967-73
[
10788523.001
]
[Cites]
Cancer Lett. 2006 Jun 8;237(1):123-9
[
16019133.001
]
[Cites]
J Mol Endocrinol. 2000 Oct;25(2):169-93
[
11013345.001
]
[Cites]
Anal Biochem. 2001 Aug 1;295(1):17-21
[
11476540.001
]
[Cites]
Biochim Biophys Acta. 2002 Mar 19;1574(2):152-6
[
11955624.001
]
[Cites]
Science. 2002 Apr 19;296(5567):557-9
[
11964485.001
]
[Cites]
Nucleic Acids Res. 2002 May 1;30(9):e36
[
11972351.001
]
[Cites]
Exp Hematol. 2002 Jun;30(6):503-12
[
12063017.001
]
[Cites]
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
[
12184808.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2474-86
[
14562124.001
]
[Cites]
Biotechniques. 2004 Jan;36(1):84-6, 88, 90-1
[
14740490.001
]
[Cites]
J Pathol. 2004 Apr;202(4):395-402
[
15095266.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5245-50
[
15289330.001
]
[Cites]
Genome Biol. 2004;5(8):R59
[
15287981.001
]
[Cites]
J Biomol Tech. 2004 Sep;15(3):155-66
[
15331581.001
]
[Cites]
In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90
[
3114226.001
]
[Cites]
Cancer Res. 1987 Nov 1;47(21):5616-9
[
3664468.001
]
[Cites]
Biotechnology (N Y). 1992 Apr;10(4):413-7
[
1368485.001
]
[Cites]
Epithelial Cell Biol. 1992 Jul;1(3):99-104
[
1307945.001
]
[Cites]
Biotechnology (N Y). 1993 Sep;11(9):1026-30
[
7764001.001
]
[Cites]
BMC Cancer. 2006;6:49
[
16515701.001
]
[Cites]
Breast Cancer Res. 2006;8(2):R23
[
16626501.001
]
[Cites]
J Clin Oncol. 2006 Aug 10;24(23):3726-34
[
16720680.001
]
[Cites]
Biotechnol Lett. 2006 Oct;28(19):1601-13
[
16900335.001
]
[Cites]
BMC Cancer. 2006;6:216
[
16945123.001
]
[Cites]
Nat Protoc. 2006;1(3):1559-82
[
17406449.001
]
[Cites]
Biochem Biophys Res Commun. 1995 Jun 15;211(2):491-6
[
7794260.001
]
[Cites]
Oncol Rep. 1998 Mar-Apr;5(2):469-71
[
9468581.001
]
[Cites]
Nucleic Acids Res. 2004;32(21):6212-7
[
15576347.001
]
[Cites]
Lab Invest. 2005 Jan;85(1):154-9
[
15543203.001
]
[Cites]
N Engl J Med. 2004 Dec 30;351(27):2817-26
[
15591335.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Jan;6(1):69-78
[
15688068.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3315-9
[
15867229.001
]
[Cites]
Genes Immun. 2005 Jun;6(4):279-84
[
15815687.001
]
[Cites]
Anal Biochem. 2005 Jul 1;342(1):69-77
[
15958182.001
]
[Cites]
Expert Rev Mol Diagn. 2005 Jul;5(4):493-8
[
16013967.001
]
[Cites]
Adv Physiol Educ. 2005 Sep;29(3):151-9
[
16109794.001
]
[Cites]
Clin Cancer Res. 2005 Oct 15;11(20):7376-83
[
16243810.001
]
[Cites]
Eur Respir J. 2005 Dec;26(6):1002-8
[
16319328.001
]
[Cites]
Clin Cancer Res. 2005 Dec 1;11(23):8348-57
[
16322295.001
]
[Cites]
BMC Bioinformatics. 2006;7:85
[
16504059.001
]
[Cites]
Mol Aspects Med. 2006 Apr-Jun;27(2-3):95-125
[
16460794.001
]
[Cites]
Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39
[
16469371.001
]
[Cites]
J Urol. 2006 May;175(5):1915-20
[
16600798.001
]
[Cites]
Nature. 2000 Aug 17;406(6797):747-52
[
10963602.001
]
(PMID = 18042273.001).
[ISSN]
1471-2199
[Journal-full-title]
BMC molecular biology
[ISO-abbreviation]
BMC Mol. Biol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
[Other-IDs]
NLM/ PMC2211316
14.
Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W:
Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Radiology
; 2006 Jun;239(3):686-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for
breast
cancer
diagnosis
: preliminary study.
MATERIALS AND METHODS: After institutional review board approval and informed consent were obtained for this HIPAA-compliant study,
breast
MR spectroscopy was performed in patients with suspicious or biopsy-proved malignant lesions measuring 1 cm or larger at MR imaging.
Histologically, 31 (54%) of 57 lesions were malignant, and 26 (46%) were
benign
.
A choline peak was present in 34 of 57 lesions (including all cancers) and in three of 26
benign
lesions, giving MR spectroscopy a sensitivity of 100% and a specificity of 88%.
CONCLUSION: Proton MR spectroscopy was successfully incorporated into
breast
MR imaging studies for lesions measuring 1 cm or larger.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Breast
Neoplasms /
diagnosis
. Choline / analysis. Magnetic Resonance Spectroscopy
[MeSH-minor]
Adult. Aged. Biopsy.
Female
. Humans. Magnetic Resonance Imaging. Middle Aged. Predictive Value of Tests. Prospective Studies. Protons. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CHOLINE CHLORIDE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) RSNA, 2006.
(PMID = 16603660.001).
[ISSN]
0033-8419
[Journal-full-title]
Radiology
[ISO-abbreviation]
Radiology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Protons; N91BDP6H0X / Choline
15.
Diebold T, Hahn T, Solbach C, Rody A, Balzer JO, Hansmann ML, Marx A, Viana F, Peters J, Jacobi V, Kaufmann M, Vogl TJ:
Evaluation of the stereotactic 8G vacuum-assisted breast biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV).
Invest Radiol
; 2005 Jul;40(7):465-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of the stereotactic 8G vacuum-assisted
breast
biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV).
PURPOSE: The purpose of this study was to evaluate the potential of the new 8G stereotactic vacuum-assisted
breast
biopsy (ST-driver, Mammotome; Ethicon Endosurgery) in the histologic evaluation of BI-RADS IV microcalcifications.
MATERIALS AND METHODS: Fifty-eight patients with 61 mammographic BI-RADS IV microcalcifications underwent stereotactic vacuum-assisted
breast
biopsy (SVAB).
Those 2 patients showed evidence of severe bleeding into the
breast
tissue and operative revision had to be performed (3.5%).
In 7 of 12 of the initial DCIS histologies, the operative histology was also DCIS, whereas in 4 of 12, no residual malignant
tumor
was found.
Most frequent
benign
histologies were mastopathy (13), ductal hyperplasia (9), fibroadenoma (8), and sclerosing adenosis (5).
CONCLUSION: The 11-G SVAB has proven to be a perfect adjunct to the existing
breast
biopsy methods.
[MeSH-major]
Biopsy, Needle / instrumentation.
Breast
/ pathology.
Breast
Neoplasms / pathology. Mammography. Vacuum
[MeSH-minor]
Equipment Design.
Female
. Humans. Prospective Studies. Sensitivity and Specificity. Time Factors
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15973139.001).
[ISSN]
0020-9996
[Journal-full-title]
Investigative radiology
[ISO-abbreviation]
Invest Radiol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
16.
Pasha Q, Malik SA, Shaheen N, Shah MH:
Comparison of trace elements in the scalp hair of malignant and benign breast lesions versus healthy women.
Biol Trace Elem Res
; 2010 May;134(2):160-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of trace elements in the scalp hair of malignant and
benign breast
lesions versus healthy women.
Trace elements including Al, Ca, Cd, Co, Cr, Cu, Fe, K, Mg, Mn, Na, Ni, Pb, Sb, Sr, and Zn were analyzed in the scalp hair samples of women with malignant
breast
lesions, women with
benign breast
lesions, and healthy donors using atomic absorption spectrophotometric method.
In the scalp hair of malignant-
tumor
patients, the highest average concentration was shown by Ca (1,187 microg/g), followed by Na (655 microg/g), Mg (478 microg/g), Zn (391 microg/g), Sr (152 microg/g), Fe (114 microg/g), and K (89.8), while in the case of
benign
-
tumor
patients, the average estimated element levels were 1,522, 1,093, 572, 457, 217, 80.4, and 74.7 microg/g, respectively.
Average levels of Na, Sr, K, Cd, Co, Pb, Mg, Ca, Zn, Ni, Sb, and Mn were revealed to be significantly higher in the hair of malignant and
benign
patients compared to the healthy women; however, Fe, Cu, Al, and Cr were not significantly different in the scalp hair of the three groups.
The quartile distributions of Ca, Cd, Co, Cr, K, Mg, Mn, Na, Ni, Pb, Sb, and Sr revealed maximum spread in the scalp hair of malignant and
benign
groups; nevertheless, Al, Cu, Fe, and Zn exhibited almost comparable quartile levels in the three groups.
Strong correlation coefficients were found between Fe and Cd, Al and Na, Mn and Sr, Co and Cr, Cd and Cr, Pb and K, Pb and Mn, Cu and Na, and Al and Fe in the scalp hair of malignant-
tumor
patients, while Fe and K, Cd and Co, Na and Co, and Cr and Pb showed strong correlations in the scalp hair of
benign
-
tumor
patients, both of which were significantly different compared with the healthy subjects.
Multivariate cluster analysis also revealed divergent clustering of the elements in the scalp hair of malignant and
benign
patients in comparison with the healthy women.
[MeSH-minor]
Adult.
Female
. Humans. Middle Aged. Multivariate Analysis. Women's Health
MedlinePlus Health Information.
consumer health - Brain Tumors
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19644659.001).
[ISSN]
1559-0720
[Journal-full-title]
Biological trace element research
[ISO-abbreviation]
Biol Trace Elem Res
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Trace Elements
17.
Wen W, Ren Z, Shu XO, Cai Q, Ye C, Gao YT, Zheng W:
Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk.
Cancer Epidemiol Biomarkers Prev
; 2007 May;16(5):917-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in
breast
tissue and their associations with
breast
cancer risk.
Cytochrome P450 1B1 (CYP1B1) and catechol-O-methyltransferase (COMT) are important estrogen-metabolizing enzymes that may affect
breast
cancer risk.
Few studies have directly measured the expression of CYP1B1 and COMT genes in
breast
tissue samples.
The subjects in this study were a subgroup of participants of the Shanghai
Breast
Cancer Study including 64 patients diagnosed with
breast
cancer and 68 patients diagnosed with
benign breast
diseases (BBD) who provided samples of
tumor
tissue and adjacent nontumor tissue to the study.
We compared CYP1B1 and COMT mRNA expression in
tumor
tissue and adjacent nontumor tissue in both
breast
cancer patients and BBD patients.
High levels of CYP1B1 expression and low levels of COMT expression in adjacent nontumor tissue were associated with a significantly increased
breast
cancer risk in a nonlinear manner.
These results support the hypothesis that the formation and accumulation of catechol estrogens in
breast
tissue through increased CYP1B1 expression and reduced COMT expression may play a significant role in
breast
cancer risk.
[MeSH-major]
Aryl Hydrocarbon Hydroxylases / genetics.
Breast
/ enzymology.
Breast
Neoplasms / genetics. Catechol O-Methyltransferase / genetics. Gene Expression Regulation, Enzymologic / physiology
[MeSH-minor]
Adult.
Breast
Diseases / enzymology.
Breast
Diseases / epidemiology.
Breast
Diseases / genetics. Case-Control Studies. China / epidemiology. Confidence Intervals. Cytochrome P-450 CYP1B1. Estrogens / metabolism.
Female
. Genotype. Humans. Logistic Models. Middle Aged. Odds Ratio. Risk Factors
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17507616.001).
[ISSN]
1055-9965
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01CA64277; United States / NCI NIH HHS / CA / R01CA90899
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Estrogens; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 2.1.1.6 / Catechol O-Methyltransferase
18.
Fu XG, Li F, Wang ZH, Hu WH, Mikai RM, Jiang JF, Li HA, Li L, Zheng YQ, Shen XH, Pang LJ:
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
; 2007 Jun;24(3):341-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Analysis of the mutation of BRCA1 gene in 70 Uigur women
breast
cancer patients in Xinjiang].
OBJECTIVE: To analyze the mutations of BRCA1 in
breast
cancer patients of Uigur women in Xinjiang.
METHODS: By using single strand conformation polymorphism (SSCP) and DNA sequencing, BRCA1 mutations were detected in 70 Uigur women
breast
cancer cases and 32 cases of
benign breast
diseases and non-
tumor
tissue next to carcinoma. RESULTS:.
(1) 12 new loci of BRCA1 gene mutation were detected firstly in 70 Uigur women
breast
cancer patients. (2)The frequency of BRCA1 mutation in 70 Uigur women
breast
cancer cases was 12.86% (9/70).
The frequency of BRCA1 mutation in Uigur women early onset
breast
cancer was 31.82% (7/22), which was significantly higher than that in late onset group (2/48, 4.16%) (chi(2) =10.295, P<0.01). (3) There were BRCA1 gene polymorphisms in 9 of 70 Uigur women
breast
cancer patients.
The loci of polymorphisms in 8 of 9 cases were 3232A>G. (4)In the research group two cases of bilateral
breast
cancer were found with BRCA1 gene mutation.
CONCLUSION: The mutation of BRCA1 gene may be related to Uigur women
breast
cancer and bilateral
breast
cancer.
[MeSH-major]
Asian Continental Ancestry Group / genetics.
Breast
Neoplasms / genetics. Ethnic Groups / genetics. Genes, BRCA1. Mutation
[MeSH-minor]
Adult. Aged. China.
Female
. Humans. Introns / genetics. Middle Aged. Polymorphism, Single-Stranded Conformational
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17557253.001).
[ISSN]
1003-9406
[Journal-full-title]
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
[ISO-abbreviation]
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
19.
Ławicki S, Szmitkowski M, Wojtukiewicz M:
The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Clin Chim Acta
; 2006 Sep;371(1-2):112-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The pretreatment plasma level and diagnostic utility of M-CSF in
benign breast tumor
and
breast
cancer patients.
BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted
tumor
marker (antigen CA 15-3) in
breast
cancer patients in relation to the group with
benign breast tumor
and to the healthy controls.
Additionally, we compared the plasma level of M-CSF with the
tumor
stage of
breast
cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
METHODS: M-CSF and CA 15-3 were measured in 80 patients with
breast
cancer, 17 patients with
benign breast tumor
and in 30 healthy subjects.
RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the
breast
cancer patients comparing to the group with
benign breast tumor
and to the control group.
The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced
tumor
stage.
We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced
breast tumor
stage.
CONCLUSIONS: These results suggest that M-CSF is the good candidate for a
breast
cancer
tumor
marker.
[MeSH-major]
Biomarkers,
Tumor
/ blood.
Breast
Neoplasms / blood.
Breast
Neoplasms /
diagnosis
. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
[MeSH-minor]
Adult. Aged. Enzyme-Linked Immunosorbent Assay.
Female
. Humans. Middle Aged.
Neoplasm
Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16631152.001).
[ISSN]
0009-8981
[Journal-full-title]
Clinica chimica acta; international journal of clinical chemistry
[ISO-abbreviation]
Clin. Chim. Acta
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
20.
Destounis SV, Vogt C, Arieno AL, Morgan RC:
Difficult management of a rapidly growing benign phyllodes tumor in a 49-year-old woman.
J Ultrasound Med
; 2010 Jul;29(7):1125-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Difficult management of a rapidly growing
benign
phyllodes
tumor
in a 49-year-old woman.
[MeSH-major]
Breast
Neoplasms. Phyllodes
Tumor
[MeSH-minor]
Female
. Humans. Middle Aged.
Neoplasm
Recurrence, Local / surgery
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20587436.001).
[ISSN]
1550-9613
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
21.
Djordjevic B, Hanna WM:
Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
Mod Pathol
; 2008 Oct;21(10):1238-45
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of c-kit in fibroepithelial lesions of the
breast
is a mast cell phenomenon.
The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the
breast
has been the subject of recent investigations.
We examined stromal c-kit expression by immunohistochemistry in 68 cases comprising fibroadenomas, fibroadenomas with cellular stroma, and
benign
, borderline, and malignant phyllodes tumors.
However, when toluidine blue and tryptase staining was performed, the staining pattern matched that of c-kit in the number of cells and their distribution, thereby confirming the presence of mast cells and
excluding
any appreciable level of true stromal c-kit staining.
One borderline and one malignant phyllodes
tumor
showed a diffuse weak stromal signal, which could not be accounted for by toluidine blue and tryptase.
Our findings indicate that c-kit is an unlikely player in the pathogenesis of fibroepithelial lesions of the
breast
.
C-kit, therefore, has neither a diagnostic nor a prognostic role in phyllodes tumors, and there is no rationale for the treatment of recurrent of malignant phyllodes
tumor
patients with tyrosine kinase inhibitors.
[MeSH-major]
Breast
Neoplasms / metabolism. Mast Cells / metabolism. Phyllodes
Tumor
/ metabolism. Proto-Oncogene Proteins c-kit / metabolism
[MeSH-minor]
Biomarkers,
Tumor
/ metabolism. DNA Mutational Analysis. DNA,
Neoplasm
/ analysis.
Female
. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Mastectomy. Stromal Cells / metabolism. Stromal Cells / pathology
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18500266.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
22.
Prasad SN, Houserkova D, Svach I, Zlamalova N, Kucerova L, Cwiertka K:
Pseudoangiomatous stromal hyperplasia of breast: a case report.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 2008 Jun;152(1):117-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pseudoangiomatous stromal hyperplasia of
breast
: a case report.
MATERIALS AND METHODS: A woman 39 years of age with a history of mass in her right
breast
of 3 months duration was subjected to a routine examination of the mass using MG & USG.
RESULTS: Bilateral mammogram views revealed in the patient's right
breast
a huge well-bordered tumour of lobulated contour without halo sign.
Sonography revealed a big well-demarcated tumour in the central part of the right
breast
which was cystic and lobulated in shape.
MRI under a
breast
array coil revealed a mass of 85 x 75 x 35mm in the right
breast
.
Finally, based on the clinical, radiological and histological report the mass was diagnosed as
benign
and despite the massive size of the mass, tumour excision alone was done and not mastectomy.
The right
breast
after the huge tumour excision was almost normal in size compared to the left.
CONCLUSION: PASH should be included in the differential
diagnosis of
a circumscribed or partially circumscribed mass, especially in the pre-menopausal
female
population.
These
benign
masses often grow over time and can recur locally.
Radiological
diagnosis of
PASH is usually done by MG and USG followed by core cut biopsy for histological analysis.
However great the mass is, excision only of the
tumor
mass is recommended and not mastectomy.
[MeSH-major]
Breast
Diseases /
diagnosis
[MeSH-minor]
Adult.
Breast
/ pathology.
Female
. Humans. Hyperplasia. Magnetic Resonance Imaging. Mammography. Ultrasonography, Mammary
Genetic Alliance.
consumer health - Pseudoangiomatous stromal hyperplasia
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18795085.001).
[ISSN]
1213-8118
[Journal-full-title]
Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
[ISO-abbreviation]
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Czech Republic
23.
Garijo MF, Val-Bernal JF, Vega A, Val D:
Postoperative spindle cell nodule of the breast: Pseudosarcomatous myofibroblastic proliferation following endo-surgery.
Pathol Int
; 2008 Dec;58(12):787-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Postoperative spindle cell nodule of the
breast
: Pseudosarcomatous myofibroblastic proliferation following endo-surgery.
Presented herein is the case of a 52-year-old woman who developed a 7 mm mammary nodular lesion 66 days after removal of an area of columnar cell hyperplasia involving cellular and architectural atypia, performed with the Mammotome
Breast
Biopsy System.
PSCN is a reactive,
benign
myofibroblastic proliferation.
Differential
diagnosis
includes
benign
and malignant spindle cell lesions of the
breast
.
Recognition of this reactive lesion will avoid overdiagnosis of spindle cell malignant
tumor
.
[MeSH-major]
Biopsy, Needle / adverse effects.
Breast
Diseases / etiology. Fibroblasts / pathology. Postoperative Complications
[MeSH-minor]
Female
. Humans. Mammography. Middle Aged. Postoperative Period. Sarcoma / pathology
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19067854.001).
[ISSN]
1440-1827
[Journal-full-title]
Pathology international
[ISO-abbreviation]
Pathol. Int.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
24.
Koirala K, Shrestha ML, Chalise PR, Shrestha BB, Shrestha R:
Leiomyoma of breast: a report of rare case.
Nepal Med Coll J
; 2008 Sep;10(3):207-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leiomyoma of
breast
: a report of rare case.
Leiomyoma is a
benign
smooth muscle
neoplasm
.
Leiomyoma of
breast
is a rare
benign
non epithelial
tumor
.
Most leiomyomas in the
breast
are found in the subareolar region.
Here we report a case of 52 years old lady who presented to us with a painless right sided
breast
lump.
Excisional biopsy revealed a growth pattern of interlacing fascicles of smooth-muscle cells consistent with leiomyoma of
breast
.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Leiomyoma /
diagnosis
[MeSH-minor]
Female
. Humans. Middle Aged
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19253869.001).
[Journal-full-title]
Nepal Medical College journal : NMCJ
[ISO-abbreviation]
Nepal Med Coll J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Nepal
25.
McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, Dupont WD, Page DL:
Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy.
Cancer
; 2006 Sep 15;107(6):1227-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial
breast
biopsy.
BACKGROUND: Atypical lobular hyperplasia (ALH) is associated with a 10% to 20% risk of subsequent invasive carcinoma, primarily in the ipsilateral
breast
.
Nottingham grading, special
tumor
types, and survival after invasive cancer
diagnosis
were analyzed consistently for the first time.
METHODS: A longitudinal follow-up study of 252 women who underwent 261
benign
surgical biopsies between 1950 and 1985 with a
diagnosis of
ALH was undertaken.
Subsequent invasive
breast
cancers were graded and subtyped based on histologic features and the cohort assessed for cancer survival.
RESULTS: Forty-eight (19%) women developed invasive
breast
cancer at an average of 15.1 years.
By an average of 13 years after invasive cancer
diagnosis
, 2 (10%) of 20 women with special type and variant tumors had died of
breast
cancer, compared with 9 (32%) of 28 women with tumors of no special type (24 tumors) or an unknown type (4 tumors).
Only 1 patient with a
tumor
of low Nottingham grade died of
breast
cancer.
CONCLUSIONS: ALH is a nonobligate cancer precursor associated with a moderate risk of
breast
cancer and predicts that later cancers are associated with overall excellent survival.
Treatment of women with ALH should be influenced by their modest elevation in
breast
cancer risk and the good prognosis and low mortality of many of these cancers.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms / pathology. Carcinoma, Lobular / pathology
[MeSH-minor]
Biopsy.
Female
. Follow-Up Studies. Humans. Hyperplasia. Longitudinal Studies. Middle Aged. Prognosis. Survival Analysis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 American Cancer Society.
(PMID = 16894523.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / R01 CA-31698; United States / NCI NIH HHS / CA / R01 CA-50468; United States / NCI NIH HHS / CA / R01 CA-62212
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
26.
Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F:
Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study.
World J Gastroenterol
; 2007 Dec 21;13(47):6356-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: One hundred patients with histologically confirmed malignant or
benign
hepatic
tumor
(maximum size 5 cm) were analyzed.
The cut-off of the gray value differences between
tumor
and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.
RESULTS: One hundred patients with 59 malignant (43 colon, 5
breast
, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41
benign
(15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.
The late venous phase proved to be the most sensitive for classification of the
tumor
type.
Of the 41
benign
tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Feasibility Studies.
Female
. Germany. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Angiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prospective Studies. ROC Curve. Reproducibility of Results. Sensitivity and Specificity. Time Factors. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Hazardous Substances Data Bank.
SULFUR HEXAFLUORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18081224.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study
[Publication-country]
China
[Chemical-registry-number]
0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
[Other-IDs]
NLM/ PMC4205454
27.
Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, Karim RZ, Lee CS:
Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours.
J Clin Pathol
; 2005 Feb;58(2):185-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND/AIMS: CD10 (CALLA) has recently been reported to be expressed in spindle cell
neoplasia
, and has been used to differentiate endometrial stromal sarcoma from leiomyoma and leiomyosarcoma.
In the
breast
, myoepithelial cells express CD10, but there are few studies of the expression of CD10 in mammary fibroepithelial lesions.
METHODS: Stromal CD10 expression was studied in 181 mammary phyllodes tumours (102
benign
, 51 borderline malignant, and 28 frankly malignant) and 33 fibroadenomas using immunohistochemistry, to evaluate whether differences in expression correlated with the degree of malignancy.
Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102
benign
phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours.
Stromal CD10 expression had a high specificity (95%) for differentiating between
benign
lesions (fibroadenomas and
benign
phyllodes tumours) and malignant (borderline and frankly malignant) phyllodes tumours.
[MeSH-major]
Breast
Neoplasms / immunology. Fibroadenoma / immunology. Neprilysin / immunology. Phyllodes
Tumor
/ immunology. Stromal Cells / immunology
[MeSH-minor]
Adolescent. Adult. Aged.
Female
. Humans. Immunohistochemistry / methods. Middle Aged
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cytopathology. 1997 Jun;8(3):177-87
[
9202893.001
]
[Cites]
Mod Pathol. 2002 Apr;15(4):397-405
[
11950913.001
]
[Cites]
J Gastroenterol. 1996 Feb;31(1):12-7
[
8808423.001
]
[Cites]
J Pathol. 1999 Oct;189(2):169-75
[
10547570.001
]
[Cites]
Am J Surg Pathol. 2000 Feb;24(2):203-10
[
10680888.001
]
[Cites]
Am J Clin Pathol. 2000 Mar;113(3):374-82
[
10705818.001
]
[Cites]
Virchows Arch. 2002 Jun;440(6):589-93
[
12070597.001
]
[Cites]
Mod Pathol. 2002 Jul;15(7):734-40
[
12118111.001
]
[Cites]
Hum Pathol. 2002 Aug;33(8):806-11
[
12203213.001
]
[Cites]
Mod Pathol. 2002 Sep;15(9):923-30
[
12218209.001
]
[Cites]
Mod Pathol. 2003 Oct;16(10):1007-13
[
14559983.001
]
[Cites]
Gynecol Oncol. 2004 Jan;92(1):71-9
[
14751141.001
]
[Cites]
Mod Pathol. 2004 Jun;17(6):646-52
[
15073596.001
]
[Cites]
Mod Pathol. 2004 Jul;17(7):827-31
[
15044924.001
]
[Cites]
Clin Immunol Immunopathol. 1975 May;4(1):67-84
[
1092499.001
]
[Cites]
Eur J Immunol. 1982 Apr;12(4):354-7
[
6954072.001
]
[Cites]
Radiology. 1983 Feb;146(2):481-6
[
6294737.001
]
[Cites]
Blood. 1983 Apr;61(4):628-39
[
6338969.001
]
[Cites]
Adv Cancer Res. 1984;42:67-147
[
6395656.001
]
[Cites]
Blood. 1986 Feb;67(2):474-8
[
3080041.001
]
[Cites]
Am J Med. 1986 Jun;80(6):1249-52
[
2942034.001
]
[Cites]
J Immunol. 1987 Jul 1;139(1):313-8
[
2953817.001
]
[Cites]
Mol Cell Probes. 1989 Mar;3(1):39-44
[
2525226.001
]
[Cites]
Surg Gynecol Obstet. 1990 Mar;170(3):193-6
[
2154867.001
]
[Cites]
J Surg Oncol. 1990 Sep;45(1):46-51
[
2166186.001
]
[Cites]
Am J Pathol. 1990 Oct;137(4):895-905
[
1699423.001
]
[Cites]
Pathol Res Pract. 1990 Aug;186(4):427-38
[
2174150.001
]
[Cites]
Cancer. 1991 Nov 1;68(9):2017-22
[
1655234.001
]
[Cites]
Hum Reprod. 1992 Oct;7(9):1326-8
[
1362204.001
]
[Cites]
Am J Surg. 1993 Mar;165(3):376-9
[
8383473.001
]
[Cites]
Lab Invest. 1994 Jan;70(1):107-13
[
8302012.001
]
[Cites]
Cancer. 1996 Mar 1;77(5):910-6
[
8608483.001
]
[Cites]
Anticancer Res. 2000 Sep- Oct;20(5B):3539-44
[
11131659.001
]
[Cites]
Ultrastruct Pathol. 2000 Nov-Dec;24(6):371-81
[
11206334.001
]
[Cites]
Breast Cancer Res Treat. 2001 Jan;65(1):77-85
[
11245343.001
]
[Cites]
Mod Pathol. 2001 May;14(5):465-71
[
11353058.001
]
[Cites]
Histopathology. 2001 Jun;38(6):567-70
[
11422501.001
]
[Cites]
Histopathology. 2001 Sep;39(3):273-8
[
11532038.001
]
[Cites]
Am J Pathol. 2001 Oct;159(4):1415-21
[
11583969.001
]
[Cites]
Int J Gynecol Pathol. 2002 Jan;21(1):41-7
[
11781522.001
]
[Cites]
Am J Surg Pathol. 2002 Apr;26(4):403-12
[
11914617.001
]
[Cites]
Histopathology. 1999 Jun;34(6):491-6
[
10383692.001
]
(PMID = 15677540.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
EC 3.4.24.11 / Neprilysin
[Other-IDs]
NLM/ PMC1770579
28.
Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N:
Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
Clin Cancer Res
; 2006 Sep 1;12(17):5158-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of cripto-1 as a novel serologic marker for
breast
and colon cancer.
We evaluated whether CR-1 is present in the plasma of patients with
breast
and colon cancer, and if it can represent a new biomarker for these malignancies.
EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with
breast
cancer, 33 patients with colon carcinoma, and 21 patients with
benign breast
lesions.
A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with
breast
carcinoma (2.97+/-1.48 ng/mL; P<0.001).
Although moderate levels of plasma CR-1 were found in women with
benign
lesions of the
breast
(1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with
breast
cancer (P<0.001).
Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or
breast tumor
tissues.
CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of
breast
and colon carcinomas.
[MeSH-major]
Biomarkers,
Tumor
/ blood.
Breast
Neoplasms / blood.
Breast
Neoplasms /
diagnosis
. Colonic Neoplasms / blood. Colonic Neoplasms /
diagnosis
. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood.
Neoplasm
Proteins / blood
[MeSH-minor]
Animals. Enzyme-Linked Immunosorbent Assay / methods.
Female
. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins. Male. Mice. Mice, Transgenic.
Neoplasm
Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16951234.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
29.
Fine RE, Staren ED:
Percutaneous radiofrequency-assisted excision of fibroadenomas.
Am J Surg
; 2006 Oct;192(4):545-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
INTRODUCTION: Fibroadenomas are a frequently encountered
benign tumor
that will occur in approximately 10% of women during their lifetime.
METHODS: Between April 2004 and November 2005, 100 patients underwent ultrasound- or stereotactic-guided, radiofrequency-assisted intact percutaneous excision of 106 diagnosed fibroadenomas of the
breast
.
CONCLUSIONS: Percutaneous ultrasound- or stereotactic-guided, radiofrequency-assisted excision of fibroadenomas of the
breast
may be performed in an ambulatory setting under local anesthesia.
[MeSH-major]
Breast
Neoplasms / surgery. Electrosurgery / instrumentation. Fibroadenoma / surgery
[MeSH-minor]
Adolescent. Adult. Aged. Ambulatory Surgical Procedures. Biopsy / instrumentation. Equipment Design.
Female
. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Treatment Outcome
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16978972.001).
[ISSN]
0002-9610
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
30.
Su KL, Xu HB, Hu ZJ, He JL, Yang OO, Hu WH:
[Vacuum-assisted biopsy and wire localization for the diagnosis of non-palpable breast lesions].
Zhonghua Zhong Liu Za Zhi
; 2010 Jun;32(6):472-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Vacuum-assisted biopsy and wire localization for
the diagnosis
of non-palpable
breast
lesions].
OBJECTIVE: To compare the effectiveness and accuracy of the use of vacuum-assisted biopsy (VAB) versus wire localization (WL) in
the diagnosis
of non-palpable
breast
lesions (NPBL).
The patients were requested to score the cosmetic appearance of their
breast
after operation, and a numerical rating scale was used to measure pain on the first postoperative day.
CONCLUSION: VAB is highly reliable and may avoid diagnostic open surgery in the majority of patients with
benign
lesions.
However, because of the underestimation of histologic
diagnosis
and
tumor
margin involvement, VAB can not be used to completely substitute wire localization.
[MeSH-major]
Biopsy, Needle.
Breast
Neoplasms /
diagnosis
. Carcinoma in Situ /
diagnosis
. Carcinoma, Ductal,
Breast
/
diagnosis
. Stereotaxic Techniques / instrumentation
[MeSH-minor]
Adult.
Breast
/ pathology. Diagnostic Errors.
Female
. Fibroadenoma /
diagnosis
. Fibroadenoma / pathology. Humans. Hyperplasia. Middle Aged. Precancerous Conditions /
diagnosis
. Precancerous Conditions / pathology. Vacuum
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20819495.001).
[ISSN]
0253-3766
[Journal-full-title]
Zhonghua zhong liu za zhi [Chinese journal of oncology]
[ISO-abbreviation]
Zhonghua Zhong Liu Za Zhi
[Language]
chi
[Publication-type]
Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
[Publication-country]
China
31.
Ye C, Cai Q, Dai Q, Shu XO, Shin A, Gao YT, Zheng W:
Expression patterns of the ATM gene in mammary tissues and their associations with breast cancer survival.
Cancer
; 2007 May 1;109(9):1729-35
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression patterns of the ATM gene in mammary tissues and their associations with
breast
cancer survival.
However, to date, no study has directly investigated the association between ATM gene expression and
breast
cancer survival.
METHODS: ATM gene expression levels were evaluated in
tumor
and adjacent normal tissue from patients diagnosed with primary
breast
cancer or BBD using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) assays.
Cox regression models were used to evaluate the association of ATM gene expression and survival in a cohort of 471
breast
cancer patients.
RESULTS: In
breast
cancer cases, ATM expression in cancer tissues was decreased by approximately 50% compared with adjacent normal tissues from the same patients.
In BBD cases, the expression level of the ATM gene was similar in
benign tumor
tissue and adjacent normal tissues.
CONCLUSIONS: The ATM gene expression was down-regulated in
breast
cancer tissues and a high ATM gene expression level in
breast
cancer tissue was associated with a favorable prognosis.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Breast
Neoplasms / genetics.
Breast
Neoplasms / mortality. Cell Cycle Proteins / biosynthesis. DNA-Binding Proteins / biosynthesis. Mammary Glands, Human / metabolism. Protein-Serine-Threonine Kinases / biosynthesis.
Tumor
Suppressor Proteins / biosynthesis
[MeSH-minor]
Adult. Ataxia Telangiectasia Mutated Proteins.
Female
. Gene Expression. Gene Expression Profiling. Humans. Kaplan-Meier Estimate. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2007 American Cancer Society
(PMID = 17366603.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA64277; United States / NCI NIH HHS / CA / R01 CA90899
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
32.
Sailors JL, French SW:
The unique simultaneous occurrence of granular cell tumor, gastrointestinal stromal tumor, and gastric adenocarcinoma.
Arch Pathol Lab Med
; 2005 May;129(5):e121-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The unique simultaneous occurrence of granular cell
tumor
, gastrointestinal stromal
tumor
, and gastric adenocarcinoma.
Granular cell tumors are generally
benign
oncocytoid lesions of schwannian origin that are often incidental findings in many locations.
This report is prompted by the simultaneous appearance of 2 granular cell tumors, a gastrointestinal stromal
tumor
, and a gastric adenocarcinoma in a 65-year-old woman with a history of
breast
carcinoma and granular cell
tumor
.
[MeSH-major]
Adenocarcinoma / pathology. Gastrointestinal Neoplasms / pathology. Granular Cell
Tumor
/ pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology. Stromal Cells / pathology
[MeSH-minor]
Aged. Biomarkers,
Tumor
/ analysis.
Female
. Humans. Immunohistochemistry
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15859656.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
33.
Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF:
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
Med Clin (Barc)
; 2009 Oct 3;133(12):449-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pleural fluid mesothelin for the differential
diagnosis of
exudative pleural effusions.
BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive
tumor
that can be difficult to diagnose, resulting in a delayed
diagnosis
in some cases.
Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in
the diagnosis
of MM.
PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had
benign
pleural effusion (8 infectious disease and 13 idiopathic effusion).
RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with
benign
effusion (P=0.02).
CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in
the diagnosis
of patients presenting with pleural effusion.
[MeSH-major]
Adenocarcinoma /
diagnosis
.
Breast
Neoplasms /
diagnosis
. Carcinoma, Small Cell /
diagnosis
. Hematologic Neoplasms /
diagnosis
. Lung Neoplasms /
diagnosis
. Membrane Glycoproteins / analysis. Mesothelioma /
diagnosis
. Ovarian Neoplasms /
diagnosis
. Pancreatic Neoplasms /
diagnosis
. Pleural Effusion /
diagnosis
. Pleural Effusion, Malignant /
diagnosis
[MeSH-minor]
Biomarkers.
Diagnosis
, Differential.
Female
. GPI-Linked Proteins. Humans. Male. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Mesothelioma
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19783262.001).
[ISSN]
0025-7753
[Journal-full-title]
Medicina clínica
[ISO-abbreviation]
Med Clin (Barc)
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Biomarkers; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
34.
Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, Jin CG, Wang XC:
Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Int J Biol Markers
; 2010 Apr-Jun;25(2):59-68
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating
tumor
cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early
breast
cancer.
AIMS: To investigate the diagnostic, predictive, and prognostic value of the detection of circulating
tumor
cells (CTCs) using a three-marker (CK19, hMAM and CEA) RT-PCR assay in patients with early
breast
cancer.
PATIENTS AND METHODS: Peripheral blood was obtained from 50 patients with early-stage
breast
cancer before any systemic adjuvant therapy and analyzed for the presence of CK-19, hMAM and CEA mRNA-positive CTCs using an RT-PCR assay.
The specificity of the primers used was evaluated in 20 healthy individuals, 24 patients with
benign breast
disease, and 30 patients with metastatic
breast
cancer.
RESULTS: The detection rate of three-marker-positive CTCs in the blood of patients with early
breast
cancer was 54.0%, significantly higher than in patients with
benign breast
disease and healthy blood donors (p=0.002 and p=0.000, respectively).
For early
breast
cancer, correlation analysis between detection of three-marker-positive CTCs and clinicopathological characteristics indicated that detection of threemarker-positive CTCs was significantly correlated with elevated serum CEA levels (p=0.001).
Detection of three-marker-positive CTCs was associated with relapse and might have important predictive and prognostic implications in early
breast
cancer.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Carcinoembryonic Antigen / genetics. Carcinoma /
diagnosis
. Keratin-19 / genetics.
Neoplasm
Proteins / genetics. Neoplastic Cells, Circulating / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
[MeSH-minor]
Adult. Aged. Biomarkers,
Tumor
/ analysis. Biomarkers,
Tumor
/ blood. Biomarkers,
Tumor
/ genetics. Biomarkers,
Tumor
/ metabolism. Cell Line,
Tumor
. Disease Progression. Early Detection of Cancer / methods.
Female
. Humans. Mammaglobin A. Middle Aged. Prognosis. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20586026.001).
[ISSN]
0393-6155
[Journal-full-title]
The International journal of biological markers
[ISO-abbreviation]
Int. J. Biol. Markers
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
35.
Elayat G, Selim AG, Wells CA:
Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Ann Diagn Pathol
; 2010 Feb;14(1):1-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell turnover in apocrine metaplasia and apocrine adenosis of the
breast
.
Apocrine metaplasia (APM) is a common finding in the
breast
of postmenopausal women and is seen in a broad spectrum of lesions ranging from microscopic cysts to invasive apocrine carcinoma.
Apocrine metaplasia within sclerosing adenosis is known as apocrine adenosis (AA) and is considered a
benign
lesion of the
breast
.
The results showed that all cases studied by immunohistochemistry were positive for the expression of Bak, Mcl-1, Bcl-x, and Bcl-x(L) showing a pattern of staining similar to that seen in the normal
breast
epithelium.
There was no statistical significance between the AI of these 2 groups and that of the normal
breast
epithelium (0.3%).
There was no statistical significance between the AI of these 2 groups and that of the normal
breast
epithelium (0.3%).
[MeSH-major]
Apocrine Glands / pathology.
Breast
/ pathology.
Breast
Neoplasms / pathology. Fibrocystic
Breast
Disease / pathology. Precancerous Conditions / pathology
[MeSH-minor]
Apoptosis. Biomarkers,
Tumor
/ metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Division. Epithelium / metabolism. Epithelium / pathology.
Female
. Humans. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Metaplasia. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomerase / metabolism. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-X Protein / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2010 Elsevier Inc. All rights reserved.
(PMID = 20123450.001).
[ISSN]
1532-8198
[Journal-full-title]
Annals of diagnostic pathology
[ISO-abbreviation]
Ann Diagn Pathol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / BAK1 protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-X Protein; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
36.
Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S:
Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
Int J Oncol
; 2005 Oct;27(4):1005-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of extracellular matrix and apoptotic markers between
benign
lesions and carcinomas in human
breast
.
The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal
breast
tissue and
benign
and malignant
breast
tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2,
tumor
size, lymph node status and grading.
Seventy-three
breast
tissue samples were examined.
The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on
tumor
proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.
[MeSH-major]
Apoptosis. Biomarkers,
Tumor
.
Breast
Diseases / metabolism.
Breast
Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic
[MeSH-minor]
Cell Differentiation. Cell Line,
Tumor
. Cell Proliferation. Cytoplasm / metabolism.
Female
. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism.
Neoplasm
Metastasis.
Neoplasm
Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16142317.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2
37.
Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM:
Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
Am J Physiol Endocrinol Metab
; 2009 Nov;297(5):E1089-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A
benign breast
epithelial cells.
The effects of progesterone on
breast
epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in
breast
epithelial cells lacking nuclear receptors.
This study examined possible nongenomic effects of progesterone in
breast
epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.
Our study demonstrates a nongenomic action of progesterone on
benign breast
epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
PROGESTERONE
.
Hazardous Substances Data Bank.
CYCLOHEXIMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Mol Cell Cardiol. 1995 Oct;27(10):2167-76
[
8576933.001
]
[Cites]
Genes Dev. 1995 Sep 15;9(18):2266-78
[
7557380.001
]
[Cites]
Breast Cancer Res Treat. 1997 Sep;45(2):121-33
[
9342437.001
]
[Cites]
Exp Cell Res. 1997 Oct 10;236(1):223-30
[
9344602.001
]
[Cites]
Cancer Res. 1997 Nov 15;57(22):4987-91
[
9371488.001
]
[Cites]
J Biol Chem. 1999 Apr 30;274(18):12567-75
[
10212235.001
]
[Cites]
Breast Cancer Res Treat. 1999 Feb;53(3):217-27
[
10369068.001
]
[Cites]
J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88
[
16154741.001
]
[Cites]
Dev Cell. 2005 Dec;9(6):843-54
[
16326395.001
]
[Cites]
J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8
[
16413775.001
]
[Cites]
J Biol Chem. 2006 Mar 3;281(9):5837-44
[
16407197.001
]
[Cites]
J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27
[
16466914.001
]
[Cites]
Carcinogenesis. 2006 May;27(5):925-35
[
16361271.001
]
[Cites]
Apoptosis. 2006 Apr;11(4):473-85
[
16532373.001
]
[Cites]
Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17
[
16829228.001
]
[Cites]
Maturitas. 2006 Jul 20;54(4):327-34
[
16806749.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83
[
16460873.001
]
[Cites]
Mol Endocrinol. 2006 Dec;20(12):3146-64
[
16959873.001
]
[Cites]
FEBS J. 2007 Mar;274(6):1393-418
[
17302740.001
]
[Cites]
Endocrinology. 2007 Jun;148(6):2723-36
[
17332059.001
]
[Cites]
Cell Prolif. 2007 Oct;40(5):721-40
[
17877612.001
]
[Cites]
Biol Chem. 2007 Oct;388(10):1113-9
[
17937626.001
]
[Cites]
Mitochondrion. 2007 Dec;7(6):399-401
[
17881297.001
]
[Cites]
Methods. 2008 Mar;44(3):222-8
[
18314052.001
]
[Cites]
Breast. 2008 Apr;17(2):172-9
[
17928227.001
]
[Cites]
Cell Res. 2009 Jan;19(1):140-8
[
19079362.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65
[
10599719.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):867-72
[
10706096.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):936-43
[
10706108.001
]
[Cites]
Oncology. 2000;59 Suppl 1:39-44
[
11096355.001
]
[Cites]
Mol Endocrinol. 2001 Feb;15(2):255-70
[
11158332.001
]
[Cites]
Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103
[
11420134.001
]
[Cites]
Endocrinology. 2002 Aug;143(8):3071-82
[
12130573.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105
[
12160089.001
]
[Cites]
Nat Rev Cancer. 2002 Jun;2(6):420-30
[
12189384.001
]
[Cites]
Breast Cancer Res. 2002;4(5):187-90
[
12223122.001
]
[Cites]
Mol Endocrinol. 2003 Jan;17(1):117-27
[
12511611.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6
[
12574519.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42
[
12601167.001
]
[Cites]
Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63
[
12644308.001
]
[Cites]
J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30
[
12650698.001
]
[Cites]
Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7
[
15282185.001
]
[Cites]
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5
[
4528490.001
]
[Cites]
Nature. 1975 Feb 27;253(5494):746-7
[
1113869.001
]
[Cites]
Cancer Res. 1978 Aug;38(8):2434-7
[
667841.001
]
[Cites]
Exp Cell Res. 1988 Sep;178(1):143-53
[
3409975.001
]
[Cites]
Cancer Res. 1990 Sep 15;50(18):6075-86
[
1975513.001
]
[Cites]
Mol Endocrinol. 1990 Dec;4(12):1833-40
[
2082185.001
]
[Cites]
Cancer Res. 1994 Jan 15;54(2):340-3
[
8275464.001
]
[Cites]
Cancer Res. 1994 Jul 15;54(14):3868-77
[
8033109.001
]
[Cites]
J Exp Med. 1994 Sep 1;180(3):917-23
[
8064240.001
]
[Cites]
Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8
[
9024102.001
]
(PMID = 19690070.001).
[ISSN]
1522-1555
[Journal-full-title]
American journal of physiology. Endocrinology and metabolism
[ISO-abbreviation]
Am. J. Physiol. Endocrinol. Metab.
[Language]
ENG
[Grant]
United States / NICHD NIH HHS / HD / 1R03HD-052770-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
38.
Buch A, Rout P, Makhija P:
Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
Indian J Pathol Microbiol
; 2006 Apr;49(2):259-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adenomyoepithelioma with phyllodes
tumor
--a rare combination in a solitary
breast
lump.
An unusual combination of two
benign breast
neoplasms adenomyoepithelioma and phyllodes
tumor
presenting as a solitary
breast
lump have been described.
This patient also presented with a recurrent
breast
neoplasm
.
[MeSH-major]
Adenomyoma / pathology.
Breast
Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes
Tumor
/ pathology
[MeSH-minor]
Female
. Humans. Middle Aged.
Neoplasm
Recurrence, Local / pathology
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Indian J Pathol Microbiol. 2006 Jul;49(3):476
(PMID = 16933731.001).
[ISSN]
0377-4929
[Journal-full-title]
Indian journal of pathology & microbiology
[ISO-abbreviation]
Indian J Pathol Microbiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
39.
Orlando FA, Brown KD:
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.
Ann Surg Oncol
; 2009 Aug;16(8):2270-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unraveling
breast
cancer heterogeneity through transcriptomic and epigenomic analysis.
Breast
cancer diversity is histologically evident as various proliferative
benign
lesions, in situ carcinomas, and invasive carcinomas that may develop into distant metastases.
Breast tumor
molecular subtypes have been defined by genome-wide expression microarray technology and reveal associations between genetic alterations and the malignant phenotype.
Early work has been conducted to use subtype-specific biomarkers to elucidate targeted treatment options early in the course of
breast
cancer progression.
Additionally, DNA methylation is an epigenetic modification that contributes to
breast
cancer progression by transcriptionally silencing certain
tumor
suppressor genes.
Among the genes characterized as targets for silencing are well-established
tumor
suppressors such as RASSF1A, RARB, SFN, and TGM2.
Measuring elevated gene copy number and aberrant gene promoter methylation can further facilitate characterization of
breast tumor
molecular subtype; however, profiling of
breast
tumors based on epigenetic criteria has yet to be established.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Treat Options Oncol. 2007 Feb;8(1):47-60
[
17660958.001
]
[Cites]
Oral Oncol. 2007 Oct;43(9):878-86
[
17257884.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1812-21
[
17855699.001
]
[Cites]
J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72
[
17878233.001
]
[Cites]
Cancer Lett. 2007 Nov 8;257(1):136-44
[
17706863.001
]
[Cites]
Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51
[
17662645.001
]
[Cites]
Cancer Cell. 2007 Nov;12(5):432-44
[
17996647.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9
[
18003927.001
]
[Cites]
Lancet Oncol. 2008 Jan;9(1):45-53
[
18083636.001
]
[Cites]
Breast Cancer Res. 2007;9(4):R57
[
17764565.001
]
[Cites]
Breast Cancer Res. 2007;9(5):R61
[
17875215.001
]
[Cites]
Carcinogenesis. 2008 Mar;29(3):510-8
[
18174247.001
]
[Cites]
Breast Cancer Res Treat. 2008 May;109(1):27-34
[
17549626.001
]
[Cites]
Mol Cancer Ther. 2008 Apr;7(4):944-51
[
18413808.001
]
[Cites]
Breast Cancer Res. 2008;10(1):R12
[
18269736.001
]
[Cites]
Oncologist. 2008 Apr;13(4):350-60
[
18448548.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1051-9
[
18483325.001
]
[Cites]
J Clin Oncol. 2008 May 20;26(15):2568-81
[
18487574.001
]
[Cites]
Clin Breast Cancer. 2008 Feb;8(1):97-100
[
18501066.001
]
[Cites]
Ann Oncol. 2008 Jun;19(6):1068-74
[
18283035.001
]
[Cites]
BMC Genomics. 2008;9:239
[
18498629.001
]
[Cites]
Int J Cancer. 2008 Sep 1;123(5):998-1004
[
18546260.001
]
[Cites]
Breast Cancer Res Treat. 2008 Sep;111(1):113-20
[
17932744.001
]
[Cites]
Breast Cancer Res. 2008;10(3):R46
[
18485221.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90
[
18708376.001
]
[Cites]
Cancer Biol Ther. 2008 Jun;7(6):958-65
[
18379196.001
]
[Cites]
Cancer Res. 1999 Nov 1;59(21):5438-42
[
10554013.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
[
10749912.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1835-9
[
10766168.001
]
[Cites]
J Natl Cancer Inst. 2000 May 17;92(10):826-32
[
10814678.001
]
[Cites]
Nature. 2000 Aug 17;406(6797):747-52
[
10963602.001
]
[Cites]
Int J Cancer. 2001 May 1;92(3):404-8
[
11291078.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3225-9
[
11309270.001
]
[Cites]
J Natl Cancer Inst. 2001 May 2;93(9):684-90
[
11333290.001
]
[Cites]
Lancet. 2001 Apr 28;357(9265):1335-6
[
11343741.001
]
[Cites]
Oncogene. 2001 May 28;20(24):2988-90
[
11420713.001
]
[Cites]
Oncogene. 2001 Jun 7;20(26):3348-53
[
11423985.001
]
[Cites]
Science. 2001 Aug 10;293(5532):1074-80
[
11498575.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801
[
11481438.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
[
11553815.001
]
[Cites]
Genes Dev. 2001 Sep 15;15(18):2343-60
[
11562345.001
]
[Cites]
J Natl Cancer Inst. 2001 Nov 7;93(21):1624-32
[
11698566.001
]
[Cites]
Genes Dev. 2002 Jan 1;16(1):6-21
[
11782440.001
]
[Cites]
Am J Pathol. 2002 Feb;160(2):605-12
[
11839581.001
]
[Cites]
Nat Rev Cancer. 2001 Nov;1(2):157-62
[
11905807.001
]
[Cites]
Nat Rev Genet. 2002 Jun;3(6):415-28
[
12042769.001
]
[Cites]
Oncogene. 2002 Aug 12;21(35):5400-13
[
12154403.001
]
[Cites]
Oncogene. 2002 Aug 12;21(35):5462-82
[
12154408.001
]
[Cites]
Cancer Res. 2002 Nov 15;62(22):6634-8
[
12438260.001
]
[Cites]
Mol Cell Biol. 2003 Jan;23(1):206-15
[
12482974.001
]
[Cites]
Cancer Res. 2002 Dec 15;62(24):7213-8
[
12499261.001
]
[Cites]
Cancer Res. 2003 May 1;63(9):2024-7
[
12727813.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
[
12829800.001
]
[Cites]
J Pathol. 2008 Oct;216(2):141-50
[
18720457.001
]
[Cites]
Clin Cancer Res. 2008 Oct 1;14(19):5939-40
[
18829469.001
]
[Cites]
Clin Cancer Res. 2008 Oct 1;14(19):6005-13
[
18829479.001
]
[Cites]
Breast Cancer Res Treat. 2008 Dec;112(3):533-43
[
18188694.001
]
[Cites]
Clin Cancer Res. 2009 Mar 1;15(5):1801-7
[
19223509.001
]
[Cites]
Breast Cancer Res Treat. 2009 May;115(2):397-404
[
18521744.001
]
[Cites]
Breast Cancer Res. 2009;11(1):R14
[
19250546.001
]
[Cites]
Cell. 1992 Jul 10;70(1):5-8
[
1377983.001
]
[Cites]
Cancer Res. 1998 Jun 15;58(12):2515-9
[
9635570.001
]
[Cites]
Nat Genet. 1999 Feb;21(2):163-7
[
9988266.001
]
[Cites]
Oncogene. 1999 Mar 18;18(11):1957-65
[
10208417.001
]
[Cites]
Nucleic Acids Res. 1999 Jun 1;27(11):2291-8
[
10325416.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
[
10411935.001
]
[Cites]
Cancer Genet Cytogenet. 2004 Dec;155(2):108-18
[
15571796.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):166-72
[
15671542.001
]
[Cites]
Lab Invest. 2005 Feb;85(2):214-24
[
15608662.001
]
[Cites]
Nature. 2005 Mar 17;434(7031):400-4
[
15772666.001
]
[Cites]
Nat Genet. 2005 Apr;37(4):391-400
[
15765097.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8
[
15824145.001
]
[Cites]
Cell Res. 2005 Apr;15(4):237-46
[
15857578.001
]
[Cites]
Breast Cancer Res Treat. 2005 May;91(2):179-86
[
15868446.001
]
[Cites]
Biochem Cell Biol. 2005 Jun;83(3):296-321
[
15959557.001
]
[Cites]
Nat Genet. 2005 Aug;37(8):906-10
[
16025112.001
]
[Cites]
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
[
16115903.001
]
[Cites]
Nat Rev Genet. 2005 Aug;6(8):597-610
[
16136652.001
]
[Cites]
Clin Lab Med. 2005 Dec;25(4):827-43, viii-ix
[
16308095.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2912-9
[
12912936.001
]
[Cites]
Clin Cancer Res. 2003 Aug 15;9(9):3413-7
[
12960130.001
]
[Cites]
Biochem Soc Symp. 2003;(70):179-99
[
14587292.001
]
[Cites]
Int J Cancer. 2003 Dec 20;107(6):970-5
[
14601057.001
]
[Cites]
Cancer Biol Ther. 2003 Sep-Oct;2(5):559-63
[
14614327.001
]
[Cites]
Mod Pathol. 2003 Nov;16(11):1095-101
[
14614048.001
]
[Cites]
Cancer Res. 2003 Nov 15;63(22):7641-5
[
14633683.001
]
[Cites]
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32
[
14734448.001
]
[Cites]
Mol Cell Biol. 2004 Jun;24(11):4605-12
[
15143157.001
]
[Cites]
Cancer Res. 2004 Jun 1;64(11):3807-13
[
15172987.001
]
[Cites]
Cancer Res. 2004 Jul 1;64(13):4442-52
[
15231653.001
]
[Cites]
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
[
15328174.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005
[
15447983.001
]
[Cites]
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93
[
15448006.001
]
[Cites]
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
[
16341240.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):29-33
[
16397211.001
]
[Cites]
Cancer Cell. 2006 Feb;9(2):121-32
[
16473279.001
]
[Cites]
Endocr Relat Cancer. 2006 Mar;13(1):39-49
[
16601278.001
]
[Cites]
Cancer Res. 2006 May 1;66(9):4636-44
[
16651414.001
]
[Cites]
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3306-10
[
16740751.001
]
[Cites]
JAMA. 2006 Jun 7;295(21):2492-502
[
16757721.001
]
[Cites]
Carcinogenesis. 2006 Jul;27(7):1341-8
[
16501252.001
]
[Cites]
BMC Genomics. 2006;7:127
[
16729877.001
]
[Cites]
FEBS J. 2006 Jul;273(14):3121-35
[
16857008.001
]
[Cites]
Curr Top Microbiol Immunol. 2006;310:251-74
[
16909914.001
]
[Cites]
Cancer Res. 2006 Aug 15;66(16):7899-909
[
16912163.001
]
[Cites]
Cancer. 2007 Jan 1;109(1):25-32
[
17146782.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6
[
17220331.001
]
[Cites]
Breast Cancer Res. 2006;8(4):R38
[
16846527.001
]
[Cites]
Gastroenterology. 2007 Jan;132(1):127-38
[
17087942.001
]
[Cites]
Cell. 2007 Feb 23;128(4):683-92
[
17320506.001
]
[Cites]
Oncogene. 2007 Mar 29;26(14):2126-32
[
17016441.001
]
[Cites]
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
[
17438091.001
]
[Cites]
Histopathology. 2007 Mar;50(4):434-8
[
17448018.001
]
[Cites]
Nat Genet. 2007 May;39(5):655-60
[
17417639.001
]
[Cites]
Breast Cancer Res. 2007;9(2):R24
[
17417968.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):950-5
[
17507621.001
]
[Cites]
Nat Rev Cancer. 2007 Aug;7(8):628-33
[
17611545.001
]
(PMID = 19452229.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / T32 CA106493; United States / NCI NIH HHS / CA / 5T32CA106493-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Proteins
[Number-of-references]
119
[Other-IDs]
NLM/ NIHMS565761; NLM/ PMC4011015
40.
Román-Díaz J, Alayón-Laguer D, Fernández Nelson M, Luis B, Caceres-Perkins W, Conde-Sterling D:
Rare benign breast tumor.
Bol Asoc Med P R
; 2010 Apr-Jun;102(2):50-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rare
benign breast tumor
.
We report the case of a
female
patient with an incidental finding at routine mammography evaluation which consisted of a
benign
spindle cell
tumor
, namely
Breast
Myofibroblastoma.
It is important to recognize the
benign
nature of this
neoplasm
to prevent extensive mutilating surgical procedures.
[MeSH-major]
Breast
Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology
[MeSH-minor]
Female
. Humans. Middle Aged
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20939206.001).
[ISSN]
0004-4849
[Journal-full-title]
Boletín de la Asociación Médica de Puerto Rico
[ISO-abbreviation]
Bol Asoc Med P R
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Puerto Rico
41.
Wu ZS, Wu Q, Ding XD, Wang HQ, Shen YX, Fang SY:
[Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance].
Zhonghua Bing Li Xue Za Zhi
; 2008 Feb;37(2):109-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in
breast
cancer and its clinical and prognostic significance].
OBJECTIVE: To investigate the expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in
breast
cancer and its clinical and prognostic significance.
METHODS: AGR2 expression was assessed in 160 cases of
breast
cancer and 20 cases of
benign breast
diseases by immunohistochemistry using tissue chip technology.
In addition the expression of ERa, PR and c-erbB-2 in
breast
cancer was also evaluated.
Follow-up information of 5-year duration was available in 127 patients with
breast
cancer.
RESULTS: The expression of AGR2 was significantly higher in
breast
cancers than that in
benign
diseases (68.3% vs. 25.0% , P < 0.01).
There was a negative correlation between AGR2 expression and the histological grade of
breast
cancer (P <0.05) , whereas positive correlations was found between the expression of AGR2 and ERalpha (P <0.05), and between the expression of AGR2 and PR (P <0.01).
In the subgroup of ERalpha-positive
breast
cancer, Logistic regression model demonstrated AGR2 and TNM stage were important factors affecting lymph node metastasis (both P < 0.01).
Moreover, COX regression model confirmed the expression of AGR2 as an independent prognostic factor among patients with ERa-positive
breast
cancer (P <0.01).
CONCLUSIONS: The abnormal expression of AGR2 may play a role in the pathogenesis and progression of
breast
cancer.
Therefore, AGR2 may be a useful molecular marker for prognostication for patient with hormone-responsive
breast
cancer.
[MeSH-major]
BRCA2 Protein / metabolism.
Breast
Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / genetics.
Neoplasm
Metastasis /
diagnosis
. Proteins / metabolism. Receptor, ErbB-2 / metabolism
[MeSH-minor]
Antineoplastic Agents, Hormonal / analysis. Biomarkers,
Tumor
/ analysis. Estrogen Receptor alpha / metabolism.
Female
. Humans. Immunohistochemistry.
Neoplasm
Staging. Prognosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18681322.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.3.4.1 / AGR2 protein, human
42.
Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Sadanaga N, Yamamoto H, Honda H:
Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
J Magn Reson Imaging
; 2008 Nov;28(5):1157-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Enhanced mass on contrast-enhanced
breast
MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
PURPOSE: To evaluate the diagnostic accuracy of a combination of dynamic contrast-enhanced MR imaging (DCE-MRI) and diffusion-weighted MR imaging (DWI) in characterization of enhanced mass on
breast
MR imaging and to find the strongest discriminators between carcinoma and benignancy.
MATERIALS AND METHODS: We analyzed consecutive
breast
MR images in 270 patients; however, 13 lesions in 93 patients were excluded based on our criteria.
We analyzed
tumor
size, shape, margin, internal mass enhancement, kinetic curve pattern, and apparent diffusion coefficient (ADC) values.
We added the corresponding categories to these prediction probabilities for malignancy and calculated diagnostic accuracy when we consider category 4b, 4c, and 5 lesions as malignant and category 4a, 3, and 2 lesions as
benign
.
CONCLUSION: The combination of DWI and DCE-MRI could produce high diagnostic accuracy in the characterization of enhanced mass on
breast
MR imaging.
[MeSH-major]
Algorithms.
Breast
/ pathology.
Breast
Neoplasms /
diagnosis
. Gadolinium DTPA. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media.
Female
. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2008 Wiley-Liss, Inc.
(PMID = 18972357.001).
[ISSN]
1053-1807
[Journal-full-title]
Journal of magnetic resonance imaging : JMRI
[ISO-abbreviation]
J Magn Reson Imaging
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
43.
Yavelsky V, Rohkin S, Shaco-Levy R, Tzikinovsky A, Amir T, Kohn H, Delgado B, Rabinovich A, Piura B, Chan G, Kalantarov G, Trakht I, Lobel L:
Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary.
BMC Cancer
; 2008;8:247
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the
breast
and ovary.
We previously described the isolation and characterization of two fully human monoclonal antibodies, 27.F7 and 27.B1, from
breast
cancer patients that target the protein known as GIPC1, an accessory PDZ-domain binding protein involved in regulation of G-protein signaling.
Human monoclonal antibodies, 27.F7 and 27.B1, to GIPC1 demonstrate specific binding to malignant
breast
cancer tissue with no reactivity with normal
breast
tissue.
To further clarify the association of GIPC1 with
breast
and ovarian cancer we carefully studied 27.F7 and 27.B1 using immunocytochemical and immunohistochemical techniques.
An immunohistochemical study of normal ovarian tissue,
benign
, borderline and malignant ovarian serous tumors, and different types of
breast
cancer revealed high expression of GIPC1 protein in neoplastic cells.
Examination of different types of
breast
cancer demonstrates that the level of GIPC1 expression depends on
tumor
invasiveness and displays a higher expression than in
benign
tumors.
CONCLUSION: The present pilot study demonstrates that the GIPC1 protein is overexpressed in ovarian and
breast
cancer, which may provide an important diagnostic and prognostic marker and will constitute the basis for further study of the role that this protein plays in malignant diseases.
[MeSH-major]
Adaptor Proteins, Signal Transducing / biosynthesis. Adaptor Proteins, Signal Transducing / immunology. Autoantibodies / chemistry.
Breast
Neoplasms / metabolism. Ovarian Neoplasms / metabolism
[MeSH-minor]
Antibodies, Monoclonal / chemistry.
Breast
/ metabolism. Cell Line,
Tumor
. Disease Progression. Enzyme-Linked Immunosorbent Assay / methods.
Female
. Humans. Immunohistochemistry / methods. Pilot Projects
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Ther. 2001 Jan;23(1):146-59
[
11219474.001
]
[Cites]
Biosens Bioelectron. 2007 Feb 15;22(7):1508-16
[
16904309.001
]
[Cites]
Curr Opin Oncol. 2001 Sep;13(5):399-402
[
11555720.001
]
[Cites]
J Biol Chem. 2001 Oct 26;276(43):39608-17
[
11546783.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Jan 25;290(3):1030-6
[
11798178.001
]
[Cites]
Breast Cancer Res Treat. 2002 Jan;71(2):103-12
[
11881908.001
]
[Cites]
J Am Soc Nephrol. 2002 Apr;13(4):918-27
[
11912251.001
]
[Cites]
Int J Mol Med. 2002 May;9(5):509-13
[
11956658.001
]
[Cites]
Int J Mol Med. 2002 Jun;9(6):585-9
[
12011974.001
]
[Cites]
Hum Antibodies. 2002;11(3):85-96
[
12454369.001
]
[Cites]
Hybrid Hybridomics. 2002 Dec;21(6):405-14
[
12573104.001
]
[Cites]
Cancer Immunol Immunother. 2004 Mar;53(3):204-16
[
14722672.001
]
[Cites]
Eur J Gynaecol Oncol. 2004;25(2):207-10
[
15032283.001
]
[Cites]
Curr Opin Obstet Gynecol. 2004 Feb;16(1):5-9
[
15128001.001
]
[Cites]
Ann Oncol. 2004;15 Suppl 1:I18-I26
[
15280183.001
]
[Cites]
CMAJ. 2004 Aug 17;171(4):323-4
[
15313987.001
]
[Cites]
J Cell Biol. 1995 Jul;130(1):67-77
[
7790378.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15203-8
[
8986788.001
]
[Cites]
Mol Biol Cell. 1999 Apr;10(4):819-32
[
10198040.001
]
[Cites]
Arch Biochem Biophys. 2006 Oct 15;454(2):160-9
[
16962991.001
]
[Cites]
Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4
[
11176234.001
]
(PMID = 18721484.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Autoantibodies; 0 / GIPC1 protein, human
[Other-IDs]
NLM/ PMC2535783
44.
Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, Kraeft SK, Collins LC, Sabel MS, Argani P, Gelman R, Schnitt SJ, Krop IE, Polyak K:
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.
Clin Cancer Res
; 2008 Sep 1;14(17):5357-67
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epithelial and stromal cathepsin K and CXCL14 expression in
breast tumor
progression.
PURPOSE: To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human
breast tumor
progression.
EXPERIMENTAL DESIGN: We did immunohistochemical analyses of CTSK and CXCL14 expression in normal
breast
tissue, biopsy sites,
benign
lesions, ductal carcinoma in situ, and invasive
breast
tumors of different stages.
The effect of CTSK+
breast
stromal fibroblasts on CTSK-
breast
cancer cells was assessed in coculture.
The expression of CXCL14 was not associated with any
tumor
or patient characteristics analyzed.
Stromal CTSK expression was significantly higher in invasive compared with in situ carcinomas, and in one of the two data sets analyzed, it correlated with higher
tumor
stage.
Coculture of CTSK+ fibroblasts enhanced the invasion of CTSK-
breast tumor
epithelial cells and this was blocked by CTSK inhibitors.
CONCLUSIONS: CTSK may function as a paracrine factor in
breast
tumorigenesis.
CTSK+ fibroblasts may play a role in
tumor
progression by promoting the invasiveness of
tumor
epithelial cells.
The possibility that CTSK inhibitors may have a clinical role in decreasing the risk of
tumor
progression merits further investigation.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Exp Hematol. 2006 Aug;34(8):1101-5
[
16863917.001
]
[Cites]
Curr Opin Cell Biol. 2003 Dec;15(6):753-62
[
14644202.001
]
[Cites]
Cancer Res. 2006 Dec 15;66(24):11550-3
[
17158190.001
]
[Cites]
Mol Cell Biol. 2007 Feb;27(3):983-92
[
17130243.001
]
[Cites]
Curr Pharm Des. 2007;13(4):387-403
[
17311556.001
]
[Cites]
Cancer Cell. 2007 Mar;11(3):259-73
[
17349583.001
]
[Cites]
Cancer Res. 2007 Aug 1;67(15):7378-85
[
17671208.001
]
[Cites]
J Biol Chem. 2007 Oct 19;282(42):30794-803
[
17724031.001
]
[Cites]
Cancer Res. 2007 Oct 15;67(20):9894-902
[
17942921.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Dec 28;364(4):1037-42
[
17971304.001
]
[Cites]
Biochimie. 2008 Feb;90(2):380-6
[
17991442.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91
[
14973383.001
]
[Cites]
Cancer Cell. 2004 May;5(5):443-53
[
15144952.001
]
[Cites]
Cancer Cell. 2004 Jul;6(1):17-32
[
15261139.001
]
[Cites]
N Engl J Med. 1986 Dec 25;315(26):1650-9
[
3537791.001
]
[Cites]
Cancer Res. 1997 Dec 1;57(23):5386-90
[
9393764.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8
[
9811821.001
]
[Cites]
Cancer Res. 2004 Nov 15;64(22):8262-70
[
15548693.001
]
[Cites]
Biol Chem. 2004 Nov;385(11):1017-27
[
15576321.001
]
[Cites]
J Immunol. 2005 May 1;174(9):5490-8
[
15843547.001
]
[Cites]
Prostate. 2005 Jun 15;64(1):67-74
[
15651028.001
]
[Cites]
Nat Genet. 2005 Aug;37(8):899-905
[
16007089.001
]
[Cites]
Genes Dev. 2006 Mar 1;20(5):543-56
[
16481467.001
]
[Cites]
Am J Pathol. 2000 Jun;156(6):1937-50
[
10854217.001
]
[Cites]
J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6
[
10904098.001
]
[Cites]
Nature. 2001 Mar 1;410(6824):50-6
[
11242036.001
]
[Cites]
Semin Cancer Biol. 2001 Apr;11(2):97-104
[
11322829.001
]
[Cites]
Cancer Res. 2001 Aug 1;61(15):5697-702
[
11479200.001
]
[Cites]
Mol Cancer Res. 2003 Mar;1(5):362-75
[
12651909.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
[
14500907.001
]
[Cites]
Biochem Soc Symp. 2003;(70):179-99
[
14587292.001
]
[Cites]
Biochem Biophys Res Commun. 2006 Sep 22;348(2):406-12
[
16884687.001
]
(PMID = 18765527.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA116235-01A1; United States / NCI NIH HHS / CA / CA116235; United States / NCI NIH HHS / CA / CA116235-01A1; United States / NCI NIH HHS / CA / R01 CA094074-04; United States / NCI NIH HHS / CA / CA116235-02; United States / NCI NIH HHS / CA / R01 CA116235-02; United States / NCI NIH HHS / CA / CA089393-050004; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / CA089393-060014; United States / NCI NIH HHS / CA / P50 CA089393-060014; United States / NCI NIH HHS / CA / R01 CA116235; United States / NCI NIH HHS / CA / CA094074-05; United States / NCI NIH HHS / CA / CA094074-04; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA006516; United States / NCI NIH HHS / CA / P50 CA089393-050004; United States / NCI NIH HHS / CA / R01 CA094074-05; United States / NCI NIH HHS / CA / K08 CA090876; United States / NCI NIH HHS / CA / CA107469; United States / NCI NIH HHS / CA / CA89393; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA089393-070014; United States / NCI NIH HHS / CA / P50 CA089393-070014; United States / NCI NIH HHS / CA / R01 CA094074
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / CXCL14 protein, human; 0 / Chemokines, CXC; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
[Other-IDs]
NLM/ NIHMS72319; NLM/ PMC2630242
45.
Ilić I, Randelović P, Ilić R, Katić V, Milentijević M, Velicković L, Krstić M:
An approach to malignant mammary phyllodes tumors detection.
Vojnosanit Pregl
; 2009 Apr;66(4):277-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
They are divided into
benign
, borderline malignant and malignant groups.
A total of 35 cases of MPT were included: 20
benign
(57%), 6 borderline malignant (17%) and 9 malignant (26%).
The mean size of malignant MPT (7.8 cm) was larger than that of
benign
MPT (4.5 cm).
Significant features of the malignant MPT were: stromal cellularity, stromal cellular atypism, high mitotic activity, atypic mitoses, stromal overgrowth, infiltrative
tumor
contour and heterologous stromal elements.
Benign
MPT showed strong enzymohistochemical Leucine Amino Peptidase (LAP) activity in both epithelial and stromal components while it was weak or absent in the epithelial parts of the malignant tumors.
Benign
MPT had a lower Ki-67 than did borderline malignant MPT (4 versus 28).
Malignant MPT had a greater than 8-fold higher Ki-67 activity than did
benign
tumors (35 versus 4).
Intracyto-plasmatic c-kit expression was associated with a pathological
diagnosis of
malignant MPT, correlating with increasing grade (p < 0.05).
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Phyllodes
Tumor
/
diagnosis
[MeSH-minor]
Adult. Biomarkers,
Tumor
/ analysis.
Female
. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Receptors, Estrogen / analysis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19441158.001).
[ISSN]
0042-8450
[Journal-full-title]
Vojnosanitetski pregled
[ISO-abbreviation]
Vojnosanit Pregl
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Serbia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen
46.
Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA:
Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process.
PLoS One
; 2010 Nov 04;5(11):e13813
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Discovering new melanoma biomarkers would improve early detection and
diagnosis
.
Volatiles released from fresh biopsy tissue of melanoma and
benign
naevus were compared based on their difference in frequency distribution and their expression level.
MedlinePlus Health Information.
consumer health - Birthmarks
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Moles
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Chem. 2000 Feb 15;72(4):747-56
[
10701259.001
]
[Cites]
J Am Chem Soc. 2010 Mar 24;132(11):3642-3
[
20196537.001
]
[Cites]
Philos Trans R Soc Lond B Biol Sci. 2002 Jan 29;357(1417):17-23
[
11839178.001
]
[Cites]
Breast J. 2003 May-Jun;9(3):184-91
[
12752626.001
]
[Cites]
Trends Biochem Sci. 2003 Jun;28(6):329-35
[
12826405.001
]
[Cites]
Cancer Treat Rev. 2003 Dec;29(6):489-99
[
14585259.001
]
[Cites]
Lancet. 2004 Feb 28;363(9410):728-30
[
15005091.001
]
[Cites]
Prev Med. 2004 Apr;38(4):382-7
[
15020171.001
]
[Cites]
Environ Health Perspect. 2004 May;112(7):A396-7
[
15159211.001
]
[Cites]
Nat Rev Cancer. 2004 Jul;4(7):551-61
[
15229480.001
]
[Cites]
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):269-77
[
15261821.001
]
[Cites]
Nature. 1966 Nov 26;212(5065):933-5
[
4306794.001
]
[Cites]
J Biol Chem. 1980 Nov 10;255(21):10493-501
[
7430132.001
]
[Cites]
Anticancer Res. 1985 Jan-Feb;5(1):1-30
[
3888043.001
]
[Cites]
Mutat Res. 1989 Jan;219(1):71-9
[
2911273.001
]
[Cites]
Biochem Pharmacol. 1995 Dec 22;50(12):1955-62
[
8849320.001
]
[Cites]
Science. 1996 Jul 5;273(5271):59-63
[
8658196.001
]
[Cites]
J Biol Chem. 1997 May 2;272(18):11895-901
[
9115250.001
]
[Cites]
Nucleic Acids Res. 1999 Jun 1;27(11):2291-8
[
10325416.001
]
[Cites]
Cancer Res. 1999 Aug 15;59(16):3855-60
[
10463569.001
]
[Cites]
J Invest Dermatol. 1964 Aug;43:111-3
[
14196302.001
]
[Cites]
Biochemistry. 2004 Nov 16;43(45):14332-9
[
15533037.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):720-4
[
16079850.001
]
[Cites]
J Invest Dermatol. 2006 Dec;126(12):2565-75
[
17108903.001
]
[Cites]
Mass Spectrom Rev. 2007 Jan-Feb;26(1):51-78
[
16921475.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):843-50
[
17314970.001
]
[Cites]
Am J Clin Nutr. 2007 Apr;85(4):946-9
[
17413090.001
]
[Cites]
Cancer Biomark. 2007;3(2):95-109
[
17522431.001
]
[Cites]
Int J Epidemiol. 2008 Apr;37 Suppl 1:i23-30
[
18381390.001
]
[Cites]
Skin Res Technol. 2008 May;14(2):226-36
[
18412567.001
]
[Cites]
PLoS Med. 2008 Jun 3;5(6):e120
[
18532874.001
]
[Cites]
J Thorac Oncol. 2008 Jul;3(7):774-80
[
18594325.001
]
[Cites]
Int J Cancer. 2008 Nov 15;123(10):2446-55
[
18729182.001
]
[Cites]
Br J Dermatol. 2008 Sep;159(4):780-91
[
18637798.001
]
[Cites]
J Am Chem Soc. 2008 Oct 29;130(43):14111-3
[
18831549.001
]
[Cites]
Nature. 2008 Oct 23;455(7216):1054-6
[
18948945.001
]
[Cites]
Lung Cancer. 2009 Feb;63(2):164-8
[
18599152.001
]
[Cites]
Can Fam Physician. 2009 Jan;55(1):24; autor reply 24
[
19155361.001
]
[Cites]
Anal Bioanal Chem. 2009 Feb;393(3):781-95
[
18836706.001
]
[Cites]
Nature. 2009 Feb 12;457(7231):910-4
[
19212411.001
]
[Cites]
J Am Soc Mass Spectrom. 2009 Mar;20(3):464-8
[
19070510.001
]
[Cites]
Am J Pathol. 2009 Apr;174(4):1524-33
[
19342374.001
]
[Cites]
Nat Rev Genet. 2009 May;10(5):295-304
[
19308066.001
]
[Cites]
Cancer Control. 2009 Jul;16(3):200-18
[
19556960.001
]
[Cites]
Eur Respir J. 2009 Jul;34(1):261-75
[
19567608.001
]
[Cites]
BMC Cancer. 2009;9:348
[
19788722.001
]
[Cites]
Pigment Cell Melanoma Res. 2009 Dec;22(6):750-60
[
19735457.001
]
[Cites]
Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71
[
19788535.001
]
[Cites]
Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20
[
20143319.001
]
[Cites]
J Invest Dermatol. 2001 Apr;116(4):520-4
[
11286617.001
]
(PMID = 21079799.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA132046-02; United States / NCI NIH HHS / CA / R21 CA132046; United States / NCI NIH HHS / CA / R21CA 132046; United States / NCI NIH HHS / CA / R21 CA132046-01A1; United States / NCI NIH HHS / CA / R21 CA132046-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Volatile Organic Compounds
[Other-IDs]
NLM/ PMC2973952
47.
Boyer B, Graef C:
[Breast hamartoma: a rare benign tumor diagnosed by mammography].
Presse Med
; 2007 Dec;36(12 Pt 3):1999-2000
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Breast
hamartoma: a rare
benign tumor
diagnosed by mammography].
[Transliterated title]
Hamartome
du sein
: une
tumeur
bénigne rare
de
diagnostic mammographique.
[MeSH-major]
Breast
Neoplasms / diagnostic imaging. Hamartoma / diagnostic imaging. Mammography
[MeSH-minor]
Adult.
Female
. Humans
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17604590.001).
[ISSN]
0755-4982
[Journal-full-title]
Presse medicale (Paris, France : 1983)
[ISO-abbreviation]
Presse Med
[Language]
fre
[Publication-type]
Case Reports; Journal Article
[Publication-country]
France
48.
Kooistra B, Wauters C, Strobbe L:
Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy?
Ann Surg Oncol
; 2009 Feb;16(2):281-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Indeterminate
breast
fine-needle aspiration: repeat aspiration or core needle biopsy?
Fine-needle aspiration (FNA) of
breast
lesions provides indeterminate (C1, C3, and C4) diagnoses in a high proportion of cases.
The aim of the present study was to retrospectively determine whether repeat FNA or core needle biopsy (CNB) most frequently provides a correct and more conclusive
diagnosis
.
Improvement in preoperative
diagnosis
by repeat FNA or CNB was defined as C2/B2 in
benign
lesions, C3/B3 in premalignant lesions, C4/B4 or C5/B5 in malignant lesions where primary FNA was C1, and C5/B5 in malignant lesions where primary FNA was C3 or C4.
Among 255 eligible cases, CNB improved the preoperative
diagnosis
more often than did repeat FNA (78.0% vs. 54.8%, odds ratio = 2.9, P < .001).
When corrected for patient age, appearance on mammogram (mass or not), clinical findings (palpable or not),
tumor
size, and aspiration mode (freehand vs. image guided), this difference slightly increased (odds ratio = 3.0, P = .001).
CNB should be performed after an indeterminate FNA of a
breast
lesion to obtain a reliable and clear preoperative
diagnosis
.
[MeSH-major]
Breast
Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Lobular / pathology
[MeSH-minor]
Biopsy, Fine-Needle. Biopsy, Needle.
Diagnosis
, Differential.
Female
. Follow-Up Studies. Humans. Middle Aged.
Neoplasm
Staging. Prognosis. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19050965.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
49.
Büchler T, Vorzilková E, Koukolík F, Melínova H, Abrahámová J:
[Malignant subtype of cystosarcoma phyllodes with brain metastases].
Klin Onkol
; 2010;23(6):446-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cystosarcoma phyllodes is an uncommon type of
breast
tumour.
Benign
, borderline, and malignant subtypes have been described.
We report on a patient with malignant cystosarcoma phyllodes who developed metastatic disease six years after resection of the primary
breast
tumour.
[MeSH-major]
Brain Neoplasms / secondary.
Breast
Neoplasms / pathology. Phyllodes
Tumor
/ secondary
[MeSH-minor]
Adult.
Female
. Humans
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21351423.001).
[ISSN]
0862-495X
[Journal-full-title]
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
[ISO-abbreviation]
Klin Onkol
[Language]
cze
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Czech Republic
50.
Tiling R, Kessler M, Untch M, Sommer H, Linke R, Hahn K:
Initial evaluation of breast cancer using Tc-99m sestamibi scintimammography.
Eur J Radiol
; 2005 Feb;53(2):206-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Initial evaluation of
breast
cancer using Tc-99m sestamibi scintimammography.
AIM: Aim of the study was to elaborate on the diagnostic role of Tc-99m sestamibi scintimammography (SMM) in the initial
diagnosis of
breast
cancer, partially in comparison to MRI.
A subgroup of 68 patients with indeterminate preliminary
diagnosis
underwent additional MRI.
Depending on
tumor
size sensitivity ranged from 60% for stage pT1a,b carcinomas to 94% stage pT1c or higher.
In the subgroup with indeterminate preliminary
diagnosis
sensitivity of SMM decreased to 76% which was lower as compared to MRI (84%).
CONCLUSION: SMM has severe limitations in
the diagnosis
of small carcinoma and therefore should not be used for
breast
cancer screening.
SMM can be used to further evaluate indeterminate or probably
benign
mammographic findings, especially when conventional mammography is inconclusive due to dense
breast
tissue.
[MeSH-major]
Breast
Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sestamibi
[MeSH-minor]
Contrast Media.
Diagnosis
, Differential.
Female
. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15664284.001).
[ISSN]
0720-048X
[Journal-full-title]
European journal of radiology
[ISO-abbreviation]
Eur J Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Contrast Media; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi; K2I13DR72L / Gadolinium DTPA
51.
Zúbor P, Kajo K, Dussan CA, Szunyogh N, Danko J:
Rapidly growing nodular pseudoangiomatous stromal hyperplasia of the breast in an 18-year-old girl.
APMIS
; 2006 May;114(5):389-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rapidly growing nodular pseudoangiomatous stromal hyperplasia of the
breast
in an 18-year-old girl.
Pseudoangiomatous stromal hyperplasia (PASH) of the
breast
is a rare
benign
proliferation of mesenchymal stromal cells with irregular slit-like formations resembling angiomatous structures.
In the majority of cases this lesion is a focal microscopic finding in
breast
biopsies performed for
benign
or malignant diseases.
The exact etiology and pathogenesis of this
tumor
-like lesion is still unknown, but a proliferative response of myofibroblasts to hormonal stimuli has been postulated.
A large 12 x 9 x 3.5 cm rapidly growing nodular form of PASH of the
breast
in an 18-year-old woman is here described with clinical and histological findings.
To the authors' knowledge this is only the fourth case of nodular PASH of the
breast
reported in the English literature.
[MeSH-major]
Breast
/ cytology.
Breast
/ pathology.
Breast
Neoplasms /
diagnosis
. Neoplasms, Muscle Tissue / pathology
[MeSH-minor]
Adolescent. Anovulation.
Diagnosis
, Differential.
Female
. Humans. Hyperplasia /
diagnosis
. Hyperplasia / pathology. Progesterone / blood. Stromal Cells / pathology
Genetic Alliance.
consumer health - Pseudoangiomatous stromal hyperplasia
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
PROGESTERONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16725017.001).
[ISSN]
0903-4641
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
4G7DS2Q64Y / Progesterone
52.
Zeng Y, Yang WT, Zhang GH, Zhu XZ:
[Study of HOXA5 gene expression in breast carcinoma].
Zhonghua Bing Li Xue Za Zhi
; 2005 Sep;34(9):569-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Study of HOXA5 gene expression in
breast
carcinoma].
OBJECTIVE: To study mRNA and protein expression of HOXA5 gene in
breast
carcinoma, to correlate the expression of HOXA5 gene with clinicopathologic parameters and to explore the possible role of HOXA5 gene in carcinogenesis, progression and metastasis of
breast
carcinoma.
METHODS: TaqMan real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was applied on 60 cases of primary
breast
carcinoma and 24 cases of
benign
mammary lesions in order to detect mRNA expression of HOXA5 gene.
Statistical analysis was carried out to analyze the correlation between HOXA5 gene expression and various clinical parameters in these
breast
cancer patients. RESULTS:.
(1) The relative expression level of HOXA5 mRNA ranged from 0.73 to 193.07 (average = 20.85) in primary
breast
carcinoma, in contrast to 5.42 to 81.91 (average = 30.94) in
benign
mammary lesions.
Compared with
benign
mammary lesions, a significant reduction in expression of HOXA5 mRNA was noted in primary
breast
carcinoma (P < 0.01). (2) There was a decreased or completely diminished HOXA5 protein expression in
breast
carcinoma. (3) HOXA5 mRNA expression was significantly lower in lymph node-positive cases, when compared with that in lymph node-negative cases (P < 0.05).
On the other hand, moderately or strongly positive HOXA5 staining was noted in lymph node-negative cases. (4) Neither mRNA nor protein expression of HOXA5 gene correlated with clinicopathologic parameters such as age of patients, size of
tumor
, clinical stage, pathologic subtype or histologic grade (P > 0.05).
CONCLUSIONS: Disordered expression of HOXA5 gene may play a role in the carcinogenesis of
breast
cancer.
Reduced expression of HOXA5 gene may be related to the metastatic potential of
breast
carcinoma cells.
[MeSH-major]
Breast
Neoplasms / metabolism. Carcinoma, Ductal,
Breast
/ metabolism. Homeodomain Proteins / biosynthesis
[MeSH-minor]
Adult. Aged.
Breast
/ metabolism.
Breast
/ pathology.
Female
. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged.
Neoplasm
Staging. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16468307.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / HOXA5 protein, human; 0 / Homeodomain Proteins; 0 / RNA, Messenger
53.
Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C:
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Cancer Invest
; 2008 Aug;26(7):734-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell cycle dysregulation influences survival in high risk
breast
cancer patients.
Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with
breast
cancer.
Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in
tumor
tissue and adjacent
benign breast
tissue from 69 primarily untreated
breast
cancer patients.
RESULTS: Sixty-nine patients with untreated, invasive
breast
cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
A subgroup of high risk
breast
cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
Regarding
benign breast
tissue adjacent to
breast
cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated
breast
cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Breast
Neoplasms / chemistry.
Breast
Neoplasms / mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
[MeSH-minor]
Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival.
Female
. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate.
Neoplasm
Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18665474.001).
[ISSN]
1532-4192
[Journal-full-title]
Cancer investigation
[ISO-abbreviation]
Cancer Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
54.
Cox K, North M, Burke M, Singhal H, Renton S, Aqel N, Islam S, Knight SC:
Plasmacytoid dendritic cells (PDC) are the major DC subset innately producing cytokines in human lymph nodes.
J Leukoc Biol
; 2005 Nov;78(5):1142-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cell suspensions were prepared from
tumor
draining LN (n=20) and control LN (n=11) of women undergoing surgical resection for primary
breast
cancer and elective surgery for
benign
conditions, respectively.
Thus, PDC innately producing cytokines were identified in cell suspensions from human LN, and the character of PDC cytokine secretion may differ between two
breast
cancer prognostic groups.
We speculate that a shift towards PDC IL-10 and IL-4 expression could promote
tumor
tolerance in LN draining poor px
breast
cancer.
[MeSH-major]
Breast
Neoplasms / immunology. Cytokines / biosynthesis. Dendritic Cells / immunology. Immunity, Innate / immunology. Lymph Nodes / immunology
[MeSH-minor]
Adult. Aged.
Female
. Flow Cytometry. Humans. Interferon-gamma / biosynthesis. Interferon-gamma / immunology. Interleukin-10 / biosynthesis. Interleukin-10 / immunology. Interleukin-12 / biosynthesis. Interleukin-12 / immunology. Interleukin-4 / biosynthesis. Interleukin-4 / immunology. Lymphatic Metastasis. Middle Aged.
Tumor
Cells, Cultured.
Tumor
Escape / immunology
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Leukoc Biol. 2008 Mar;83(3):797
(PMID = 16260587.001).
[ISSN]
0741-5400
[Journal-full-title]
Journal of leukocyte biology
[ISO-abbreviation]
J. Leukoc. Biol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cytokines; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
55.
Liu H, Jiang YX, Liu JB, Zhu QL, Sun Q, Chang XY:
Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation.
J Ultrasound Med
; 2009 Jul;28(7):911-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Contrast-enhanced
breast
ultrasonography: imaging features with histopathologic correlation.
OBJECTIVE: The purpose of this study was to identify histopathologic correlates for the varied appearances of
breast
masses on contrast-enhanced ultrasonography (CEUS).
RESULTS: In malignant masses, heterogeneous enhancement corresponded to
tumor
cell cords or clusters in a variable amount of desmoplastic stroma.
In
benign
masses, heterogeneous enhancement corresponded to loose cell proliferation in a more sclerotic stroma.
CONCLUSIONS:
Breast
mass CEUS findings correlated with histologic features.
[MeSH-major]
Breast
Diseases / pathology.
Breast
Diseases / ultrasonography. Image Enhancement. Ultrasonography, Mammary / methods
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Breast
/ pathology.
Breast
Neoplasms / pathology.
Breast
Neoplasms / ultrasonography. Contrast Media.
Diagnosis
, Differential.
Female
. Humans. Image Interpretation, Computer-Assisted. Microbubbles. Middle Aged. Sensitivity and Specificity. Software. Sulfur Hexafluoride. Young Adult
MedlinePlus Health Information.
consumer health - Breast Diseases
.
Hazardous Substances Data Bank.
SULFUR HEXAFLUORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19546333.001).
[ISSN]
1550-9613
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media; WS7LR3I1D6 / Sulfur Hexafluoride
56.
del Cura JL, Elizagaray E, Zabala R, Legórburu A, Grande D:
The use of unenhanced Doppler sonography in the evaluation of solid breast lesions.
AJR Am J Roentgenol
; 2005 Jun;184(6):1788-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The use of unenhanced Doppler sonography in the evaluation of solid
breast
lesions.
OBJECTIVE: The objectives of our study were to investigate differences in Doppler sonography features between
benign
and malignant
breast
lesions and between malignant lesions with different prognostic factors and to propose diagnostic criteria for Doppler sonography of
breast
lesions.
SUBJECTS AND METHODS: We performed power and duplex Doppler sonography examinations in 826
breast
lesions scheduled for sonographically guided core needle biopsy.
RESULTS: Color flow was more frequently seen in malignant (237/348 lesions, 68%) than in
benign
(171/478, 36%) lesions (p < 0.001).
Although an overlap in these values between
benign
and malignant lesions was observed, all but one nodule with an RI of greater than 0.99 (those with null or inverted diastolic flow) or a PI of greater than 4 were malignant.
No significant relationship was found between PI, RI, or flow visualization on power Doppler sonography and
tumor
grade or lymph node involvement in cancers.
Doppler findings are not useful to predict
tumor
grade or lymph node involvement.
[MeSH-major]
Breast
Neoplasms / ultrasonography
[MeSH-minor]
Adult. Aged. Biopsy, Needle.
Breast
/ blood supply.
Breast
/ pathology.
Female
. Humans. Middle Aged. Neovascularization, Pathologic. Predictive Value of Tests. Prognosis. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler. Ultrasonography, Mammary
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15908531.001).
[ISSN]
0361-803X
[Journal-full-title]
AJR. American journal of roentgenology
[ISO-abbreviation]
AJR Am J Roentgenol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
57.
Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, Hsieh FJ:
SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
Breast J
; 2010 May-Jun;16(3):305-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
SPARC (osteonectin) in
breast
tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
The purpose of this study was to characterize the immunohistochemical distribution of secreted protein acidic and rich in cystein (SPARC) in
benign
and malignant
breast
tumors of different histologic types and define its association with the outcome of invasive ductal carcinoma (IDC) patients.
A total of 286 samples of
benign
and malignant
breast
lesions between 1994 and 2005 were retrieved from National Taiwan University Hospital.
Secreted protein acidic and rich in cystein was not expressed in
benign breast
phylloides and all
benign breast
tumors, while expressed in 17.2% of IDC, 85% of metaplastic carcinoma of the
breast
(MCB), and all malignant
breast
phylloides.
Individuals with positive SPARC expression had 2.34 times higher hazard of death compared with those with negative SPARC expression after adjusting for factors including positive lymph node, TNM
tumor
stage, estrogen receptor, and progesterone receptor.
[MeSH-major]
Breast
Neoplasms / chemistry. Carcinoma, Ductal,
Breast
/ chemistry. Osteonectin / analysis
[MeSH-minor]
Female
. Humans. Immunohistochemistry.
Neoplasm
Staging. Proportional Hazards Models
Genetic Alliance.
consumer health - invasive ductal carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20210803.001).
[ISSN]
1524-4741
[Journal-full-title]
The breast journal
[ISO-abbreviation]
Breast J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Osteonectin
58.
Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G:
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Med Oncol
; 2009;26(1):10-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from
breast
cancer (BCa) or prostate cancer (PCa).
Mean IL-6 levels were also higher in PCa patients and in patients with
benign
prostatic hyperplasia (BPH) than in HS while Cyst C resulted significantly higher in PCa but not in BPH patients as compared to HS.
[MeSH-major]
Bone Neoplasms / blood. Bone Neoplasms / secondary.
Breast
Neoplasms / pathology. Cystatin C / blood. Interleukin-6 / blood. Prostatic Neoplasms / pathology
[MeSH-minor]
Aged. Aged, 80 and over. Biomarkers,
Tumor
/ blood. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use.
Female
. Humans. Imidazoles / therapeutic use. Male. Middle Aged. Osteoporosis / blood. Osteoporosis / complications. Prostate-Specific Antigen / blood. ROC Curve
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Bone. 2005 Nov;37(5):601-6
[
16112634.001
]
[Cites]
Breast Cancer Res Treat. 2007 Apr;102(2):129-35
[
16927176.001
]
[Cites]
Arthritis Res Ther. 2007;9 Suppl 1:S5
[
17634144.001
]
[Cites]
Anticancer Res. 2006 Jan-Feb;26(1A):23-6
[
16475674.001
]
[Cites]
Pathol Res Pract. 2005;200(11-12):753-62
[
15792117.001
]
[Cites]
Radiology. 1983 Sep;148(3):839-43
[
6878708.001
]
[Cites]
Urology. 2001 Dec;58(6):1008-15
[
11744478.001
]
[Cites]
Bone. 2004 Sep;35(3):689-96
[
15336605.001
]
[Cites]
J Clin Endocrinol Metab. 2001 May;86(5):2032-42
[
11344203.001
]
[Cites]
Int J Biol Markers. 2000 Jan-Mar;15(1):84-9
[
10763147.001
]
[Cites]
Cancer Lett. 2006 Apr 28;235(2):159-76
[
15893421.001
]
[Cites]
Biochimie. 2008 Feb;90(2):208-26
[
17935853.001
]
[Cites]
Oncology. 2005;69(1):35-43
[
16088233.001
]
[Cites]
Br J Cancer. 2004 Jun 14;90(12):2312-6
[
15150588.001
]
[Cites]
Palliat Med. 2003 Sep;17(6):539-53
[
14526888.001
]
[Cites]
Acta Physiol Scand. 1997 Sep;161(1):81-92
[
9381954.001
]
[Cites]
Oncologist. 2004;9(6):687-95
[
15561812.001
]
[Cites]
Radiology. 1982 Apr;143(1):29-36
[
7063747.001
]
[Cites]
Cancer. 2007 Nov 1;110(9):1911-28
[
17849470.001
]
[Cites]
Eur Urol. 2007 May;51(5):1202-16
[
17182170.001
]
[Cites]
Clin Biochem. 2007 Mar;40(5-6):383-91
[
17316593.001
]
[Cites]
Bull World Health Organ. 2001;79(4):373-4
[
11357217.001
]
[Cites]
J Clin Pharmacol. 2002 Nov;42(11):1228-36
[
12412821.001
]
[Cites]
J Chemother. 2005 Oct;17(5):555-9
[
16323446.001
]
[Cites]
BJU Int. 2006 Jul;98(1):189-96
[
16831167.001
]
[Cites]
Bone. 2004 Mar;34(3):412-24
[
15003789.001
]
[Cites]
J Cell Biochem. 2004 Mar 1;91(4):718-29
[
14991763.001
]
[Cites]
Ann Oncol. 2006 Jun;17(6):986-9
[
16533874.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Aug 17;360(1):199-204
[
17592728.001
]
[Cites]
Int J Cancer. 2003 Feb 20;103(5):642-6
[
12494472.001
]
[Cites]
J Cell Biochem. 2005 Jun 1;95(3):497-505
[
15838876.001
]
[Cites]
Prostate. 1999 Jun 1;39(4):246-61
[
10344214.001
]
[Cites]
J Pathol. 2004 Jan;202(1):41-9
[
14694520.001
]
[Cites]
J Endocrinol Invest. 2002 Jun;25(6):539-46
[
12109626.001
]
[Cites]
Cancer Treat Rev. 2008 Apr;34(2):183-92
[
18061356.001
]
[Cites]
Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60
[
14746813.001
]
(PMID = 18461289.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Cystatin C; 0 / Diphosphonates; 0 / Imidazoles; 0 / Interleukin-6; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
59.
Jeryong K, Jinsun L, Hyegyong K, Eilsung C, Jiyoung S, Insang S, Moonsang A, Jiyeon K, Jaeeun H:
Total endoscopic thyroidectomy with bilateral breast areola and ipsilateral axillary (BBIA) approach.
World J Surg
; 2008 Nov;32(11):2488-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Total endoscopic thyroidectomy with bilateral
breast
areola and ipsilateral axillary (BBIA) approach.
The present study reviews our experiences with endoscopic thyroidectomy using bilateral
breast
areola and ipsilateral axillary (BBIA) approach to evaluate its safety and feasibility.
METHODS: From June 2003 through November 2007, the study group was comprised of 68 consecutive patients with
benign
thyroid nodules (66 women; mean age, 33.28 +/- 10.3 (range, 15-72) years).
RESULTS: The mean maximum diameter of the
tumor
was 3.14 +/- 1.61 (range, 1-10.7) cm.
[MeSH-minor]
Adolescent. Adult. Aged. Cohort Studies. Feasibility Studies.
Female
. Humans. Length of Stay. Male. Middle Aged. Nipples. Retrospective Studies. Treatment Outcome. Young Adult
MedlinePlus Health Information.
consumer health - Endoscopy
.
MedlinePlus Health Information.
consumer health - Thyroid Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Laryngoscope. 2006 Oct;116(10):1745-8
[
17003721.001
]
[Cites]
Thyroid. 2002 Aug;12(8):703-6
[
12225638.001
]
[Cites]
Am J Surg. 2001 Jun;181(6):567-70
[
11513788.001
]
[Cites]
J Surg Oncol. 1998 Nov;69(3):178-80
[
9846506.001
]
[Cites]
Surg Endosc. 2002 Dec;16(12 ):1741-5
[
12140635.001
]
[Cites]
Am J Surg. 2000 Aug;180(2):82-5
[
11044518.001
]
[Cites]
Anesth Analg. 1997 May;84(5):1154-6
[
9141952.001
]
[Cites]
Biomed Pharmacother. 2002;56 Suppl 1:68s-71s
[
12487256.001
]
[Cites]
World J Surg. 2004 Nov;28(11):1075-8
[
15490052.001
]
[Cites]
J Am Coll Surg. 2003 Feb;196(2):189-95
[
12595044.001
]
[Cites]
Anesth Analg. 2000 Mar;90(3):760-2
[
10702471.001
]
[Cites]
Br J Surg. 1996 Jun;83(6):875
[
8696772.001
]
[Cites]
Surg Laparosc Endosc. 1994 Apr;4(2):92-9
[
8180774.001
]
[Cites]
Biomed Pharmacother. 2002;56 Suppl 1:64s-67s
[
12487255.001
]
[Cites]
Surgery. 2000 Dec;128(6):1035-42
[
11114640.001
]
[Cites]
J Am Coll Surg. 2000 Sep;191(3):336-40
[
10989910.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4
[
10872517.001
]
(PMID = 18668282.001).
[ISSN]
0364-2313
[Journal-full-title]
World journal of surgery
[ISO-abbreviation]
World J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
60.
Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ:
c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer.
Hum Pathol
; 2006 Jun;37(6):668-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
c-Jun activation is associated with proliferation and angiogenesis in invasive
breast
cancer.
To evaluate expression patterns of activated c-Jun in
breast
cancer in relation to angiogenesis and proliferation, we performed immunohistochemistry on 103 cases of invasive
breast
cancer with an antibody recognizing phosphorylated c-Jun at serine 73.
Activated c-Jun showed a predominantly nuclear expression at the invasive front in 38% of invasive
breast
cancer cases.
Occasionally, fibroblasts, endothelial cells, and
benign breast
cells showed nuclear expression.
Our results show that activated c-Jun is predominantly expressed at the invasive front in
breast
cancer and is associated with proliferation and angiogenesis.
Earlier studies have established a functional, in vitro link between activated c-Jun and
tumor
angiogenesis.
Our present results in
breast
cancer patients confirm this relation in vivo for the first time.
Therefore, c-Jun/AP-1 targeting may provide new ways to block
tumor
angiogenesis.
[MeSH-major]
Breast
Neoplasms / enzymology.
Breast
Neoplasms / metabolism. Cell Proliferation. Neovascularization, Pathologic / metabolism. Proto-Oncogene Proteins c-jun / analysis
[MeSH-minor]
Antineoplastic Agents, Hormonal / therapeutic use. Enzyme Activation.
Female
. Follow-Up Studies. Humans. Immunohistochemistry.
Neoplasm
Invasiveness.
Neoplasm
Recurrence, Local. Survival Analysis. Tamoxifen / therapeutic use. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16733206.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Hormonal; 0 / Proto-Oncogene Proteins c-jun; 094ZI81Y45 / Tamoxifen
61.
Grosso M, Chiacchio S, Bianchi F, Traino C, Marini C, Cilotti A, Manca G, Volterrani D, Roncella M, Rampin L, Marzola MC, Rubello D, Mariani G:
Comparison between 99mTc-sestamibi scintimammography and X-ray mammography in the characterization of clusters of microcalcifications: a prospective long-term study.
Anticancer Res
; 2009 Oct;29(10):4251-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The early
diagnosis of
non-palpable
breast
cancer is the object of recent developments in the imaging procedures employed for screening purposes.
In some patients, the presence of microcalcifications (MC) is the only indication of
tumor
.
The aim of this study was to compare (99m)Tc-sestamibi scintimammography (SMM) and MRx in the differential
diagnosis
between
benign
and malignant clusters of MC and to assess the possible incremental value of SMM on specificity.
Scintigraphic images were acquired 10 minutes after
the i
.v. injection of (99m)Tc-sestamibi (740 MBq).
Sixty-nine women underwent surgery, whereas the remaining 214 patients had completely negative follow-up for 5 years (a 5-year follow-up period is considered the "gold standard" for diagnosing
benign
lesions).
RESULTS: Histology demonstrated 32/69 primary
breast
carcinomas (prevalence of disease: 11% of all the 283 patients) and 37/69
benign
lesions.
CONCLUSION: SMM can be considered as a complementary tool in the pre-operative work-up of patients with
breast
lesions.
Furthermore, the high negative predictive value of this technique, makes it especially valuable in the perspective of reducing the number of negative
breast
biopsies or unnecessary surgical interventions.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Calcinosis /
diagnosis
. Radiopharmaceuticals. Technetium Tc 99m Sestamibi
[MeSH-minor]
Adult. Aged.
Female
. Humans. Mammography / methods. Middle Aged. Prospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19846982.001).
[ISSN]
1791-7530
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
62.
Veltman J, Mann R, Kok T, Obdeijn IM, Hoogerbrugge N, Blickman JG, Boetes C:
Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.
Eur Radiol
; 2008 May;18(5):931-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Breast tumor
characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI.
Thus, 29 BRCA-MCs with
breast
cancer were retrospectively evaluated and the results compared with an age,
tumor
size and
tumor
type matched control group of 29 sporadic
breast
cancer cases.
Malignant lesions in BRCA-MC frequently have morphological characteristics commonly seen in
benign
lesions, like a rounded shape or sharp margins.
[MeSH-major]
Breast
Neoplasms / genetics.
Breast
Neoplasms / pathology. Genes, BRCA1. Genes, BRCA2. Magnetic Resonance Imaging
[MeSH-minor]
Adult. Case-Control Studies. Contrast Media. False Negative Reactions.
Female
. Gadolinium DTPA. Humans. Image Processing, Computer-Assisted. Mammography. Mutation. Retrospective Studies
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2007 Aug 11;370(9586):485-92
[
17693177.001
]
[Cites]
Breast Cancer Res Treat. 2007 May;102(3):357-63
[
17051427.001
]
[Cites]
J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7
[
10880551.001
]
[Cites]
Am J Surg Pathol. 2001 Mar;25(3):331-7
[
11224603.001
]
[Cites]
N Engl J Med. 2001 Jul 19;345(3):159-64
[
11463009.001
]
[Cites]
Eur Radiol. 2001;11(9):1645-50
[
11511885.001
]
[Cites]
N Engl J Med. 2002 May 23;346(21):1609-15
[
12023992.001
]
[Cites]
Int J Cancer. 2002 Nov 1;102(1):91-5
[
12353239.001
]
[Cites]
Radiology. 2002 Oct;225(1):165-75
[
12355001.001
]
[Cites]
Lancet. 2003 Jan 25;361(9354):296-300
[
12559863.001
]
[Cites]
J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):89-95
[
12585661.001
]
[Cites]
Eur Radiol. 2003 Nov;13 Suppl 3:N28-36
[
15015878.001
]
[Cites]
Cancer. 2004 May 15;100(10):2079-83
[
15139048.001
]
[Cites]
N Engl J Med. 2004 Jul 29;351(5):427-37
[
15282350.001
]
[Cites]
Eur Radiol. 2004 Sep;14(9):1647-53
[
15083333.001
]
[Cites]
Clin Radiol. 2004 Oct;59(10):895-902
[
15451348.001
]
[Cites]
Radiology. 1992 Sep;184(3):623-7
[
1324506.001
]
[Cites]
Mayo Clin Proc. 1993 May;68(5):454-60
[
8479209.001
]
[Cites]
Radiology. 1994 Feb;190(2):485-93
[
8284404.001
]
[Cites]
Lancet. 1994 Mar 19;343(8899):692-5
[
7907678.001
]
[Cites]
Radiology. 1994 Aug;192(2):439-42
[
8029411.001
]
[Cites]
N Engl J Med. 1997 May 15;336(20):1416-21
[
9145678.001
]
[Cites]
Radiology. 1999 Apr;211(1):101-10
[
10189459.001
]
[Cites]
Lancet. 2005 May 21-27;365(9473):1769-78
[
15910949.001
]
[Cites]
J Clin Oncol. 2005 Nov 20;23(33):8469-76
[
16293877.001
]
[Cites]
Radiology. 2006 Jan;238(1):42-53
[
16373758.001
]
[Cites]
JAMA. 2006 May 24;295(20):2374-84
[
16720823.001
]
[Cites]
Eur Radiol. 2006 Dec;16(12):2842-8
[
16924440.001
]
[Cites]
Radiology. 2007 Mar;242(3):698-715
[
17244718.001
]
[Cites]
Eur Radiol. 2007 Apr;17(4):873-87
[
17008989.001
]
[Cites]
Radiology. 2000 Apr;215(1):267-79
[
10751498.001
]
(PMID = 18270717.001).
[ISSN]
0938-7994
[Journal-full-title]
European radiology
[ISO-abbreviation]
Eur Radiol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
[Other-IDs]
NLM/ PMC2292493
63.
Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P:
Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
J Nucl Med
; 2008 Sep;49(9):1429-36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with
benign
and malignant etiology.
Our objective was to evaluate features of these foci associated with
benign
or malignant etiology.
Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary
tumor
, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time.
The gold standard was histologic
diagnosis
or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo).
On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for
benign
, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for
benign
, P < 0.01; t test).
Variables associated with
benign
etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for
benign
vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were
benign
vs. 34% of
breast
, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test).
CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a
benign
etiology.
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Female
. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Nucl Med. 2009 Mar;50(3):489-90
[
19223415.001
]
(PMID = 18765585.001).
[ISSN]
0161-5505
[Journal-full-title]
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
[ISO-abbreviation]
J. Nucl. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
64.
Sasaki Y, Kamata S, Saito K, Nishikawa Y, Ogawa J:
Pseudoangiomatous stromal hyperplasia (PASH) of the mammary gland: report of a case.
Surg Today
; 2008;38(4):340-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pseudoangiomatous stromal hyperplasia (PASH) is an uncommon
benign breast
disease.
We herein report the case of a 48-year-old woman who presented with a huge mass in her right
breast
.
Histopathologically, the
tumor
was composed of abundant fibrous stroma containing non-vascular slit-like spaces and scattered ducts and lobules.
We therefore diagnosed the
tumor
to be PASH.
[MeSH-major]
Angiomatosis / pathology.
Breast
/ pathology.
Breast
Diseases / pathology. Stromal Cells / pathology
[MeSH-minor]
Biopsy, Fine-Needle. Cell Proliferation.
Diagnosis
, Differential.
Female
. Humans. Hyperplasia / pathology. Mammography. Middle Aged. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Pseudoangiomatous stromal hyperplasia
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 1995 Mar;19(3):270-7
[
7872425.001
]
[Cites]
Breast J. 2004 Sep-Oct;10 (5):427-32
[
15327497.001
]
[Cites]
Am J Surg Pathol. 1991 Feb;15(2):145-9
[
1989462.001
]
[Cites]
Cancer. 1989 Mar 15;63(6):1154-60
[
2917318.001
]
[Cites]
Hum Pathol. 1986 Feb;17(2):185-91
[
3949338.001
]
[Cites]
Pathol Res Pract. 1998;194(8):535-40
[
9779487.001
]
[Cites]
J Clin Pathol. 1998 Mar;51(3):204-6
[
9659260.001
]
[Cites]
Radiology. 1996 Jan;198(1):117-20
[
8539361.001
]
[Cites]
Breast. 2004 Oct;13(5):431-5
[
15454202.001
]
[Cites]
Diagn Cytopathol. 2004 May;30(5):353-5
[
15108236.001
]
(PMID = 18368324.001).
[ISSN]
0941-1291
[Journal-full-title]
Surgery today
[ISO-abbreviation]
Surg. Today
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
65.
Tanaka Y, Bhunchet E, Shibata T:
A case of malignant eccrine spiradenoma metastatic to intramammary lymph node.
Breast Cancer
; 2008;15(2):175-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Eccrine spiradenoma (ES) is a fairly common,
benign
, cutaneous
tumor
originating from the sweat glands.
We present the first reported case of this
tumor
metastasizing to an intramammary lymph node (IMLN).
The uncommon metastasizing focus of the periumbilical MES and its histopathological similarity with a primary
breast
carcinoma made
the diagnosis
difficult.
[MeSH-minor]
Aged.
Female
. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis / pathology. Mammary Glands, Human. Tomography, X-Ray Computed. Ultrasonography, Mammary
Genetic Alliance.
consumer health - Malignant eccrine spiradenoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18270794.001).
[ISSN]
1880-4233
[Journal-full-title]
Breast cancer (Tokyo, Japan)
[ISO-abbreviation]
Breast Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
66.
Huang YL, Kuo SJ, Chang CS, Liu YK, Moon WK, Chen DR:
Image retrieval with principal component analysis for breast cancer diagnosis on various ultrasonic systems.
Ultrasound Obstet Gynecol
; 2005 Oct;26(5):558-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Image retrieval with principal component analysis for
breast
cancer
diagnosis
on various ultrasonic systems.
OBJECTIVES: We present a computer-aided diagnostic (CAD) system with textural features and image retrieval strategies for classifying
benign
and malignant
breast
tumors on various ultrasonic systems.
This study evaluated a series of pathologically proven
breast
tumors using various ultrasonic systems.
METHODS: Altogether, 600 ultrasound images of solid
breast
nodules comprising 230 malignant and 370
benign
tumors were investigated.
The suspicious
tumor
area in the ultrasound image was manually chosen as the region-of-interest (ROI) subimage.
Textural features extracted from the ROI subimage are supported in classifying the
breast tumor
as
benign
or malignant.
In practice, high-dimensional vectors are unsatisfactory at differentiating
breast
tumors.
The image retrieval techniques were employed to differentiate
breast
tumors, according to the similarities of the principal vectors.
The query ROI subimages were identified as malignant or
benign
tumors according to characteristics of retrieved images from the ultrasound image database.
CONCLUSION: The CAD system identified solid
breast
nodules with comparatively high accuracy in the different ultrasound systems investigated.
[MeSH-major]
Breast
Neoplasms / ultrasonography. Image Interpretation, Computer-Assisted / methods
[MeSH-minor]
Area Under Curve.
Breast
Diseases / classification.
Breast
Diseases / ultrasonography. Databases, Factual.
Female
. Humans. Principal Component Analysis. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 ISUOG.
(PMID = 16086435.001).
[ISSN]
0960-7692
[Journal-full-title]
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
[ISO-abbreviation]
Ultrasound Obstet Gynecol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
67.
Galiè M, Farace P, Merigo F, Fiorini S, Tambalo S, Nicolato E, Sbarbati A, Marzola P:
Washout of small molecular contrast agent in carcinoma-derived experimental tumors.
Microvasc Res
; 2009 Dec;78(3):370-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of
breast
carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling.
Its capability to differentiate
benign
from malignant lesion is under continuous investigation.
In particular, the study of the washout pattern is considered a promising tool to improve in vivo
diagnosis
and even to evaluate the response under chemotherapy.
To provide a comprehensive characterization of this parameter in malignant
tumor
models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features.
It resulted that in all models around 40% of
tumor
volume lacks efficient washout; washout areas are frequently, but not always, restricted to the
tumor
periphery and that non-washout areas are not restricted to necrotic regions.
[MeSH-major]
Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Mammary Neoplasms, Experimental /
diagnosis
[MeSH-minor]
Animals.
Female
. Lymphatic Vessels / pathology. Mice. Mice, Inbred Strains. Microvessels / pathology.
Neoplasm
Transplantation. Neovascularization, Pathologic / pathology
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19804787.001).
[ISSN]
1095-9319
[Journal-full-title]
Microvascular research
[ISO-abbreviation]
Microvasc. Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
68.
Balci P, Kabakci N, Topcu I, Canda T, Güray M, Ozfidan S:
Breast myxoma: Radiologic and histopathologic features.
Breast J
; 2007 Jan-Feb;13(1):88-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Breast
myxoma: Radiologic and histopathologic features.
Myxomas are
benign
mesenchymal tumors, which rarely develop in the
breast
.
We present a case of this rare type of
breast tumor
with sonographic and mammographic findings.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Myxoma /
diagnosis
[MeSH-minor]
Adult.
Diagnosis
, Differential.
Female
. Humans. Mammography
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17214801.001).
[ISSN]
1075-122X
[Journal-full-title]
The breast journal
[ISO-abbreviation]
Breast J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
69.
Yang W, Zhang S, Chen Y, Li W, Chen Y:
Shape symmetry analysis of breast tumors on ultrasound images.
Comput Biol Med
; 2009 Mar;39(3):231-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Shape symmetry analysis of
breast
tumors on ultrasound images.
Shape characteristics of malignant and
benign breast
tumors are significantly different.
In this paper, the reflective symmetry of
breast tumor
shapes on ultrasound images was investigated.
A new reflective symmetry measure (RSML) derived from multiscale local area integral invariant was proposed to quantify the shape symmetry of
breast tumor
, which could be computed directly from the binary mask image without the shape parameterization in terms of arc length.
The performance of several symmetry measures for differentiating malignant and
benign breast
tumors at varying scales was evaluated and compared by receiver operating characteristic (ROC) analysis.
RSML with Gaussian kernel at scale 0.04 (related to the maximal diameter) achieved the highest area under the ROC curve (0.85) on the image data of 168 tumors (104
benign
and 64 malignant).
The experimental results showed that the reflective symmetry of
breast tumor
shape was capable of providing potential diagnostic information, which could be characterized quantitatively by RSML with the appropriate scale parameter.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms /
diagnosis
. Image Interpretation, Computer-Assisted / methods. Ultrasonography / methods. Ultrasonography, Mammary / methods
[MeSH-minor]
Adolescent. Adult. Aged.
Female
. Humans. Middle Aged. Normal Distribution. Principal Component Analysis. ROC Curve. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Ultrasound
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19178908.001).
[ISSN]
1879-0534
[Journal-full-title]
Computers in biology and medicine
[ISO-abbreviation]
Comput. Biol. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
70.
Yavisheva TM, Shcherbakov SD, Golubeva IS, Savluchinskaya LA:
Comparative analysis of the work of morphofunctional zones in normal epithelium, fibroadenoma, and cancer of the breast.
Bull Exp Biol Med
; 2005 Aug;140(2):231-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparative analysis of the work of morphofunctional zones in normal epithelium, fibroadenoma, and cancer of the
breast
.
The number of cambial cells in morphofunctional zone of a malignant
tumor
is reduced at least 2-fold.
The percentage of cambial cells in a
benign tumor
decreases 1.5 times.
[MeSH-major]
Breast
Neoplasms / metabolism. Epithelium / metabolism. Fibroadenoma / metabolism
[MeSH-minor]
Adult. Cell Differentiation. Cells, Cultured. Culture Techniques. Electromagnetic Fields.
Female
. Humans. Microscopy, Video. Middle Aged
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16283009.001).
[ISSN]
0007-4888
[Journal-full-title]
Bulletin of experimental biology and medicine
[ISO-abbreviation]
Bull. Exp. Biol. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
71.
Iqbal J, He G, Biesecker LG, Rosen P, Duray PH, Schwartzentruber D, Beg M, Kahn E:
Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ.
Ann Clin Lab Sci
; 2006;36(4):469-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Morphological characterization of the
breast
in Proteus syndrome complicated by ductal carcinoma in situ.
Proteus syndrome (PS) is a severe, variable, and rare
disorder
with asymmetric and disproportionate overgrowth of body parts, cerebriform connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations.
It is associated with
benign
and occasionally malignant tumors.
This case highlights the difficulty of recognizing small foci of carcinoma in an asymmetrical overgrowth of the
breast
in a young woman with PS.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Proteus Syndrome / pathology
[MeSH-minor]
Adult. Biomarkers,
Tumor
/ analysis.
Female
. Humans. Mastectomy
Genetic Alliance.
consumer health - Proteus syndrome
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17127737.001).
[ISSN]
0091-7370
[Journal-full-title]
Annals of clinical and laboratory science
[ISO-abbreviation]
Ann. Clin. Lab. Sci.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Case Reports; Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
72.
Hsu SD, Chou SJ, Hsieh HF, Chen TW, Cheng MF, Yu JC:
Giant malignant mammary phyllodes tumor: report of a case and review of the literature.
Onkologie
; 2007 Feb;30(1-2):45-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Giant malignant mammary phyllodes
tumor
: report of a case and review of the literature.
BACKGROUND: To distinguish between a
benign
and malignant phyllodes
tumor
before surgery is difficult.
Wide excision or mastectomy with adequate free margins is necessary in the case of a malignant phyllodes
tumor
.
However, repairing the skin defect after removal of a giant malignant phyllodes
tumor
is a great challenge for the
breast
surgeon.
CASE REPORT: We report the case of a 45-year-old Taiwanese woman with a giant malignant phyllodes
tumor
measuring 30 x 25 x 22 cm.
[MeSH-major]
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / surgery. Mastectomy, Simple / methods. Phyllodes
Tumor
/
diagnosis
. Phyllodes
Tumor
/ surgery. Surgical Flaps
[MeSH-minor]
Diagnosis
, Differential.
Female
. Humans. Middle Aged. Treatment Outcome
Genetic Alliance.
consumer health - Phyllodes Tumor
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17264525.001).
[ISSN]
0378-584X
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Switzerland
[Number-of-references]
7
73.
Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC:
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.
Breast Cancer Res
; 2005;7(6):R871-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive
breast
tumors: results from a population-based study.
INTRODUCTION: Evidence suggests that alterations in estrogen signaling pathways, including estrogen receptor-alpha (ER-alpha), occur during
breast
cancer development.
This mutation was initially reported in one-third of hyperplastic
benign breast
lesions, although several recent studies failed to detect it in
benign
or malignant
breast
tissues.
METHODS: We screened 653 microdissected, newly diagnosed invasive
breast
tumors from patients in the Carolina
Breast
Cancer Study, a population-based case-control study of
breast
cancer in African American and white women in North Carolina, for the presence of the ER-alpha A908G mutation by using single-strand conformational polymorphism (SSCP) analysis and 33P-cycle sequencing.
RESULTS: We detected the ER-alpha A908G mutation in 37 of 653 (5.7%)
breast
tumors.
The ER-alpha A908G mutation was found more frequently in higher-grade
breast
tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
CONCLUSION: This population-based study, the largest so far to screen for the ER-alpha A908G mutation in
breast
cancer, confirms the presence of the mutant in invasive
breast
tumors.
The mutation was associated with higher
tumor
grade and mixed lobular/ductal
breast tumor
histology.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7
[
10619354.001
]
[Cites]
Breast Cancer Res Treat. 1999 Nov;58(1):31-9
[
10634516.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7
[
10377423.001
]
[Cites]
Nucleic Acids Res. 1999 Mar 1;27(5):1405-7
[
9973633.001
]
[Cites]
Int J Oncol. 1998 Jun;12(6):1225-8
[
9592178.001
]
[Cites]
Breast Cancer Res. 2005;7(1):R113-8
[
15642159.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):9199-208
[
15604293.001
]
[Cites]
Endocr Rev. 2004 Dec;25(6):869-98
[
15583021.001
]
[Cites]
Carcinogenesis. 2000 Mar;21(3):427-33
[
10688862.001
]
[Cites]
Am J Epidemiol. 2000 Apr 1;151(7):703-14
[
10752798.001
]
[Cites]
Cancer Res. 2000 Aug 1;60(15):4026-9
[
10945602.001
]
[Cites]
Int J Cancer. 2000 Dec 1;88(5):733-6
[
11072241.001
]
[Cites]
Breast Cancer. 2003;10(1):70-3
[
12525766.001
]
[Cites]
Breast Cancer Res Treat. 2004 Apr;84(3):289-92
[
15026626.001
]
[Cites]
Genes Chromosomes Cancer. 2004 May;40(1):51-4
[
15034868.001
]
[Cites]
Cancer Cell. 2004 Jun;5(6):597-605
[
15193262.001
]
[Cites]
Epidemiol Rev. 1993;15(1):17-35
[
8405201.001
]
[Cites]
Breast Cancer Res Treat. 1995 Jul;35(1):51-60
[
7612904.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Jul;82(7):2371-4
[
9215322.001
]
[Cites]
Nucleic Acids Res. 1997 Nov 15;25(22):4500-4
[
9358158.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65
[
9398750.001
]
[Cites]
J Steroid Biochem Mol Biol. 1997 Aug;62(5-6):363-72
[
9449239.001
]
(PMID = 16280033.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / 5-P50-CA58223
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / DNA Primers; 0 / Estrogen Receptor alpha
[Other-IDs]
NLM/ PMC1410768
74.
Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE:
Tumors associated with superficial thrombophlebitis.
Vasa
; 2009 May;38(2):167-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early
tumor
detection.
RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant
tumor
:
breast
cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .
In two patients thrombophlebitis preceded
the diagnosis
of the malignancy.
Superficial thrombophlebitis may have been associated in four cases (2.9%) with a
benign tumor
.
CONCLUSIONS:
Breast
, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.
In case of a thrombophlebitis without a known malignancy a thorough clinical examination with special regard to skin,
breast
and abdomen is mandatory.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Early
Diagnosis
.
Female
. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Ultrasonography, Doppler, Duplex. Venous Insufficiency / complications. Venous Insufficiency / epidemiology. Venous Insufficiency / ultrasonography
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19588305.001).
[ISSN]
0301-1526
[Journal-full-title]
VASA. Zeitschrift für Gefässkrankheiten
[ISO-abbreviation]
VASA
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
75.
Cichon MA, Degnim AC, Visscher DW, Radisky DC:
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.
J Mammary Gland Biol Neoplasia
; 2010 Dec;15(4):389-97
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microenvironmental influences that drive progression from
benign breast
disease to invasive
breast
cancer.
Invasive
breast
cancer represents the endpoint of a developmental process that originates in the terminal duct lobular units and is believed to progress through stages of increasing proliferation, atypical hyperplasia, and carcinoma in situ before the cancer acquires invasive and metastatic capabilities.
By comparison with invasive
breast
cancer, which has been studied extensively, the preceding stages of
benign breast
disease are more poorly understood.
Much less is known about the molecular changes underlying
benign breast
disease development and progression, as well as the transition from in situ into invasive disease.
More challenges are posed by limitations of the models used to investigate the lesions preceding invasive
breast
cancer.
However, recent studies have identified alterations in stromal cell function that may be critical for disease progression from
benign
disease to invasive cancer: key functions of myoepithelial cells that maintain tissue structure are lost, while tissue fibroblasts become activated to produce proteases that degrade the extracellular matrix and trigger the invasive cellular phenotype.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
[
12714683.001
]
[Cites]
Cancer Res. 2004 Jan 15;64(2):590-8
[
14744773.001
]
[Cites]
Med Hypotheses. 1997 Jan;48(1):37-46
[
9049988.001
]
[Cites]
J Natl Cancer Inst. 1998 May 6;90(9):697-703
[
9586667.001
]
[Cites]
Clin Cancer Res. 1997 Nov;3(11):1949-58
[
9815584.001
]
[Cites]
Virchows Arch. 1999 Mar;434(3):227-34
[
10190302.001
]
[Cites]
Cancer Res. 1999 Oct 1;59(19):5002-11
[
10519415.001
]
[Cites]
J Theor Biol. 2005 Jan 21;232(2):179-89
[
15530488.001
]
[Cites]
J Am Coll Surg. 2005 Mar;200(3):328-35
[
15737842.001
]
[Cites]
Cell. 2005 May 6;121(3):335-48
[
15882617.001
]
[Cites]
PLoS Biol. 2005 Jun;3(6):e187
[
15869330.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6130-8
[
16024614.001
]
[Cites]
N Engl J Med. 2005 Jul 21;353(3):275-85
[
16034013.001
]
[Cites]
Nat Genet. 2005 Aug;37(8):899-905
[
16007089.001
]
[Cites]
Breast Cancer Res. 2005;7(5):190-7
[
16168137.001
]
[Cites]
Ann Intern Med. 2005 Sep 20;143(6):446-57
[
16172443.001
]
[Cites]
Cell Cycle. 2005 Aug;4(8):1022-5
[
16082203.001
]
[Cites]
Cancer Res. 2006 Jan 1;66(1):29-33
[
16397211.001
]
[Cites]
Nat Rev Cancer. 2006 May;6(5):392-401
[
16572188.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5278-86
[
16707453.001
]
[Cites]
Oncologist. 2006 May;11(5):435-49
[
16720843.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47
[
16807803.001
]
[Cites]
Breast Cancer Res. 2006;8(5):R58
[
17054791.001
]
[Cites]
Breast Cancer Res. 2006;8(5):R61
[
17069663.001
]
[Cites]
J Clin Oncol. 2007 Jul 1;25(19):2671-7
[
17563394.001
]
[Cites]
Rev Endocr Metab Disord. 2007 Sep;8(3):279-87
[
17447144.001
]
[Cites]
J Pathol. 2008 Feb;214(3):357-67
[
18044827.001
]
[Cites]
Clin Cancer Res. 2008 Jan 15;14(2):370-8
[
18223211.001
]
[Cites]
Cancer. 2008 May 15;112(10):2130-42
[
18383519.001
]
[Cites]
Cancer Cell. 2008 May;13(5):394-406
[
18455123.001
]
[Cites]
Breast Cancer Res Treat. 2008 May;109(2):189-98
[
17624587.001
]
[Cites]
Nat Med. 2008 May;14(5):518-27
[
18438415.001
]
[Cites]
Lab Invest. 2008 Jun;88(6):591-601
[
18414401.001
]
[Cites]
Anticancer Res. 1999 Sep-Oct;19(5B):4257-64
[
10628384.001
]
[Cites]
J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6
[
10904098.001
]
[Cites]
Breast Cancer Res Treat. 2000 Dec;64(3):235-40
[
11200773.001
]
[Cites]
Breast Cancer Res Treat. 2001 Jan;65(2):101-10
[
11261825.001
]
[Cites]
Endocr Relat Cancer. 2001 Mar;8(1):47-61
[
11350726.001
]
[Cites]
J Cell Sci. 2002 Jan 1;115(Pt 1):39-50
[
11801722.001
]
[Cites]
J Clin Oncol. 2003 Jan 1;21(1):41-5
[
12506168.001
]
[Cites]
Cancer. 2003 Apr 1;97(7):1601-8
[
12655515.001
]
[Cites]
Clin Cancer Res. 2008 Sep 1;14(17):5357-67
[
18765527.001
]
[Cites]
Breast Cancer Res. 2008;10(5):R87
[
18928525.001
]
[Cites]
J Clin Oncol. 2009 Jan 10;27(2):279-88
[
19064970.001
]
[Cites]
Am J Surg Pathol. 2009 Feb;33(2):227-32
[
18936688.001
]
[Cites]
Clin Cancer Res. 2009 Feb 1;15(3):778-87
[
19188147.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7
[
19218449.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7022-7
[
19369208.001
]
[Cites]
Breast Cancer Res. 2009;11(1):R7
[
19187537.001
]
[Cites]
Breast Cancer Res. 2009;11(1):101
[
19291276.001
]
[Cites]
Breast Cancer Res. 2009;11 Suppl 3:S16
[
20030867.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12
[
20440544.001
]
[Cites]
Mol Oncol. 2010 Jun;4(3):192-208
[
20452298.001
]
[Cites]
Breast Cancer Res Treat. 2010 Sep;123(2):397-404
[
19949854.001
]
[Cites]
Histopathology. 2010 Aug;57(2):171-92
[
20500230.001
]
[Cites]
Cancer. 2010 Nov 1;116(21):4944-53
[
20645399.001
]
[Cites]
J Pathol. 2011 Jan;223(2):307-17
[
21125683.001
]
[Cites]
FEBS J. 2011 Jan;278(1):16-27
[
21087457.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91
[
14973383.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71
[
15051869.001
]
[Cites]
N Engl J Med. 2004 Apr 1;350(14):1430-41
[
15070793.001
]
[Cites]
Cancer Cell. 2004 Jul;6(1):17-32
[
15261139.001
]
[Cites]
J Natl Cancer Inst. 1973 May;50(5):1111-8
[
4123242.001
]
[Cites]
J Natl Cancer Inst. 1975 Aug;55(2):231-73
[
169369.001
]
[Cites]
N Engl J Med. 1985 Jan 17;312(3):146-51
[
3965932.001
]
[Cites]
Cancer Res. 1990 Sep 15;50(18):6075-86
[
1975513.001
]
[Cites]
JAMA. 1992 Feb 19;267(7):941-4
[
1734106.001
]
[Cites]
J Natl Cancer Inst. 1993 Nov 3;85(21):1725-32
[
8411256.001
]
[Cites]
Eur J Cancer Prev. 1993 Nov;2 Suppl 3:67-76
[
7507749.001
]
[Cites]
J Natl Cancer Inst. 1994 Apr 20;86(8):614-9
[
7511693.001
]
[Cites]
J Cell Biochem Suppl. 1996;25:112-22
[
9027607.001
]
(PMID = 21161341.001).
[ISSN]
1573-7039
[Journal-full-title]
Journal of mammary gland biology and neoplasia
[ISO-abbreviation]
J Mammary Gland Biol Neoplasia
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA116201; United States / NCI NIH HHS / CA / CA90628-08; United States / NCI NIH HHS / CA / CA122086; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA132879; United States / NCI NIH HHS / CA / CA128660; United States / NCI NIH HHS / CA / R21 CA128660; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / R01 CA132879; United States / NCI NIH HHS / CA / R01 CA122086
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3011086
76.
Wong CM, Anderton DL, Smith-Schneider S, Wing MA, Greven MC, Arcaro KF:
Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women.
Epigenetics
; 2010 Oct 1;5(7):645-55
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from
breast
milk of healthy women.
Promoter methylation analysis of genes frequently silenced in
breast
cancer is a promising indicator of
breast
cancer risk, as these methylation events are thought to occur long before presentation of disease.
The numerous exfoliated epithelial cells present in
breast
milk may provide the
breast
epithelial DNA needed for detailed methylation analysis and assessment of
breast
cancer risk.
Fresh
breast
milk samples and health, lifestyle, and reproductive history questionnaires were collected from 111 women.
Pyrosequencing analysis was conducted on DNA isolated from the exfoliated epithelial cells immunomagnetically separated from the total cell population in the
breast
milk of 102 women.
A total of 65 CpG sites were examined in six
tumor
suppressor genes: PYCARD (also known as ASC or TMS1), CDH1, GSTP1, RBP1 (also known as CRBP1), SFRP1, and RASSF1.
Methylation scores were in general low as expected of
benign
tissue, but analysis of outlier methylation scores revealed a significant relationship between
breast
cancer risk, as indicated by previous biopsy, and methylation score for several CpG sites in CDH1, GSTP1, SFRP1, and RBP1.
Promoter methylation patterns in DNA from
breast
milk epithelial cells can likely be used to assess
breast
cancer risk.
Additional studies of women at high
breast
cancer risk are warranted.
[MeSH-major]
DNA Methylation. Genes,
Tumor
Suppressor. Milk, Human / cytology. Milk, Human / metabolism. Promoter Regions, Genetic
[MeSH-minor]
Adult. Age Factors.
Breast
/ cytology.
Breast
/ metabolism.
Breast
Neoplasms / genetics. Cadherins / genetics. CpG Islands. Cytoskeletal Proteins / genetics. Epithelial Cells / metabolism.
Female
. Glutathione S-Transferase pi / genetics. Humans. Intercellular Signaling Peptides and Proteins / genetics. Lactation / genetics. Membrane Proteins / genetics. Middle Aged. Retinol-Binding Proteins, Cellular / genetics. Risk Factors.
Tumor
Suppressor Proteins / genetics. Young Adult
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2003 Aug 15;9(9):3413-7
[
12960130.001
]
[Cites]
J Surg Res. 2003 Jul;113(1):102-8
[
12943817.001
]
[Cites]
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32
[
14734448.001
]
[Cites]
Mol Cancer. 2004 Apr 27;3:13
[
15113415.001
]
[Cites]
Int J Cancer. 1983 Jun 15;31(6):701-4
[
6862681.001
]
[Cites]
Oncologist. 2004;9(6):599-605
[
15561804.001
]
[Cites]
Nat Rev Cancer. 2004 Dec;4(12):988-93
[
15573120.001
]
[Cites]
J Natl Cancer Inst. 2005 Jan 5;97(1):21-9
[
15632377.001
]
[Cites]
J Natl Cancer Inst. 2000 Mar 15;92(6):475-80
[
10716965.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):166-72
[
15671542.001
]
[Cites]
Br J Cancer. 2005 Jan 17;92(1):167-75
[
15597097.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):324-8
[
15734953.001
]
[Cites]
Clin Cancer Res. 2005 Mar 15;11(6):2156-62
[
15788661.001
]
[Cites]
Cancer Lett. 2005 Apr 28;221(2):135-43
[
15808399.001
]
[Cites]
Cancer Res. 2005 May 1;65(9):3497-508
[
15867337.001
]
[Cites]
Endocr Relat Cancer. 2005 Jun;12(2):185-213
[
15947097.001
]
[Cites]
Br J Cancer. 2006 Feb 27;94(4):561-8
[
16449996.001
]
[Cites]
Nat Rev Cancer. 2006 Apr;6(4):281-91
[
16557280.001
]
[Cites]
Cancer Lett. 2006 Jun 18;237(2):272-80
[
16029926.001
]
[Cites]
Oncogene. 2006 Jun 8;25(24):3479-88
[
16449975.001
]
[Cites]
Breast Cancer Res Treat. 2006 Jul;98(1):63-70
[
16685591.001
]
[Cites]
BMC Cancer. 2006;6:48
[
16512896.001
]
[Cites]
Cell. 2007 Feb 23;128(4):683-92
[
17320506.001
]
[Cites]
Mod Pathol. 2007 Jul;20(7):711-21
[
17464311.001
]
[Cites]
Virchows Arch. 2007 Jun;450(6):637-42
[
17479284.001
]
[Cites]
Clin Cancer Res. 2007 Jul 1;13(13):3796-802
[
17606710.001
]
[Cites]
Life Sci. 2007 Jul 4;81(4):280-7
[
17599361.001
]
[Cites]
Trends Genet. 2007 Aug;23(8):413-8
[
17559965.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1812-21
[
17855699.001
]
[Cites]
J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72
[
17878233.001
]
[Cites]
Expert Rev Mol Diagn. 2007 Sep;7(5):533-44
[
17892362.001
]
[Cites]
Epigenetics. 2006 Apr-Jun;1(2):88-93
[
17998817.001
]
[Cites]
Annu Rev Med. 2008;59:267-80
[
17937590.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1051-9
[
18483325.001
]
[Cites]
Pathobiology. 2008;75(2):149-52
[
18544970.001
]
[Cites]
Isr Med Assoc J. 2008 Oct;10(10):722-7
[
19009954.001
]
[Cites]
Semin Cancer Biol. 2009 Jun;19(3):165-71
[
19429480.001
]
[Cites]
Clin Cancer Res. 2009 Jun 1;15(11):3802-11
[
19470737.001
]
[Cites]
Oncogene. 2009 Aug 20;28(33):2969-78
[
19503099.001
]
[Cites]
Cancer Res. 2000 Nov 15;60(22):6236-42
[
11103776.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3225-9
[
11309270.001
]
[Cites]
Cancer Res. 2001 May 1;61(9):3573-7
[
11325821.001
]
[Cites]
Lancet. 2001 Apr 28;357(9265):1335-6
[
11343741.001
]
[Cites]
Breast Cancer Res. 2001;3(5):289-93
[
11597316.001
]
[Cites]
Am J Pathol. 2002 Feb;160(2):605-12
[
11839581.001
]
[Cites]
J Biol Chem. 2002 Jun 14;277(24):21119-22
[
11967258.001
]
[Cites]
J Obstet Gynaecol Can. 2002 Feb;24(2):164-80; quiz 181-4
[
12196882.001
]
[Cites]
Cancer Res. 2002 Oct 15;62(20):5902-5
[
12384555.001
]
[Cites]
Cancer Res. 2003 Oct 1;63(19):6178-86
[
14559801.001
]
(PMID = 20716965.001).
[ISSN]
1559-2308
[Journal-full-title]
Epigenetics
[ISO-abbreviation]
Epigenetics
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CDH1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PYCARD protein, human; 0 / RASSF1 protein, human; 0 / RBP1 protein, human; 0 / Retinol-Binding Proteins, Cellular; 0 / SFRP1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
[Other-IDs]
NLM/ PMC3052848
77.
Zhao TT, Li JG, Li YM:
[Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
Zhonghua Zhong Liu Za Zhi
; 2007 Mar;29(3):206-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Performance of 18F-FDG PET/CT in the detection of primary
breast
cancer and staging of the regional lymph nodes].
OBJECTIVE: To evaluate the performance of 18F-FDG PET/CT in the detection of primary
breast
cancer, and the staging of regional lymph nodes.
METHODS: Twenty four females with highly suspected
breast
cancer, underwent PET/CT imaging of the
breast
preoperatively.
Three nuclear medicine physicians analyzed the image and made
the diagnosis
.
32
breast
lesions were evaluated by histology, revealing 25
breast
carcinomas and 7
benign
pathological changes.
23 patients had histological
diagnosis of
the
breast tumor
and regional lymph nodes.
RESULTS: 20 of 25
breast
carcinomas were successfully diagnosed by FDG-PET/CT.
No Tis
breast
carcinoma was detected.
75.0% of T1
breast
carcinomas were detected, and with 85.7% of stage T2, 100.0% of T3.
As to a suspicious distant metastasis, PET/CT convinced
the diagnosis
.
CONCLUSION: As a noninvasive technique, FDG PET/CT appears to be a useful method in staging patient with
breast
cancer, especially in cases in which the lesion is hard to predict by routine examination.
In the detection of
breast
lesions, PET/CT doesn't seem to have a high sensitivity, especially in early stage
breast
cancers.
The high cost and the space resolution limit its use as a routine diagnostic method of
breast
cancer.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Carcinoma, Ductal,
Breast
/
diagnosis
. Lymph Nodes / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
[MeSH-minor]
Adult. Aged.
Female
. Fibroadenoma /
diagnosis
. Fibroadenoma / pathology. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Middle Aged.
Neoplasm
Staging. Reproducibility of Results. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - CT Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17649638.001).
[ISSN]
0253-3766
[Journal-full-title]
Zhonghua zhong liu za zhi [Chinese journal of oncology]
[ISO-abbreviation]
Zhonghua Zhong Liu Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18
78.
Deutscher SL, Dickerson M, Gui G, Newton J, Holm JE, Vogeltanz-Holm N, Kliethermes B, Hewett JE, Kumar SR, Quinn TP, Sauter ER:
Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.
BMC Cancer
; 2010 Oct 01;10:519
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic
breast
biopsy.
BACKGROUND: The goal of this prospective study was to determine (a) concentrations of the carbohydrate biomarkers Thomsen Friedenreich (TF) antigen and its precursor, Tn antigen, in nipple discharge (ND) collected from women requiring biopsy because of a suspicious
breast
lesion; and (b) if concentration levels predicted pathologic
diagnosis
.
METHODS: Adult women requiring biopsy to exclude
breast
cancer were enrolled and ND obtained.
TF was higher in women with 1) cancer (DCIS or invasive) vs. either no cancer (atypia or
benign
pathology, p = .048), or
benign
pathology (p = .018); and 2) abnormal (atypia or cancer) versus
benign
pathology (p = .016); and was more predictive of atypia or cancer in post- compared to premenopausal women.
High TF concentration and age were independent predictors of disease, correctly classifying either cancer or abnormal vs.
benign
pathology 83% of the time in postmenopausal women.
CONCLUSIONS: TF concentrations in ND were higher in women with precancer and cancer compared to women with
benign
disease, and TF was an independent predictor of
breast
atypia and cancer.
TF may prove useful in early
breast
cancer detection.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2000 Jun 15;86(6):753-9
[
10842187.001
]
[Cites]
Anticancer Res. 2001 Mar-Apr;21(2B):1327-34
[
11396208.001
]
[Cites]
Curr Treat Options Oncol. 2004 Apr;5(2):131-44
[
14990207.001
]
[Cites]
J Natl Cancer Inst. 1975 Feb;54(2):335-9
[
163330.001
]
[Cites]
Science. 1984 Jun 15;224(4654):1198-206
[
6729450.001
]
[Cites]
Diagn Cytopathol. 2010 Apr;38(4):244-51
[
19795490.001
]
[Cites]
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6868-71
[
16203776.001
]
[Cites]
Bioconjug Chem. 2006 Mar-Apr;17(2):501-6
[
16536483.001
]
[Cites]
JAMA. 2006 Jun 21;295(23):2727-41
[
16754727.001
]
[Cites]
Cancer Detect Prev. 2007;31(1):50-8
[
17317033.001
]
[Cites]
Br J Cancer. 1997;76(4):494-501
[
9275027.001
]
(PMID = 20920311.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA119095
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens; 0 / Biomarkers, Tumor; 0 / Carbohydrates
[Other-IDs]
NLM/ PMC2958935
79.
Kennedy S, Geradts J, Bydlon T, Brown JQ, Gallagher J, Junker M, Barry W, Ramanujam N, Wilke L:
Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast.
Breast Cancer Res
; 2010;12(6):R91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Optical
breast
cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast.
INTRODUCTION: Residual cancer following
breast
conserving surgery increases the risk of local recurrence and mortality.
Breast
tissue is markedly heterogeneous, which makes distinguishing small foci of cancer within the spectrum of normal tissue potentially challenging.
Here, we evaluate
ex
-vivo
breast
tissue and determine which sources of optical contrast have the potential to detect malignancy at the margins in women of differing
breast
composition.
The diagnostic ability of the optical parameters was affected by distance of
tumor
from the margin as well as menopausal status.
CONCLUSIONS: The data indicate that the ability of an optical parameter to differentiate
benign
from malignant
breast
tissues may be dictated by patient demographics.
Patient demographics are therefore an important component to incorporate into optical characterization of
breast
specimens.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BETA-CAROTENE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lasers Surg Med. 2010 Jan;42(1):15-23
[
20077490.001
]
[Cites]
J Surg Res. 2010 May 15;160(2):277-81
[
19628225.001
]
[Cites]
Blood. 2010 May 20;115(20):4111-9
[
20107229.001
]
[Cites]
Opt Express. 2010 Apr 12;18(8):8058-76
[
20588651.001
]
[Cites]
Cancer Res. 2009 Nov 15;69(22):8790-6
[
19910294.001
]
[Cites]
Neoplasia. 2000 Jan-Apr;2(1-2):26-40
[
10933066.001
]
[Cites]
J Biomed Opt. 2000 Apr;5(2):221-8
[
10938787.001
]
[Cites]
Photochem Photobiol. 2000 Sep;72(3):383-91
[
10989610.001
]
[Cites]
Acad Radiol. 2001 Mar;8(3):211-8
[
11249084.001
]
[Cites]
Am J Surg. 2002 Nov;184(5):383-93
[
12433599.001
]
[Cites]
J Biomed Opt. 2003 Apr;8(2):223-36
[
12683848.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12349-54
[
14514888.001
]
[Cites]
J Biomed Opt. 2004 Jan-Feb;9(1):230-8
[
14715078.001
]
[Cites]
J Biomed Opt. 2004 May-Jun;9(3):541-52
[
15189092.001
]
[Cites]
Arch Surg. 1991 Apr;126(4):490-3
[
2009065.001
]
[Cites]
Cancer J Sci Am. 1997 Sep-Oct;3(5):273-7
[
9327150.001
]
[Cites]
Am Surg. 2005 Jan;71(1):22-7; discussion 27-8
[
15757052.001
]
[Cites]
J Am Coll Surg. 2005 Aug;201(2):194-8
[
16038815.001
]
[Cites]
J Am Coll Surg. 2005 Dec;201(6):855-61
[
16310688.001
]
[Cites]
Lancet. 2005 Dec 17;366(9503):2087-106
[
16360786.001
]
[Cites]
Appl Opt. 2006 Feb 10;45(5):1062-71
[
16512550.001
]
[Cites]
Appl Opt. 2006 Feb 10;45(5):1072-8
[
16512551.001
]
[Cites]
Technol Cancer Res Treat. 2006 Aug;5(4):301-9
[
16866560.001
]
[Cites]
Lasers Surg Med. 2006 Aug;38(7):714-24
[
16799981.001
]
[Cites]
Ann Surg Oncol. 2007 Mar;14(3):1045-50
[
17206481.001
]
[Cites]
Ann Surg Oncol. 2007 Apr;14(4):1458-71
[
17260108.001
]
[Cites]
Am J Surg. 2007 Oct;194(4):467-73
[
17826057.001
]
[Cites]
Ann Surg Oncol. 2007 Sep;14(9):2425-7
[
17597344.001
]
[Cites]
Ann Surg Oncol. 2007 Oct;14(10):2953-60
[
17674109.001
]
[Cites]
Ann Surg Oncol. 2008 May;15(5):1297-303
[
18259820.001
]
[Cites]
Ann Surg Oncol. 2008 May;15(5):1271-2
[
18320287.001
]
[Cites]
J Biomed Opt. 2008 Mar-Apr;13(2):024012
[
18465975.001
]
[Cites]
J Am Coll Surg. 2008 Jun;206(3):1116-21
[
18501808.001
]
[Cites]
J Biomed Opt. 2008 May-Jun;13(3):034015
[
18601560.001
]
[Cites]
Am J Surg. 2008 Oct;196(4):483-9
[
18809049.001
]
[Cites]
Breast J. 2009 Jan-Feb;15(1):34-40
[
19141132.001
]
[Cites]
J Clin Oncol. 2009 Apr 1;27(10):1615-20
[
19255332.001
]
[Cites]
Cancer Res. 2009 Apr 1;69(7):2919-26
[
19293184.001
]
[Cites]
Curr Opin Biotechnol. 2009 Feb;20(1):119-31
[
19268567.001
]
[Cites]
Ann Surg Oncol. 2009 Oct;16(10):2717-30
[
19609829.001
]
[Cites]
Am J Surg. 2009 Oct;198(4):566-74
[
19800470.001
]
[Cites]
JAMA. 2009 Oct 14;302(14):1551-6
[
19826024.001
]
[Cites]
J Biomed Opt. 2009 Sep-Oct;14(5):054023
[
19895125.001
]
(PMID = 21054873.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / 1R41CA128160-01; United States / NCRR NIH HHS / RR / 1UL1 RR024128-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Hemoglobins; 01YAE03M7J / beta Carotene
[Other-IDs]
NLM/ PMC3046432
80.
Dietzel M, Baltzer PA, Vag T, Herzog A, Gajda M, Camara O, Kaiser WA:
The adjacent vessel sign on breast MRI: new data and a subgroup analysis for 1,084 histologically verified cases.
Korean J Radiol
; 2010 Mar-Apr;11(2):178-86
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The adjacent vessel sign on
breast
MRI: new data and a subgroup analysis for 1,084 histologically verified cases.
OBJECTIVE: The adjacent vessel sign (AVS) is a descriptor for differentiating malignant from
benign breast
lesions on
breast
MRI (bMRI).
This investigation was designed to verify the previous reports on the diagnostic accuracy of AVS and to assess correlation between AVS, histopathological
diagnosis
, lesion size and lesion grade.
The exclusion criteria were no histological verification after bMRI and
breast
interventions that were done up to one year before bMRI (surgery, core biopsy, chemo- or radiation therapy).
There was no correlation of the AVS with the
tumor
grade.
Thus, it can be used to accurately assess
breast
lesions on bMRI.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoplasms, Ductal, Lobular, and Medullary / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media.
Diagnosis
, Differential.
Female
. Gadolinium DTPA. Humans. Image Enhancement / methods. Middle Aged. Observer Variation. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity. Young Adult
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
Hazardous Substances Data Bank.
GADOPENTETATE DIMEGLUMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1991 Jan 3;324(1):1-8
[
1701519.001
]
[Cites]
NMR Biomed. 2009 Jan;22(1):77-91
[
19086016.001
]
[Cites]
Virchows Arch. 2000 Dec;437(6):611-7
[
11193472.001
]
[Cites]
Korean J Radiol. 2001 Apr-Jun;2(2):80-6
[
11752975.001
]
[Cites]
Histopathology. 1991 Nov;19(5):403-10
[
1757079.001
]
[Cites]
J Biol Chem. 1992 Jun 5;267(16):10931-4
[
1375931.001
]
[Cites]
J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87
[
1281237.001
]
[Cites]
J Comput Assist Tomogr. 1996 Jan-Feb;20(1):9-14
[
8576489.001
]
[Cites]
Rofo. 1996 Nov;165(5):425-7
[
8998312.001
]
[Cites]
Radiology. 1997 Mar;202(3):833-41
[
9051042.001
]
[Cites]
AJR Am J Roentgenol. 1997 May;168(5):1331-4
[
9129437.001
]
[Cites]
Stat Med. 1998 Apr 30;17(8):857-72
[
9595616.001
]
[Cites]
Radiology. 1998 Jun;207(3):675-81
[
9609890.001
]
[Cites]
Invest Radiol. 2005 Jul;40(7):430-5
[
15973134.001
]
[Cites]
Am J Surg. 2005 Oct;190(4):633-40
[
16164938.001
]
[Cites]
AJR Am J Roentgenol. 2005 Oct;185(4):964-70
[
16177416.001
]
[Cites]
AJR Am J Roentgenol. 2006 Feb;186(2):426-30
[
16423948.001
]
[Cites]
AJR Am J Roentgenol. 2006 Aug;187(2):W147-51
[
16861503.001
]
[Cites]
Eur J Radiol. 2007 Feb;61(2):212-5
[
17145155.001
]
[Cites]
Korean J Radiol. 2007 Jan-Feb;8(1):32-9
[
17277561.001
]
[Cites]
Radiology. 2007 Jul;244(1):94-103
[
17507720.001
]
[Cites]
Radiology. 2007 Sep;244(3):672-91
[
17709824.001
]
[Cites]
Korean J Radiol. 2007 Sep-Oct;8(5):382-9
[
17923780.001
]
[Cites]
Radiology. 2008 Jan;246(1):116-24
[
18024435.001
]
[Cites]
Korean J Radiol. 2008 Jan-Feb;9(1):10-8
[
18253071.001
]
[Cites]
Invest Radiol. 2008 Apr;43(4):236-42
[
18340247.001
]
[Cites]
Rofo. 2008 Nov;180(11):968-76
[
18855300.001
]
[Cites]
J Magn Reson Imaging. 2008 Nov;28(5):1157-65
[
18972357.001
]
[Cites]
NMR Biomed. 2009 Jan;22(1):54-64
[
19086012.001
]
[Cites]
Eur J Radiol. 2009 Apr;70(1):69-76
[
18295425.001
]
[Cites]
Acta Radiol. 2010 Mar;51(2):137-43
[
20092368.001
]
[Cites]
Radiology. 1999 Dec;213(3):881-8
[
10580970.001
]
(PMID = 20191065.001).
[ISSN]
2005-8330
[Journal-full-title]
Korean journal of radiology
[ISO-abbreviation]
Korean J Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
[Other-IDs]
NLM/ PMC2827781
[Keywords]
NOTNLM ; Breast, MR / Contrast media / Descriptor / Histology / Neoangiogenesis / Sign
81.
Hauth E, Umutlu L, Kümmel S, Kimmig R, Forsting M:
Follow-up of probably benign lesions (BI-RADS 3 category) in breast MR imaging.
Breast J
; 2010 May-Jun;16(3):297-304
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Follow-up of probably
benign
lesions (BI-RADS 3 category) in
breast
MR imaging.
The purpose of our study was to determine the frequency of BI-RADS 3 lesions in
breast
MR imaging in a clinical patient population and their frequency of malignancy in follow-up
breast
MR imaging.
In 44/698 (6.3%) patients with
breast
MR imaging, 56 lesions were categorized to BI-RADS 3.
In follow-up, lesions were score in complete resolved (CRL), partial resolved (PRL), stable lesions (SL), and progressive lesions (
PL
).
In first follow-up
breast
MR imaging 23/56 (41%) lesions were PRL, 14/56 (25%) lesions were CRL, 14/56 (25%) lesions remained SL.
In one of five
PL
lesions, histopathology revealed a malignant
tumor
.
In initial
breast
MR imaging, CRL showed significant fewer high pixels (p = 0.002), medium pixels (p = 0.006) significant more low pixels (p = 0.005) and significant more increase pixels (p = 0.037) than PRL.
In a clinical patient population the frequency of malignancy of BI-RADS 3 lesions in
breast
MR imaging and their frequency of malignancy are similar to that in conventional mammography.
In initial
breast
MR imaging, complete resolved lesions showed less suspicious contrast kinetics than other lesions.
In follow-up, the increase of lesion size should warrant histopathological
diagnosis
.
[MeSH-major]
Breast
/ pathology.
Breast
Neoplasms / epidemiology. Magnetic Resonance Imaging / methods
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over.
Female
. Follow-Up Studies. Humans. Middle Aged. Young Adult
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20565469.001).
[ISSN]
1524-4741
[Journal-full-title]
The breast journal
[ISO-abbreviation]
Breast J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
82.
Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK:
18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma.
Laryngoscope
; 2005 Jun;115(6):1074-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from
benign
disease.
Cytologic
diagnosis
was available in 32 of 45 focal thyroid FDG uptakes.
In 16 (50%) patients, the
tumor
was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic
tumor
from
breast
and esophagus.
Sixteen were cytologically diagnosed as follicular cell lesions: follicular
neoplasm
(n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
There was no significant difference in maximum SUV between
benign
and malignant nodules.
From 45 patients with diffuse thyroid FDG uptake, presumptive
diagnosis of
chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
CONCLUSION: Our data suggest that a cytologic
diagnosis of
focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool.
Female
. Humans. Male. Middle Aged.
Neoplasm
Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15933524.001).
[ISSN]
0023-852X
[Journal-full-title]
The Laryngoscope
[ISO-abbreviation]
Laryngoscope
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18
83.
Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim SJ, Sohn YM, Kim EK:
Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
Ultrasound Med Biol
; 2010 Apr;36(4):551-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant lesions initially categorized as probably
benign breast
lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
The primary objective of this study was to review the ultrasonographic features of BI-RADS category 3 ("probably
benign
") lesions that eventually proved to be malignant.
Thirty-two (0.8%) of 4000 women with lesions that were initially classified as "probably
benign
" proved to be malignant and formed the study group.
There was no statistical difference in the mean age, mean size of lesions, or
tumor
stage between patients who underwent early biopsy (n = 19) or biopsy after 6 months (n = 13).
[MeSH-major]
Biopsy / statistics & numerical data.
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / epidemiology. Ultrasonography, Mammary / statistics & numerical data
[MeSH-minor]
Adult. Aged.
Female
. Humans. Korea / epidemiology. Male. Middle Aged. Prevalence. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
(PMID = 20350681.001).
[ISSN]
1879-291X
[Journal-full-title]
Ultrasound in medicine & biology
[ISO-abbreviation]
Ultrasound Med Biol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
84.
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR:
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.
J Immunol
; 2005 Jul 15;175(2):1197-205
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Tumor
-associated macrophages may influence
tumor
progression, angiogenesis and invasion.
To investigate mechanisms by which macrophages interact with
tumor
cells, we developed an in vitro coculture model.
Previously we reported that coculture enhanced invasiveness of the
tumor
cells in a TNF-alpha- and matrix metalloprotease-dependent manner.
We report that coculture of macrophages with ovarian or
breast
cancer cell lines led to TNF-alpha-dependent activation of JNK and NF-kappaB pathways in
tumor
cells, but not in
benign
immortalized epithelial cells.
Tumor
cells with increased JNK and NF-kappaB activity exhibited enhanced invasiveness.
Inhibition of the NF-kappaB pathway by TNF-alpha neutralizing Abs, an NF-kappaB inhibitor, RNAi to RelA, or overexpression of IkappaB inhibited
tumor
cell invasiveness.
Cocultured
tumor
cells were screened for the expression of 22 genes associated with inflammation and invasion that also contained an AP-1 and NF-kappaB binding site.
EMMPRIN and MIF were up-regulated in cocultured
tumor
cells in a JNK- and NF-kappaB-dependent manner.
Knocking down either MIF or EMMPRIN by RNAi in the
tumor
cells significantly reduced
tumor
cell invasiveness and matrix metalloprotease activity in the coculture supernatant.
We conclude that TNF-alpha, via NF-kappaB, and JNK induces MIF and EMMPRIN in macrophage to
tumor
cell cocultures and this leads to increased invasive capacity of the
tumor
cells.
[MeSH-major]
Epithelial Cells / pathology. JNK Mitogen-Activated Protein Kinases / physiology. Macrophages / immunology. NF-kappa B / physiology.
Neoplasm
Invasiveness
[MeSH-minor]
Antigens, CD / biosynthesis. Antigens, CD / genetics. Antigens, CD / physiology. Antigens, CD147. Binding Sites / genetics.
Breast
Neoplasms / immunology.
Breast
Neoplasms / pathology. Cell Line, Transformed. Cell Line,
Tumor
. Cells, Cultured. Coculture Techniques.
Female
. Humans. Macrophage Migration-Inhibitory Factors / antagonists & inhibitors. Macrophage Migration-Inhibitory Factors / biosynthesis. Macrophage Migration-Inhibitory Factors / physiology. Matrix Metalloproteinases / secretion. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. RNA Interference / physiology. Transcription Factor RelA. Up-Regulation / immunology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16002723.001).
[ISSN]
0022-1767
[Journal-full-title]
Journal of immunology (Baltimore, Md. : 1950)
[ISO-abbreviation]
J. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / BSG protein, human; 0 / Macrophage Migration-Inhibitory Factors; 0 / NF-kappa B; 0 / Transcription Factor RelA; 136894-56-9 / Antigens, CD147; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.24.- / Matrix Metalloproteinases
85.
Kiuru M, Lehtonen R, Eerola H, Aittomäki K, Blomqvist C, Nevanlinna H, Aaltonen LA, Launonen V:
No germline FH mutations in familial breast cancer patients.
Eur J Hum Genet
; 2005 Apr;13(4):506-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
No germline FH mutations in familial
breast
cancer patients.
Fumarate hydratase: (FH) was recently identified as the predisposing gene for a
tumor
predisposition syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC) (MIM 605839).
In HLRCC, individuals with a germline heterozygous mutation in the FH gene typically develop
benign
leiomyomas of the skin and the uterus (fibroids, myomas).
Other malignancies including
breast
cancer have also been detected in patients with a germline FH mutation.
To examine whether FH could be involved in predisposition to
breast
cancer, we analyzed germline FH mutations from 85 Finnish
breast
cancer patients.
These results show that FH is not a major predisposing gene for familial
breast
cancer.
[MeSH-major]
Breast
Neoplasms / genetics. Fumarate Hydratase / genetics. Genetic Predisposition to Disease. Germ-Line Mutation / genetics
[MeSH-minor]
Female
. Humans
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
SciCrunch.
OMIM: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15523491.001).
[ISSN]
1018-4813
[Journal-full-title]
European journal of human genetics : EJHG
[ISO-abbreviation]
Eur. J. Hum. Genet.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
EC 4.2.1.2 / Fumarate Hydratase
86.
Nabhan ZM, West KW, Eugster EA:
Oophorectomy in McCune-Albright syndrome: a case of mistaken identity.
J Pediatr Surg
; 2007 Sep;42(9):1578-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Variables analyzed included presenting features, presence of café au lait macules, presence of fibrous dysplasia, radiographic studies, estradiol levels,
tumor
markers, surgery, and pathology reports.
Eight (88%) also had
breast
development and 2 (22%) had associated pubic hair.
Four (44%) girls underwent salpingo-oophorectomy before
the diagnosis
of MAS was made.
Surgical pathology revealed
benign
ovarian cysts in all 4 patients.
CONCLUSION: Unnecessary oophorectomy is common in girls with MAS who are taken to the operating room for a presumed ovarian
tumor
.
[MeSH-major]
Fibrous Dysplasia, Polyostotic /
diagnosis
. Ovarian Cysts / surgery. Ovariectomy. Puberty, Precocious /
diagnosis
[MeSH-minor]
Child, Preschool.
Diagnosis
, Differential.
Female
. Humans. Infant. Uterine Hemorrhage / complications
Genetic Alliance.
consumer health - McCune Albright syndrome
.
MedlinePlus Health Information.
consumer health - Ovarian Cysts
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17848252.001).
[ISSN]
1531-5037
[Journal-full-title]
Journal of pediatric surgery
[ISO-abbreviation]
J. Pediatr. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
87.
Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M:
Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
Onkologie
; 2007 Mar;30(3):113-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phyllodes tumors of the
breast
diagnostic and therapeutic dilemmas.
BACKGROUND: This article compares experiences in
the diagnosis
and treatment of phyllodes tumors from 2 regional institutions with the relevant literature.
PATIENTS AND METHODS: From 1991 to 2005, 2,848
breast
cancer patients were treated in our institutions, 36 (1.44%) for phyllodes tumors.
The average
tumor
size was 5.1 cm (range 1.4-19.6).
Wide excision with
tumor
-free margins was carried out in 29 (80.5%) cases and mastectomy in 7 (19.4%) cases.
RESULTS: Histology showed the phyllodes tumors to be
benign
in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases.
In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%)
benign
phyllodes tumors were diagnosed and treated.
CONCLUSION: Our study shows that
tumor
size, margin infiltration, mitotic activity and degree of cellular atypia are important prognostic factors.
Although wide local excision is usually the treatment of choice,
tumor
recurrence is common.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Phyllodes
Tumor
/
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Breast
/ pathology.
Diagnosis
, Differential.
Female
. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Mitotic Index. Necrosis.
Neoplasm
Invasiveness / pathology.
Neoplasm
Recurrence, Local /
diagnosis
.
Neoplasm
Recurrence, Local / mortality.
Neoplasm
Recurrence, Local / pathology.
Neoplasm
Recurrence, Local / surgery. Prognosis. Reoperation. Survival Rate
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17341897.001).
[ISSN]
0378-584X
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
88.
Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R, Frost AR:
Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues.
J Histochem Cytochem
; 2010 Oct;58(10):857-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary cilia are decreased in
breast
cancer: analysis of a collection of human
breast
cancer cell lines and tissues.
PC were detected by immunofluorescence of cultured cells and
breast
tissues.
After growth for 7 days in vitro, PC were detected in ∼70% of
breast
fibroblasts and in 7-19% of epithelial cells derived from
benign breast
(184A1 and MCF10A).
In 11
breast
cancer cell lines, PC were present at a low frequency in four (from 0.3% to 4% of cells), but were absent in the remainder.
The cancer cell lines with PC were all of the basal B subtype, which is analogous to the clinical triple-negative
breast
cancer subtype.
In histologically normal
breast
tissues, PC were frequent in fibroblasts and myoepithelial cells and less common in luminal epithelial cells.
Of 26
breast
cancers examined, rare PC were identified in cancer epithelial cells of only one cancer, which was of the triple-negative subtype.
These data indicate a decrease or loss of PC in
breast
cancer and an association of PC with the basal B subtype.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2009 Jul 1;69(13):5292-3
[
19549886.001
]
[Cites]
Nat Med. 2009 Sep;15(9):1062-5
[
19701203.001
]
[Cites]
Nat Med. 2009 Sep;15(9):1055-61
[
19701205.001
]
[Cites]
J Biol Chem. 2009 Dec 18;284(51):35325-37
[
19812034.001
]
[Cites]
BMC Cancer. 2009;9:448
[
20017937.001
]
[Cites]
Am J Pathol. 1999 Dec;155(6):1941-51
[
10595924.001
]
[Cites]
Nat Genet. 2000 Mar;24(3):227-35
[
10700174.001
]
[Cites]
Nature. 2000 Aug 17;406(6797):747-52
[
10963602.001
]
[Cites]
Oncogene. 2000 Sep 7;19(38):4337-45
[
10980609.001
]
[Cites]
Breast Cancer Res Treat. 2000 Dec;64(3):235-40
[
11200773.001
]
[Cites]
Semin Cancer Biol. 2001 Apr;11(2):97-104
[
11322829.001
]
[Cites]
Am J Physiol Renal Physiol. 2002 Mar;282(3):F541-52
[
11832437.001
]
[Cites]
Int J Cancer. 2002 Mar 1;98(1):118-27
[
11857395.001
]
[Cites]
Nat Genet. 2003 Feb;33(2):129-37
[
12514735.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Sep 12;309(1):232-40
[
12943687.001
]
[Cites]
Breast Cancer Res Treat. 2004 Feb;83(3):249-89
[
14758095.001
]
[Cites]
Cancer Res. 2004 Feb 15;64(4):1331-7
[
14973050.001
]
[Cites]
Cancer Res. 2004 May 15;64(10):3479-85
[
15150101.001
]
[Cites]
Anat Rec. 1976 Nov;186(3):413-6
[
999034.001
]
[Cites]
J Natl Cancer Inst. 1977 Jun;58(6):1795-806
[
864756.001
]
[Cites]
In Vitro. 1980 May;16(5):415-25
[
6993343.001
]
[Cites]
J Immunol. 1984 Oct;133(4):1710-5
[
6206131.001
]
[Cites]
Proc Natl Acad Sci U S A. 1985 Apr;82(8):2394-8
[
3857588.001
]
[Cites]
J Cell Biol. 1987 Feb;104(2):289-302
[
2879846.001
]
[Cites]
Br J Surg. 1987 Mar;74(3):227-9
[
3567520.001
]
[Cites]
Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;56(1):25-33
[
2907198.001
]
[Cites]
Cancer Res. 1990 Sep 15;50(18):6075-86
[
1975513.001
]
[Cites]
Cytometry. 1991;12(1):42-9
[
1999122.001
]
[Cites]
Br J Cancer. 1993 Nov;68(5):909-15
[
8217606.001
]
[Cites]
Am J Pathol. 1996 Jan;148(1):313-9
[
8546221.001
]
[Cites]
Br J Cancer. 1996 Jan;73(2):154-61
[
8546900.001
]
[Cites]
Cell Biol Int. 1996 Jan;20(1):73-81
[
8936410.001
]
[Cites]
Membr Cell Biol. 1999;12(6):895-905
[
10512057.001
]
[Cites]
Breast Cancer Res. 2005;7(1):R46-59
[
15642169.001
]
[Cites]
Cell. 2005 May 6;121(3):335-48
[
15882617.001
]
[Cites]
Curr Biol. 2005 Oct 25;15(20):1861-6
[
16243034.001
]
[Cites]
Oncogene. 2006 Apr 6;25(15):2273-84
[
16288205.001
]
[Cites]
Nat Rev Cancer. 2006 May;6(5):392-401
[
16572188.001
]
[Cites]
Curr Biol. 2006 Aug 8;16(15):R604-14
[
16890522.001
]
[Cites]
J Histochem Cytochem. 2006 Sep;54(9):1005-14
[
16651393.001
]
[Cites]
Science. 2006 Oct 13;314(5797):268-74
[
16959974.001
]
[Cites]
Cancer Cell. 2006 Dec;10(6):515-27
[
17157791.001
]
[Cites]
Traffic. 2007 Feb;8(2):97-109
[
17241444.001
]
[Cites]
Am J Pathol. 2007 May;170(5):1546-60
[
17456761.001
]
[Cites]
Breast Cancer Res Treat. 2007 Jul;104(1):13-9
[
17004106.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13325-30
[
17673554.001
]
[Cites]
Annu Rev Cell Dev Biol. 2007;23:345-73
[
17506691.001
]
[Cites]
Subcell Biochem. 2007;43:209-35
[
17953396.001
]
[Cites]
Cancer Res. 2007 Nov 1;67(21):10123-8
[
17974953.001
]
[Cites]
Science. 2007 Nov 16;318(5853):1108-13
[
17932254.001
]
[Cites]
J Neurosci. 2007 Nov 21;27(47):12757-60
[
18032646.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19138-43
[
18024594.001
]
[Cites]
Cancer Res. 2008 Apr 1;68(7):2058-61
[
18381407.001
]
[Cites]
Biotech Histochem. 2008 Feb;83(1):5-14
[
18568671.001
]
[Cites]
Trends Genet. 2008 Jul;24(7):361-71
[
18514358.001
]
[Cites]
Clin Exp Metastasis. 2008;25(6):629-42
[
18461285.001
]
[Cites]
Dev Dyn. 2008 Aug;237(8):1993-2006
[
18393310.001
]
[Cites]
Clin Cancer Res. 2008 Oct 1;14(19):5995-6004
[
18829478.001
]
[Cites]
Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G725-34
[
18687752.001
]
[Cites]
PLoS One. 2008;3(11):e3728
[
19008961.001
]
[Cites]
Pathology. 2009 Jan;41(1):40-7
[
19089739.001
]
[Cites]
Mod Pathol. 2009 Jan;22(1):31-6
[
18660794.001
]
[Cites]
Cancer Res. 2009 Jan 15;69(2):422-30
[
19147554.001
]
[Cites]
Curr Top Dev Biol. 2008;85:261-301
[
19147009.001
]
[Cites]
Curr Top Dev Biol. 2008;85:303-32
[
19147010.001
]
[Cites]
Curr Top Dev Biol. 2008;85:371-427
[
19147012.001
]
[Cites]
Curr Top Dev Biol. 2008;84:249-310
[
19186246.001
]
[Cites]
Cancer Res. 2009 Feb 15;69(4):1279-83
[
19190326.001
]
[Cites]
Curr Opin Genet Dev. 2009 Feb;19(1):67-73
[
19211240.001
]
(PMID = 20530462.001).
[ISSN]
1551-5044
[Journal-full-title]
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
[ISO-abbreviation]
J. Histochem. Cytochem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R03-CA130057
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2942739
89.
Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J, Quackenbush J, Yeatman T:
Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue.
Breast Cancer Res Treat
; 2010 Jan;119(2):335-46
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proliferative genes dominate malignancy-risk gene signature in histologically-normal
breast
tissue.
Historical data have indicated the potential for the histologically-normal
breast
to harbor pre-malignant changes at the molecular level.
We postulated that a histologically-normal tissue with "
tumor
-like" gene expression pattern might harbor substantial risk for future cancer development.
From a total of 90
breast
cancer patients, we collected a set of 143 histologically-normal
breast
tissues derived from patients harboring
breast
cancer who underwent curative mastectomy, as well as a set of 42 invasive ductal carcinomas (IDC) of various histologic grades.
For the purpose of this study we defined normal
breast
tissue to include histologically normal and
benign
lesions.
Here we report the discovery of a "malignancy-risk" gene signature that may portend risk of
breast
cancer development in
benign
, but molecularly-abnormal,
breast
tissue.
These results suggest a predictive role for the malignancy-risk signature in normal
breast
tissue.
Proliferative biology dominates the earliest stages of
tumor
development.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Genetic Testing
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2005 Oct 27;353(17):1784-92
[
16251534.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
[
11309499.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9
[
12714683.001
]
[Cites]
N Engl J Med. 2002 Dec 19;347(25):1999-2009
[
12490681.001
]
[Cites]
Nat Genet. 2002 Dec;32 Suppl:533-40
[
12454650.001
]
[Cites]
Am J Pathol. 2002 Jul;161(1):28